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1 Introduction 
 
1.1 Measles virus 
1.1.1 Taxonomy and molecular basics of measles virus 
Measles virus (MV) is a member of the genus Morbillivirus in the family of 
Paramyxoviridae (subfamily: Paramyxovirinae). It is a virus with a small non-
segmented negative ssRNA genome (approx. 16 kb), encoding 6 genes (Fig. 1A). 
Due to their genomes, viruses from the family of Paramyxoviridae and the 
families of Rhabdoviridae, Bornaviridae, and Filoviridae form the order of 
Mononegavirales (non-segmented negative strand RNA viruses = NNSV). 
The genes are arranged in 3’ to 5’ direction of the genome in the following 
order: the N gene (approx. 1.7 kb), which encodes for the nucleoprotein (N; 58 
kDa), the P gene (approx. 1.7 kb) encoding the phosphoprotein (P; 54 kDa), as 
well as the two non-structural proteins V (32 kDa) and C (21 kDa), the M gene 
(approx. 1.5 kb), encoding the matrix protein (M; 38 kDa), the F gene (approx. 
2.4 kb), encoding the fusion protein (F; 60 kDa), the H gene (approx. 2.0 kb), 
encoding the hemagglutinin protein (H; 69 kDa), and the L gene (approx. 6.6 
kb), encoding the large protein (L; 247 kDa). The genome is flanked by two 
small regions encoding the viral promoters called “leader region” (genomic 
promoter at the 3’ end of the genome; 55 nt) and “trailer region” (antigenomic 
promoter at the 3’ end of the antigenome; 37 nt). 
MV emerges in eight clades (A, B, C, D, E, F, G, and H) which include up to now 
23 genotypes (reviewed in (Rota et al., 2009)). However, all viruses share the 
same serotype. 
The virus forms pleiomorphic and polyploid particles (Fig. 1B and C), consisting 
of a ribonucleoprotein complex (RNP), which is enwrapped by a lipid envelope. 
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The RNP is composed of the viral genomic RNA and the N protein, which 
encloses the RNA (6 nt/ N protein monomer). The genomic RNA strictly follows 
the “rule of six”, which means that the genome must be of polyhexameric length 
(6n+0; reviewed in (Kolakofsky et al., 2005)). P and L, which together form the 
viral RNA-dependent RNA polymerase (RdRp) are associated to the RNP. The M 
protein connects the RNP to the lipid envelope with the two viral 
transmembrane glycoproteins F and H, which are responsible for viral entry 
into host cells. 
 
 
Figure 1: Measles virus, gene expression and replication. 
(A) Schematic presentation of the MV genome, mRNA transcription gradient, structural (N, P, M, 
F, H, and L) and non-structural proteins (V, C) derived from the different genes, and replication 
cycle with antigenome intermediate. (B) Schematic MV particle. The RNP is composed of 
genomic RNA and N, and associated with P and L. The lipid envelope harbours homotrimers of 
F associated with H. M is located at the inner membrane and connects the RNPs to the envelope. 
(C) Electron micrograph of a MV particle. Published by S. Rozenblatt, Tel Aviv. (D) Electron 
micrograph of emerging MV particles. Published by S. Rozenblatt, Tel Aviv. 
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Upon infection, H protein dimers bind to cellular entry receptors. These 
receptors are, as yet identified, the signaling lymphocytic activation molecule 
(SLAM; or CD150; (Tatsuo et al., 2000)), or the membrane cofactor protein 
(MCP; or CD46; (Dörig et al., 1993; Naniche et al., 1993)). Recent publications 
suggest the existence of a third entry receptor, which is a so far uncharacterized 
epithelial cell receptor (EpR; (Takeda et al., 2007; Tahara et al., 2008)). The F 
protein mediates the fusion of cellular and viral membranes in a class I fusion 
reaction (reviewed in (Kielian and Rey, 2006; Yin et al., 2006)), leading to the 
release of the RNP into the cytoplasm. 
There, viral gene expression and replication take place (reviewed in (Rima and 
Duprex, 2009)). The P/L polymerase complex first transcribes the viral genes, 
thereby generating 5’-capped and 3’-polyadenylated mRNAs from each gene 
(Fig. 1A). In addition, the leader region is transcribed into a 5’-
triphosphorylated leader RNA (MV leader). Transcription takes place in a 
sequential way, meaning that most proximal genes (to the 3’ end of the 
genome) are transcribed to a higher extent than more distal genes, resulting in 
a mRNA gradient. The mRNAs are translated into proteins by the cellular 
translation machinery. At one point, that might be determined by the 
availability of newly synthesized N protein, the P/L complex switches from 
transcription to replication mode. Full length antigenomic RNA is generated in 
a continuous polymerization reaction starting with the MV leader. The 
antigenomic RNA is enwrapped immediately by N and serves again as a 
template for replication and production of new genomic RNA. The newly 
synthesized RNPs are transported to the cell membrane. The M protein is 
thought to mediate this transport and the subsequent virus assembly at sites of 
the cell membrane, where F and H are incorporated. Finally, the budding 
process (Fig. 1D) completes the viral replication cycle. 
A typical characteristic of MV infection in vitro and also in vivo is the formation 
of multi-nucleated giant cells (= syncytia (Bunting, 1950; Black et al., 1956)) 
which are formed upon fusion of infected cells with non-infected cells in a F and 
H mediated manner (Wild et al., 1991). 
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The P gene exhibits a special feature: While all the other genes encode only for 
a single protein, the P gene encodes for three proteins (Fig. 2A). Two 
alternative ORFs give rise to the P or to the C protein. These ORFs are 
translated via ribosomal scanning, where the ribosomes do not necessarily use 
the first start codon to initiate translation (P protein), but a start codon more 
downstream (C protein). Furthermore, the viral polymerase is able to perform 
RNA editing. This function leads to the cotranscriptional insertion of non-
coding nucleotides into the mRNA. In case of MV, an additional G is inserted 
between nt position 748/749 of the P mRNA (Fig. 2B). The insertion leads to a 
shift in the ORF and gives rise to a modified gene product, called V protein. P 
and V share a common N-terminal domain, consisting of 231 amino acids. The 
C-termini of P (276 aa) and V (68 aa) are completely individual. The V C-
terminus is highly conserved among the family of Paramyxoviridae and forms a 
unique Zn-binding motif (Liston and Briedis, 1994). All viruses from the 
subfamily of Paramyxovirinae are able to edit the mRNA of the P gene. However, 
some insert not only one G residue, but two or more (for review see 
 
 
Figure 2: MV P gene and products P, V and C. 
(A) Schematic representation of the MV P mRNA and location of start (P/V; C) and stop codons 
(C; V; P) as well as RNA editing site. (B) Nucleotide sequence (-11 - +10) of the RNA editing site 
and corresponding amino acid sequences of P (unedited mRNA; blue amino acids) and V (edited 
mRNA; red amino acids).  
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(Kolakofsky et al., 2005)). V and C of MV are known as virulence factors and 
interferon antagonists (Gotoh et al., 2001). They are not incorporated into the 
virus particle. 
 
1.1.2 Pathogenicity and control of measles virus 
Measles virus is a highly contagious pathogen that is restricted almost 
exclusively to humans and some primate species. It is transferred via 
respiratory droplets and airborne spray and initially infects mucous 
membranes of the upper respiratory tract (for review see (Naniche, 2009)). 
Infection with MV causes a characteristic disease (“measles”) with prodromal 
symptoms like fever, cough, and conjunctivitis at 10 – 12 d p. i., followed by a 
characteristic rash and high fever. Clearance of the virus occurs around day 7 – 
10 after the onset of the rash. 
In former times, measles was a major cause of childhood morbidity and 
mortality. It caused major epidemics among non-immunized native American 
tribes in the 16th century, when European immigrants brought the virus to 
North and South America. Although there is a live attenuated virus vaccine 
available today (Enders et al., 1962), which provides long-term protection from 
all MV strains (as they share the same serotype), the virus is still a risk factor in 
developing countries. Still, more than 20,000,000 acute infections with MV are 
reported annually, with 197,000 deaths due to measles in 2007 
(WHO/UNICEFJoint Statement, 2006). More than 95 % of the deaths occur in 
developing countries in Africa and Asia. 
MV is a hematotropic virus preferably infecting and replicating in lymphocytes. 
The infectious route of MV is still under discussion, as not all open questions 
are yet solved. One model proposes the infection of dendritic cells (DCs) at the 
site of initial infection, either directly or via transmission of the virus from the 
airway epithelium (Fig. 3A). Another option is the use of attachment receptors 
like DC-SIGN (de Witte et al., 2006) to attach to the surface of migrating DCs. 
MV might use these cells to enter local lymphatic tissue, where it is transmitted 
to B and T cells (Fig. 3B). Replication occurs in these cell types, causing a  
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Figure 3: Model of MV infectious route. 
(A) Primary infection of airway epithelial cells and/or dendritic cells either directly or via 
spread from epithelial cells. (B) Migration of infected DCs to local lymph nodes, the source of 
primary viremia. (C) Dissemination of MV to the whole organism upon onset of rash. Possible 
complications during infection due to MV include encephalitis, blindness, middle ear infection, 
pneumonia, and severe diarrhoea.  
 
primary viremia. MV is further transmitted to other lymphoid tissue, and also 
spleen and liver, where it causes a second viremia. In the last step of infection, 
the virus disseminates to multiple organs and also to the epithelium of organs 
and the skin (Fig. 3C). MV infection results in a strong and life-long immunity 
(section 1.2.2). Apparently contradictory to this, MV causes a strong 
immunosuppression, which is characterized by lymphopenia, cytokine 
imbalance, shift of the Th-response towards Th2, and silencing of PBMC (for 
details see section 1.2.3). Due to this immunosuppressive phenotype, MV 
infection is closely associated with severe secondary infections, which are the 
major causes of mortality. Encephalitis, blindness, middle ear infection (otitis 
media), pneumonia, and severe diarrhea are the most prominent diseases (Fig. 
3C). MV is also able to infect neurons and therefore can be the cause of diseases 
of the central nervous system (CNS) by itself. However, these cases are very 
rare (approx. 1 in 100,000 acute infections). If MV infection occurs in the early 
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childhood before the adaptive immune response has developed, some strains 
are able to persist in the host. Up to 15 years after initial infection, these viruses 
are able to reactivate and cause a slow, progressive disease with fatal outcome. 
This subacute sclerosing panencephalitis (SSPE) occurs in approx 1 in 10,000 – 
300,000 acute infections (Takasu et al., 2003) and manifests in progressive 
cognitive and motor losses, seizures, and organ failure (reviewed in (Young and 
Rall, 2009)). Other neuronal diseases resulting from MV infection are 
postinfectious encephalomyelitis (PIE; (Johnson et al., 1984)), and Measles 
inclusion body encephalitis (MIBE; reviewed in (Johnson, 1998)). 
All these complications emphasize the vaccination of the population against 
MV. So far, the World Health Organization (WHO) vaccination program resulted 
in a 74 % drop of MV mortality from the year 2000 (approx. 750,000 cases) to 
the year 2007 (approx. 197,000 cases) and the goal is to undercut 75,000 cases 
in 2010 (WHO/UNICEFJoint Statement, 2006; WHO, 2008). This goal is 
accomplishable especially due to the restriction of MV to human hosts and the 
lack of animal reservoirs. A comparable success was achieved in 1977, when 
the vaccination program led to the eradication of the smallpox virus (WHO, 
2009). However, a lack of adherence to vaccine recommendations is an 
increasing problem in industralized countries (Jansen et al., 2003), especially 
Germany. Here, in regular periods epidemics occur, like those in Hessen in 2005 
(Uphoff and Hauri, 2005), in Baden-Württemberg and Nordrhein-Westfalen in 
2006 (Siedler and Santibanez, 2006), in Nordrhein-Westfalen and Bavaria in 
2007 (van Treeck, 2007), in Baden-Württemberg and Mecklenburg-
Vorpommern in 2008 (Littmann, 2008) and in Nordrhein-Westfalen and 
Hamburg in 2009 (Jurke, 2009). 
 
1.2 Immune response to measles virus infection 
1.2.1 The Interferon system of the innate immune response 
Interferons (IFNs) are the most important cytokines involved in the antiviral 
immune response. These are small proteins, which are grouped into three 
classes. Type-I IFNs consist of the families of IFN-alpha (IFNα), IFN-beta (IFNβ), 
IFN-tau (IFNτ) and IFN-omega (IFNω). The family of IFNα is the broadest 
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amongst type-I IFNs, with 13 different genes: α1, α2, α4, α5, α6, α7, α8, α10, 
α13, α14, α16, α17, and α21, whereas IFNβ is encoded by a single gene only 
(reviewed in (Pestka et al., 2004)). IFN-gamma (IFNγ) makes up the class of 
type-II IFNs, whereas the latest family of IFN-lambda IFNλ (IFNλ1, IFNλ2, 
IFNλ3) is known as type-III IFN (Ank et al., 2006). All types of IFN are produced 
and secreted by the cell following the activation of distinct signaling pathways 
upon recognition of non-self pathogen associated molecular patterns (PAMPs) 
and other danger signals to the cell. 
 
Induction of interferon and proinflammatory cytokines by pattern 
recognition receptors 
PAMP recognition is triggered by cellular pattern recognition receptors (PRRs; 
for review see (Brzózka et al., 2007; Pichlmair and Reis e Sousa, 2007; Kawai 
and Akira, 2008; Kumar et al., 2009)). These are grouped in two classes: the 
first class that has been identified consists of the Toll-like receptors (TLRs; Fig. 
4A and B), membrane bound receptors containing leucine-rich repeats (LRRs) 
and intracellular Toll-interacting region (TIR) domains. Typical PAMPs are viral 
and bacterial nucleic acids (dsRNA: TLR3; ssRNA: TLR7/8; CpG-DNA: TLR9), or 
unusual proteins and protein modifications (peptidoglycans: TLR1/2/6; 
lipopolysaccaride (LPS): TLR4; flagellin: TLR5). Upon ligand binding, the TIR 
domain is activated and recruits a downstream signaling complex. Nucleic acid 
recognizing TLR3/7/8/9 are located in endosomal compartments, while all 
other TLRs are located at the cell surface. The second group of receptors, which 
also recognizes viral nucleic acids is located in the cytoplasm of cells and 
consists of a family of homologous helicases known as RIG-I-like receptors 
(RLRs; Fig. 4C). The first receptor identified is the retinoic acid inducible gene I 
(RIG-I), a RNA helicase which recognizes 5’-triphosphorylated (5’-ppp) 
ss/dsRNA (Hornung et al., 2006; Pichlmair et al., 2006; Cui et al., 2008). The 
melanoma differentiation-associated gene-5 (MDA-5) recognizing a so far 
unidentified RNA pattern which is contained in RNA of encephalomyocarditis 
virus (EMCV) and in synthetic poly(I:C), and laboratory of genetics and 
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Figure 4: Pathways of IFN induction and NF-κB activation by TLRs and RLRs. 
(A) MyD88-dependent induction of IFNα and activation of NF-κB by TLR7/8/9. (B) TRIF-
dependent induction of IFNβ and activation of NF-κB by TLR3. (C) IPS1-dependent induction of 
IFNβ and activation of NF-κB by RLRs RIG-I, MDA-5, and Lgp2. Color code: dark blue: receptors; 
dark red: adapter proteins; light red: kinases; light blue: E3 ubiquitin ligases; light green: 
scaffold proteins/kinases; orange: IRFs; pink: NF-κB and I-κB-α; P: phosphate residue. 
 
physiology 2 (Lgp2) complete this family of RNA helicases (Zou et al., 2009). 
They share a common architecture with two N-terminal caspase recruitment 
domains (CARDs), a DExD/H box helicase domain, and a C-terminal regulatory 
domain (RD). However, Lgp-2 lacks the CARDs. Upon recognition of viral 
nucleic acids by the RD and activation of the helicase, the CARDs are exposed 
and fulfill downstream signaling. 
The subfamily of TLR7/8/9 uses a common signaling complex (Fig. 4A), which 
is build up along the TIR-adapter protein myeloid differentiation primary 
response gene 88 (MyD88; (Honda et al., 2004)). This complex contains the E3 
ubiquitin ligases tumor necrosis factor-alpha receptor associated factor 6 
(TRAF6; (Kawai et al., 2004)) and TRAF3 (Oganesyan et al., 2006), the 
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Serine/Threonin kinases interleukin-1 receptor associated kinase (IRAK) 1 
(Uematsu et al., 2005) and IRAK4 (Kim et al., 2007), as well as the inhibitor of 
kappa-B kinase alpha (IKKα; (Hoshino et al., 2006)). The transcription factor 
interferon regulatory factor 7 (IRF7) is recuited to the signaling complex and 
activated in a concerted phosphorylation cascade (Honda et al., 2005). Upon 
activation, IRF7 builds homodimers, which translocate to the nucleus and bind 
to the promoter region of IFNα genes, thereby activating the transcription of 
multiple IFNα genes. 
A second group of proinflammatory cytokines is activated by TLR7/8/9. They 
are dependent on the activation of the nuclear factor kappa-B (NF-κB), which 
consists of two subunits p65 and p50. In the inactive form, NF-κB is complexed 
by the inhibitor of kappa-B-alpha (I-κB-α). Upon TLR activation, a 
heterotrimeric complex of the kinases IKKα, IKKβ, and IKKγ (= NF-kappa-B 
essential modulator, NEMO) is activated in a MyD88-dependent manner and 
phosphorylates I-κB-α. This leads to the degradation of I-κB-α and the release 
of NF-κB. This complex translocates to the nucleus and binds to the promoter 
regions of proinflammatory genes like interleukin-6 (IL-6). 
TLR3, which recognizes dsRNA, uses a different signaling complex compared to 
TLR7/8/9 (Fig. 4B). The TIR-domain-containing adapter-inducing interferon-
beta (TRIF) recruits TRAF3, and a kinase complex which is homologous to the 
IKK-complex and consists of IKKε, TANK-binding kinase 1 (TBK1), and the 
TRAF-associated NF-κB activator (TANK). The kinases are able to activate IRF3, 
and also IRF7, however, IRF3 is abundantly expressed in contrast to IRF7. 
Phospho-IRF3 dimers translocate to the nucleus as described for IRF7. IRF3-
dimers bind mainly to the promoter of the IFNβ gene. NF-κB is also activated by 
TLR3. 
The cytoplasmic RLRs use a different adapter protein, which is called 
interferon-beta promoter stimulator 1 (IPS1; Fig. 4C). This protein is also 
known as mitochondrial antiviral signaling protein (MAVS), virus-induced 
signaling adapter (VISA) or CARD-adapter inducing interferon-beta (CARDIF). 
It is located in the outer membrane of mitochondria (Kawai et al., 2005; Lin et 
al., 2006). RIG-I is thought to homodimerize upon ligand binding (Cui et al., 
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2008), while MDA-5 and Lgp2 may act by the formation of heterodimers, which 
still has to be proven. Upon exposure of the CARDs, these are able to bind to the 
CARD of IPS1. The signaling complex associated with IPS1 is similar to the TLR3 
complex and consists of TRAF3, TANK, TBK1, and IKKε. Other factors were 
identified recently to be involved (TNFRSF1A-associated via death domain, 
TRADD; TBK1 binding protein, TBK1BP; (Ryzhakov and Randow, 2007; 
Michallet et al., 2008)), but their contribution to the activation of IRF3 needs to 
be clarified. NF-κB activation is thought to be similar to TLR signaling. 
RLRs and the components of their signaling complex, as well as TLR3 are 
expressed almost ubiquitously in many cell types and therefore are thought to 
represent a general first line of defense against viral infections. In contrast, 
TLR7/8/9, and IRF7 are expressed constitutively only in specialized immune 
cells, the plasmacytoid dendritic cells (pDCs; (Hornung et al., 2002)), or, in 
other cell types, only after stimulation with IFNs. This places signaling of 
TLR7/8/9 in a special position at the intersection between innate and adaptive 
immune response, which will be discussed in section 1.2.2. 
While type-III IFN is upregulated by similar pathways as type-I IFN (Ank et al., 
2006), type-II IFN induction is different and will not be further explained. 
 
Type-I and type-II interferon signaling (JAK/STAT signaling) 
Upon expression, IFNs are secreted by the cell. As most cytokines, they are 
ligands for specific receptors and can activate the downstream signaling 
pathways in an autocrine or paracrine manner (Fig. 5). Type-I IFN (IFNα/β) 
binds to the type-I interferon receptor (or interferon-alpha receptor, IFNAR), 
which exists on the surface of nearly all cell types (Fig. 5A). This receptor 
belongs to the group of phospho-tyrosine receptors. Upon ligation, two 
subunits of the IFNAR (1/2) dimerize and form an intracellular signaling 
complex. Recruited Janus kinase 1 (JAK1) and tyrosin kinase 2 (TYK2) are 
phosphorylated by the receptor and phosphorylate the IFNAR1/2 subunits in 
return. This leads to the recruitment of signal transducers and activators of 
transcription (STAT) 1 and 2, which in turn are activated by tyrosin 
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phosphorylation at specific residues. Activated STAT1 and STAT2 form a 
heterotrimeric complex together with IRF9, which is called interferon-
stimulated gene factor 3 (ISGF3). This transcription factor translocates to the 
nucleus and binds to interferon stimulated response elements (ISRE), and 
promotes the expression of antiviral cytokines, so called Interferon stimulated 
genes (ISGs; reviewed in (Takaoka and Yanai, 2006; Brzózka et al., 2007)). 
Type-II IFN signaling is closely related to type-I IFN signaling. IFNγ binds to the 
type-II interferon receptor (or interferon-gamma receptor, IFNGR), which 
activates STAT1 via JAK1 and JAK2 (Fig. 5B). STAT1 homodimers translocate to 
the nucleus and bind to gamma activated sequences (GAS), a second promoter 
element for ISGs (reviewed in (Takaoka and Yanai, 2006; Brzózka et al., 2007)). 
 
 
Figure 5: Type-I and Type-II IFN signaling pathways.  
(A) Type-I IFN signaling by secreted IFNα and IFNβ in an autocrine or paracrine manner. 
Activation of ISRE-driven ISGs. IRF9, STAT1, and STAT2 form the ISGF3. (B) Type-II IFN 
signaling by IFNγ activates transcription of GAS-promoter driven ISGs. Color code: gold: 
interferons; dark blue: receptors; red: kinases: green: STATs; orange: IRF9. 
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Among ISGs there are proteins with direct antiviral properties, like 2’-5’-
oligoadenyl synthethase (2’-5’-OAS), or the Mx protein (Mx), but also signaling 
components of the IFN induction pathways are upregulated, like IRF7 and 
TLRs. This upregulation results in a positive feedback loop and further 
amplification of IFN production. To avoid overreaction of the system, also 
negative regulators of the signaling pathways are found among ISGs, like the 
suppressors of cytokine signaling (SOCS) 1 and 3, which inhibit further IFN 
signaling by interference with the JAK/STAT pathway (Song and Shuai, 1998). 
In addition to the upregulation of ISG expression, IFNs fulfill functions in 
activation of the adaptive immune response upon viral infections. 
 
1.2.2 MV specific adaptive immune response 
After initial infection, macrophages (MΦs) and dendritic cells (DCs) build a first 
line of defense of the innate immune response (Fig. 6). MV is recognized by 
TLR2 via a not completely characterized mechanism (Bieback et al., 2002), 
maybe by interaction with the H protein. This leads to the production of 
proinflammatory cytokines IL-1, IL-6, and IL-12p40. In contrast, type-I IFN 
production is very low in MV infection, as MV actively suppresses the induction 
of type-I IFNs in vivo and in vitro (Naniche et al., 2000; Schlender et al., 2005). 
Following the activation of the innate immune response, cell-mediated 
immunity and humoral responses are mobilized. 
An initial T-helper 1 (Th1)-response at the onset of the rash is characterized by 
the production of IFNγ and soluble Interleukin-2 receptor (IL-2R; (Griffin et al., 
1990)). Soluble CD8 and β-2 microglobulin are present in the serum (Griffin et 
al., 1992) and MV specific CD8+ cytotoxic T-lymphocytes (CD8+CTL) are set up 
and activated (van Binnendijk et al., 1990). In the convalescent phase, a shift 
towards a Th2-biased immune response takes place (“polarization”), which is 
characterized by the production of IL-4, IL-5, and IL-10 (Griffin and Ward, 
1993). This shift might contribute to the immunosuppressive phenotype of MV 
and the high susceptibility of MV infected persons to secondary infections 
(reviewed in (Schneider-Schaulies and Schneider-Schaulies, 2009); see also 
section 1.2.3). In the following, a short term effector memory leads to the 
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recovery from the infection and virus clearance. Long term central memory 
leads to the life-long protection from re-infection. 
Activation of B cells by MV specific epitope presentation (mainly from N, H, and 
F proteins) leads to the production of neutralizing IgG1 and IgG3 antibodies. 
Further affinity maturation builds up a serologic memory (IgG2 and IgG4 
antibodies), which is maintained by CD4+ T cells (TCD4+). This serologic 
memory results also in the life-long protection from re-infection and typically 
reaches titers of >200 mIU/mL of neutralizing antibodies (reviewed in 
(Naniche, 2009)). 
DCs play a pivotal role at the intersection of innate and adaptive immune 
response (for review see (Reis e Sousa, 2004; Kadowaki, 2009)). They can be 
 
 
Figure 6: Immune response to MV infection in vivo. 
Activation of the innate immune response in macrophages (MΦ) and dendritic cells (DC) leads 
to the upregulation of cytokines. This activates a T-cell mediated immune response, leading to 
the recovery through short-term effector memory, and a humoral response, leading to the 
production of neutralizing antibodies. Long-term cental memory and serologic memory lead to 
the life-long protection from re-infection (Adapted from (Naniche, 2009)). 
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grouped in DCs of myeloid origin (mDCs) and those of plasmycytoid origin 
(pDCs). While mDCs are the major antigen presenting cell type (APC) and play a 
crucial role in activation of T and B cell responses, pDCs are the most important 
cytokine producers during infection, with IFNα as the most important cytokine. 
MV possesses several options to subvert the immune response of the host, and 
some are closely connected to DC functions. These mechanisms will be 
explained in the following. 
 
1.2.3 Immunosuppression and immune antagonistic functions of MV 
Viruses have evolved multiple mechanisms to subvert the host immune 
response. Here, cell tropism and the infectious route determine the 
implementation of these antagonistic mechanisms (reviewed in (Brzózka et al., 
2007; Loo and Gale, Jr., 2007; Goodbourn and Randall, 2009)). In the case of 
MV, which predominantly infects immune cells, a very strong 
immunosuppression is induced upon infection. This includes at least three 
major mechanisms: (i) acute lymphopenia, (ii) silencing of peripheral blood 
lymphocytes (PBLs), and (iii) a strong cytokine imbalance (reviewed in 
(Schneider-Schaulies and Schneider-Schaulies, 2009)). Lymphopenia involves B 
cells, monocytes, neutrophils, as well as CD4+ and CD8+ T cells. Silencing of 
PBLs is mediated by the viral glycoproteins and does not require infection of 
the cells, but relies on the contact of the virus with the cell surface (Schlender et 
al., 1996). Cytokine imbalance leads to the polarization of the Th-response 
towards a Th2-biased immune response. This involves the modulation of DCs, 
which have been shown to be infected by MV in vitro (Minagawa et al., 2001). 
One mechanism is the interaction of MV with TLR2 (Bieback et al., 2002), which 
leads to the induction of the expression of the MV entry receptor CD150. MV in 
addition modulates antigen presentation as well as maturation of DCs. Type-I 
IFNs play a crucial role in this process of DC maturation (Klagge et al., 2000) 
and cytolytic activity (Vidalain et al., 2000). It has been shown that wt MV 
strains are only poor inducers of type-I IFNs (Naniche et al., 2000), whereas 
attenuated MVs induce higher amounts of IFN. Crucial for this is, for example, 
the accumulation of defective interfering RNAs (DI RNAs), which induce type-I 
IFNs in a RIG-I/MDA-5 dependent manner (Shingai et al., 2007). MV interferes 
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with signaling processes of the innate immune response on multiple steps, 
which have been characterized since a while on the molecular level. It has been 
shown that P and V are able to bind STAT1 and thereby inhibit its activation 
(Palosaari et al., 2003; Takeuchi et al., 2003; Caignard et al., 2007; Devaux et al., 
2007). It has also been shown that V in addition is able to bind to STAT2 (Ohno 
et al., 2004; Ramachandran et al., 2008) via a distinct protein domain, and also 
to MDA-5 (Andrejeva et al., 2004; Childs et al., 2007). These features are 
common to almost all viruses of the Paramyxoviridae family. However, MV 
exhibits also unique mechanisms to subvert the innate immune response. The 
suppression of TLR7/9 mediated induction of IFNα in pDCs upon infection with 
the MV Schwarz vaccine strain has been reported previously (Schlender et al., 
2005). Infected pDCs are unable to produce IFNα in response to the stimulation 
with external ligands for TLR7 (R848), or TLR9 (CpG-oligodeoxynucleotide 
(ODN) 2216). This mechanism might play a central role in the modulation of 
the host immune response by MV and is the major focus of this work. 
 
1.3 Aims of this thesis 
It was shown that MV is able to block the signal transduction of TLR7 and 9 
upon infection of pDCs (Schlender et al., 2005). However, the mechanism 
behind this inhibition remained unclear. It was the aim of this study to identify 
the viral antagonist of the TLR7/9 mediated induction of IFNα and to describe 
the molecular basis underlying this antagonistic function. For this purpose, 
biochemical assays were established and the role of distinct viral proteins was 
tested in transient expression experiments. In particular, the role of the P gene 
products P, V, and C was addressed, as these proteins have been described 
previously to comprise different ways to subvert the innate immune response. 
From the data, a model was created and fit into the other known and described 
antagonistic functions of viruses of the Paramyxoviridae family and especially 
MV. 
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2  Materials and Methods 
 
2.1  Materials 
2.1.1 Chemicals 
Fine chemicals were purchased from the following companies: 
Acetic acid glacial, Rotipuran 100 % p.a.   Roth 
Acetone, Rotipuran 99.8 % p.a.    Roth 
Ammoniumchloride     Merck 
Ammoniumpersulfate     Sigma-Aldrich 
Ampicillin sodium salt (Amp)    Roth 
Bacto yeast extract      BD 
Bacto Tryptone      BD 
β-Glycerophosphate disodium salt   Sigma-Aldrich 
β-Mercaptoethanol     Sigma-Aldrich 
Boric acid, ≥ 99.8 % p.a.     Roth 
Brilliant blue      Biorad 
Bromphenol blue      Sigma-Aldrich 
BSA, fraction V      Sigma-Aldrich 
Calciumchloride dihydrate    Sigma-Aldrich 
Chloramphenicol succinate sodium salt (CAM)  Sigma-Aldrich 
D-(+)-Glucose      Roth 
Disodium-hydrogenphosphate-dihydrate  Merck 
Dimethylsulfoxide (DMSO), p.a.    Roth 
DL-Dithiothreitol, BioUltra, ≥99.5% (DTT)  Sigma-Aldrich 
Ethylene-diamin-tetraacetic acid-disodium salt (EDTA)VWR Prolabo 
Ethylene glycol tetraacetic acid (EGTA)   Sigma-Aldrich 
Ethanol, p.a.      Merck 
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Ethidium bromide solution, 1 %    Roth 
Ficoll 400       Pharm. Fine Chem. 
Formic acid, p.a.      Merck 
Geneticin (G418 sulfate)     Invitrogen Gibco 
Glycerol, Rotipuran ≥ 99.5 %    Roth 
Glycine, > 99 % p.a.     Roth 
HEPES Pufferan      Roth 
Hydrochloric acid, Rotipuran 37% p.a.   Roth 
Hygromycin B      Calbiochem 
Imidazole       Merck 
Isopropyl β-D-1-thiogalactopyranoside (IPTG)  Roth  
Isopropanol, p.a.      Merck 
Kanamycin monosulfate salt (Kan)   Sigma-Aldrich 
Lithiumchloride, p.a.     Merck 
Magnesiumchloride-hexahydrate    Fluka 
Magnesiumsulfate-heptahydrate    Merck 
Methanol, p.a.      Merck 
Milk powder, blotting grade    Roth 
NP-40 Substitute      Fluka 
Orange G       Sigma-Aldrich 
Paraformaldehyde      Merck 
Polyethyleneimine (PEI), high MW, water-free  Sigma-Aldrich 
Phenol red       Merck 
Phenylmethylsulfonylfluoride (PMSF)   Serva 
Potassiumacetate, extra pure    Merck 
Potassiumchloride, p.a.     Merck 
Potassium-dihydrogenphosphate, p.a.   Merck 
Potassiumhydrogencarbonate    Merck 
Rotiporese Gel 40 (29:1) Acrylamide/Bisacrylamide  Roth 
Sodium-dodecylsulfate (SDS)    Serva 
Sodiumacetate-trihydrate, p.a.    Merck 
Sodiumchloride, p.a.     Merck 
Sodiumhydrogencarbonate    Merck 
Sodiumhydroxide      J.T.Baker 
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Sodiumorthovanadate     Sigma-Aldrich 
Tetramethylethylenediamine (TEMED)   Roth 
Tricine, Pufferan >99 %     Roth 
Tris, Pufferan ≥ 99.9 %     Roth 
Trisodiumcitrate-dihydrate >99 % p.a.   Roth 
Triton X-100      Merck 
Tween-20       Roth 
Urea, ≥ 99.5 % p.a.      Roth 
Xylenecyanol FF      Biorad 
 
2.1.2 Kits 
Plasmid purification: 
Nucleobond PC 100 (Macherey&Nagel) 
Cloning: 
QIAquick PCR Purification Kit (QIAGEN) 
QIAquick Nucleotide Removal Kit (QIAGEN) 
QIAquick Gel Extraction Kit (QIAGEN) 
RNA isolation: 
RNeasy Mini Kit (QIAGEN) 
Protein purification: 
QIAexpress Kit (QIAGEN) 
BCA Protein Assay Kit (Pierce) 
Transfection: 
Lipofectamine 2000 (Invitrogen) 
Mammalian Transfection Kit (Stratagene) 
Luciferase reporter gene assay: 
Dual-Luciferase Reporter Assay System (Promega) 
ELISA: 
Mouse Interferon Alpha (Mu-IFN-α) ELISA Kit (PBL) 
Northern blot: 
 Ready prime II Kit (GE Healthcare) 
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2.1.3 Enzymes 
All enzymes and supplied buffers were used as recommended by the suppliers. 
Restriction enzymes (New England Biolabs) 
DNA polymerases: 
BioPfu (biomaster) 
Herculase (Stratagene) 
RNase: 
RNase A (Macherey&Nagel) 
Phosphatase: 
Calf Intestine Alkaline Phosphatase (CIAP; New England Biolabs) 
Ligase: 
T4 DNA Ligase (New England Biolabs) 
Kinases: 
IKKα (CHUK; Invitrogen) 
IKKβ (Invitrogen) 
TBK1 (Invitrogen) 
 
2.1.4 Recombinant proteins and peptides 
Human Flt-3/Flk-2 Ligand (Flt3L; eBioscience) 
IκB-α (Santa Cruz) 
IFN A/D (universal type-I IFN; PBC Biomedical Lab) 
TNFα (mouse; Sigma-Aldrich) 
V240-264 WNGDRVFIDRWCNPMCSKVTLGTIR (Metabion) 
Vmut240-264 WNGDRVFIDRWCNPMCSKVAAAAIR (Metabion) 
V257-266 KVTLGTIRAR (Metabion) 
Vmut257-266 KVAAAAIRAR (Metabion) 
 
2.1.5 Antibodies 
Primary antibodies: 
 Anti-FLAG M2 (mouse monoclonal; Sigma-Aldrich) 
 Anti-FLAG M2 (rabbit polyclonal; Sigma-Aldrich) 
Anti-His tag (mouse monoclonal; Cell Signaling) 
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Anti-MV-C 1240 Sompong (rabbit polyclonal; R. Cattaneo) 
Anti-MV-N (mouse monoclonal; Millipore) 
Anti-MV-N-FITC (mouse monoclonal; Millipore) 
Anti-MV-P #37069 (rabbit polyclonal; D. Gerlier; (Chen et al., 2003)) 
Anti-MV-V Sompong (rabbit polyclonal; R. Cattaneo) 
Anti-p65(RelA) (rabbit polyclonal; Santa Cruz) 
Anti-RelB (rabbit polyclonal; Santa Cruz) 
Anti-RV-N-FITC (mouse monoclonal; FDI) 
Anti-RV-N/P (S50; rabbit polyclonal; J. Cox) 
Anti-RV-P (FCA05/1; rabbit polyclonal; Metabion) 
Anti-V5 mouse monoclonal; Invitrogen) 
 
Secondary antibodies: 
Anti-Mouse-Tetramethylrhodamin (Molecular Probes, Invitrogen) 
Anti-Mouse-IgG-HRP (Dianova) 
Anti-Rabbit-Alexa 488 (Molecular Probes, Invitrogen) 
Anti-Rabbit-IgG-HRP (Dianova) 
 
2.1.6 Oligonucleotides 
Oligonucleotides were purchased from Metabion. 
Primer No. Oligo Name Sequence 5'-3'
4 Flag-IRAK1 Acc65I 5' TATGGTACCGCCACCATGGACTACAAAGACGATG
ACGATAAAGCCGGGGGGCCGGGCCCG 
5 IRAK1 NotI 3' ATATGCGGCCGCTCAGCTCTGAAATTCATC
6 Flag-IRAK4 Acc65I 5' TATGGTACCGCCACCATGGACTACAAAGACGATG
ACGATAAAAACAAACCCATAACACCATCA 
7 IRAK4 NotI 3' ATATGCGGCCGCTTAAGAAGCTGTCATCTC
8 MePVdeltaC forw AGAGCAGGCACGCCACGTGAAAAACGGACTAGA
ATGCATCC 
9 MePVdeltaC rev TGGCGTGCCTGCTCTTCTGCCATGG 
10 Flag MV-PVdeltaC 
EcoRI 5' 
ATAGAATTCGCCACCATGGACTACAAAGACGATG
ACGATAAAGCAGAAGAGCAGGCACGC 
 
2  Materials and Methods  SUBVERSION OF TOLL-LIKE RECEPTOR 7/9 SIGNALING 
BY MEASLES VIRUS − V HOLDS THE KEY 
 
22 
Primer No. Oligo Name Sequence 5'-3'
11 Flag MV-C EcoRI 5' ATAGAATTCGCCACCATGGACTACAAAGACGATG
ACGATAAATCAAAAACGGACTGGAAT 
37 MV-P XhoI 3' ATACTCGAGCTACTTCATTATTATCTTCAT
38 MV-V XhoI 3' ATACTCGAGTTATTCTGGGATCTCGGGGAG
39 MV-C XhoI 3' ATACTCGAGTCAGGAGCTCGTGGATCTCCC
40 PV Nterm EcoRI 5' ATAGAATTCGCCACCATGGCAGAAGAGCAGGCA
42 V Cterm EcoRI 5' ATAGAATTCGCCACCATGCACAGACGCGAGATT
43 P Cterm XhoI 3' ATACTCGAGCTACTTCATTATTATCTT 
45 V Cterm XhoI 3' ATACTCGAGTTATTCTGGGATCTCGGG 
46 PV Nterm rev XhoI 3' ATACTCGAGTTACCCCTTTTTAATGGG 
47 P Cterm forw EcoRI 5' ATAGAATTCGCCACCATGACAGACGCGAGATTA
48 MV-PV NheI 5‘ ATAGCTAGCATGGCAGAAGAGCAGGCA 
49 MV-P NotI 3‘ ATATGCGGCCGCCTACTTCATTATTAT 
50 MV-V Not-I 3‘ ATATGCGGCCGCTTATTCTGGGATCTC 
59 MV-C NheI 5‘ ATAGCTAGCATGTCAAAAACGGACTGGAAT
60 MV-C NotI 3‘ TATAGCGGCCGCTCAGGAGCTCGTGGATCT
69 T7 Promoter Primer TAATACGACTCACTATAGGG 
70 T7 Terminator Primer GCTAGTTATTGCTCAGCGG 
93 IRF7 NheI fwd ATAGCTAGCATGGCTGAAGTGAGGGGG 
94 IRF7 NotI rev ATATGCGGCCGCTCAAGGCCACTGACC 
97 MV-V (165) NheI ATAGCTAGCATCACTGACCGGGGA 
98 MV-V (232) NheI ATAGCTAGCCACAGACGCGAGATT 
99 MV-V (164rev) NotI ATATGCGGCCGCTTAAGCATATCCCTCGGT
100 MV-V (231rev) NotI ATATGCGGCCGCTTACCCCTTTTTAATGGG
101 MV-P (232) NheI ATAGCTAGCACAGACGCGAGATTA 
104 IRF7-EcoRV-fwd ATAGATATCATGGCCTTGGCTCCTGAGAGG
105 IRF7-XhoI-rev TATCTCGAGCTAGGCGGGCTGCTCCAGCTC
106 IRF3-EcoRV-fwd ATAGATATCATGGGAACCCCAAAGCCACGG
107 IRF3-XhoI-rev TATCTCGAGTCAGCTCTCCCCAGGGCCCTG
110 H232D fwd CCCATTAAAAAGGGGGACAGACGCGAGATTAGCC
TCATTTGGA 
111 H232D,S237G fwd CCCATTAAAAAGGGGGACAGACGCGAGATTGGCC
TCATTTGGA 
113 H232D,S237G rev CCCCTTTTTAATGGGTGTCCCGGAA 
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Primer No. Oligo Name Sequence 5'-3'
114 T259A fwd ACCCAATGTGCTCGAAAGTCGCCCTCGGAACCAT
CAGGGCCAG 
115 T259A rev CTGGCCCTGATGGTTCCGAGGGCGACTTTCGAGC
ACATTGGGT 
116 C272R fwd CCAGGTGCACCTGCGGGGAACGTCCCCGAGTGTG
TGAGCAATG 
117 C272R rev CATTGCTCACACACTCGGGGACGTTCCCCGCAGG
TGCACCTGG 
126 SV5-V EcoRI fwd ATAGAATTCGCCACCATGGATCCCACTGAT
127 SV5-V XhoI rev TATCTCGAGTTAAGTATCTCGTTC 
128 SV5-V-MVV284-299 
XhoI rev 
TATCTCGAGTTATTCTGGGATCTCGGGGAGATTG
TGGTACCAGATTCGGGTGTCCACTCCAGTATCTC
GTTCACATTCAGAGCA 
129 MV-Vd284-299 XhoI 
rev 
TATCTCGAGTTATGTATCAGTGCGGCA 
130 SV5-V E183R fwd CAATCGGATGGGTGGGAGATAGAGTCAAGGTCA
CTGAGTGGTG 
131 SV5-V E183R rev CACCACTCAGTGACCTTGACTCTATCTCCCACCC
ATCCGATTG 
132 SV5-V F204A,E205R 
fwd 
TCACCGCTGCAGCAAGGCGAGCTAGATGCACTTG
TCACCAGTGTCC 
133 SV5-V F204A,E205R 
rev 
GGACACTGGTGACAAGTGCATCTAGCTCGCCTTG
CTGCAGCGGTGA 
134 MV-V R244E fwd GCCTCATTTGGAACGGAGATGAGGTCTTTATTGA
CAGGTGGTG 
135 MV-V R244E rev CACCACCTGTCAATAAAGACCTCATCTCCGTTCC
AAATGAGGC 
136 MV-V A265F,R266E 
fwd 
TCACCCTCGGAACCATCAGGTTCGAGTGCACCTG
CGGGGAATGTCC 
 
137 MV-V A265F,R266E 
rev 
GGACATTCCCCGCAGGTGCACTCGAACCTGATGG
TTCCGAGGGTGA 
140 MV-V 
R244E,F246R,D248F 
fwd 
GCC TCA TTT GGA ACG GAG ATG AGG TCC GTA 
TTT TCA GGT GGT GCA ACC CAA TGT G 
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Primer No. Oligo Name Sequence 5'-3'
141 MV-V 
R244E,F246R,D248F 
rev 
CAC ATT GGG TTG CAC CAC CTG AAA ATA CGG 
ACC TCA TCT CCG TTC CAA ATG AGG C 
142 MV-V 
244E,F246K,D248T 
fwd 
GCCTCATTTGGAACGGAGATGAGGTCAAAATTA
CCAGGTGGTGCAACCCAATGTG 
143 MV-V 
244E,F246K,D248T rev
CACATTGGGTTGCACCACCTGGTAATTTTGACCT
CATCTCCGTTCCAAATGAGGC 
144 MV-V 259AAAA fwd ACCCAATGTGCTCGAAAGTCGCCGCCGCAGCCAT
CAGGGCCAGGTGCACCTG 
145 MV-V 259AAAA rev CAGGTGCACCTGGCCCTGATGGCTGCGGCGGCGA
CTTTCGAGCACATTGGGT 
 
ODN 2216 CpG oligonucleotide type A (InvivoGen): 
GGG GGA CGA TCG TCG GGG GG 
Poly(I:C) (Sigma-Aldrich) 
 
2.1.7 Cell lines and media 
BSR-T7/5  
(BHK21-derived cells stably expressing T7 RNA polymerase)  G-MEM+4 
HEK-293T 
(Human embryonic kidney cells )     D-MEM+3 
HEp-2 
(Human epidermoid cancer cells)     D-MEM+2 
Huh7.5 
(Human hepatoblastoma cells, clone 7.5)    D-MEM+3 
U3A3 
(Human fibrosarcoma cells stably expressing GFP-LC3; L. Fragnet) D-MEM+3 
Vero 
(African Green Monkey kidney cells)     D-MEM+3 
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Cell culture media and supplements: 
• Dulbecco's Modified Eagle Medium (D-MEM)  Invitrogen 
• Earles Balanced Salt Solution (EBSS)    Invitrogen 
• Glasgow Minimum Essential Medium BHK-21 (G-MEM) Invitrogen 
• VLE-RPMI 1640      Biochrom 
• Trypsin/EDTA       Invitrogen 
• 100x Glutamine      Invitrogen 
• Non-essential amino acids (NEAA)    Invitrogen 
• Tryptose-phosphate broth     Invitrogen 
• Penicillin/Streptomycin     Invitrogen 
• Fetal bovine serum (FBS)     Invitrogen 
• Newborn calf serum (NCS)     Invitrogen 
 
D-MEM+3 
= D-MEM + 10 % (v/v) FBS + 1 % (v/v) 100x L-Glutamine + 
Penicillin/Streptomycin 
 
D-MEM+2 
= D-MEM + 5 % (v/v) FBS + Penicillin/Streptomycin 
 
G-MEM+4 
= G-MEM + 10 % (v/v) NCS + 4 % (v/v) Tryptose-phosphate broth + 2 % (v/v) 
NEAA + Penicillin/Streptomycin 
 
RPMI+5 
= VLE-RPMI 1640 + 10 % (v/v) FBS + 1 % (v/v) l-Glutamine + 1 % Sodium-
pyruvate (v/v) + 1 % NEAA (v/v) + Penicillin/Streptomycin 
 
2.1.8 Viruses 
All recombinant rabies viruses are derived from SAD-L16, a recombinant RV 
carrying the nucleotide sequence (completely sequenced) of the Street Alabama 
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Dufferin (SAD) B19 strain (NCBI accession no. EF206709; (Conzelmann et al., 
1990)), which is an attenuated strain used for the oral immunization of foxes. 
Measles virus was originated from a commercial batch of the Schwarz vaccine 
strain (MV(Schwarz); NCBI accession no. AF266291; (Schwarz, 1964)) and 
produced through 10 passages on HEp-2 cells and 2 passages on Vero cells (S. 
Moghim). 
2.1.9 Plasmids and bacteria 
Following bacteria strains were used for 
plasmid DNA amplification: XL-1 Blue Supercompetent Cells (Stratagene) 
recombinant protein expression: Rosetta (DE3) Competent Cells (Novagen) 
 
Plasmids commercially available were purchased from following companies: 
pCR3   Invitrogen  eukar. expr. vector (CMV promoter) 
pDNR-LIB-IRAK4  RZPD  vector with IRAK4 cDNA 
pISRE-Luc   Clontech  firefly luciferase (ISRE controlled) 
pEGFP-N3  Clontech  eGFP vector (CMV promoter) 
pET28a   Novagen  6xHis-tag bacterial expression vector 
pNF-κB-Luc  Stratagene  firefly luciferase (NF-κB promoter) 
pOTB7-IRAK1  RZPD  vector with IRAK1 cDNA 
pOTB7-IRAK1c  RZPD  vector with IRAK1c cDNA 
pRL-CMV  Promega  renilla luciferase (CMV promoter) 
 
The following plasmids were kindly provided: 
p55C1B-Luc   T. Fujita (Yoneyama et al., 1998) 
pCDNA3.1-Flag-IRF3  J. Hiscott (Lin et al., 2000) 
pCDNA3.1-TRAF6  A. Kieser (Schultheiss et al., 2001) 
pCOOL-PIV5-V  N. Zheng (Li et al., 2006) 
pFLAG-CMV2-hIRF7  J. Hiscott (Lin et al., 2000) 
pFLAG-CMV2-mIRF7 S. Akira (Kawai et al., 2004) 
pFLAG-IKKε  K. Ruckdeschel (expression vector for Fl-IKKε) 
pGL3-IFNα4-Luc  S. Akira (Kawai et al., 2004) 
pGL3-IFNα6-Luc   S. Akira (Kawai et al., 2004) 
pIRF3-5D  J. Hiscott (Lin et al., 2000) 
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pIRF7-2D  J. Hiscott (Lin et al., 2000) 
pRK5- IKKβ-Fl   K. Ruckdeschel (expression vector for Fl-IKKβ (C-term. 
tag!)) 
pRK7-Fl-IKKα   K. Ruckdeschel (expression vector for Fl-IKKα) 
pRK7-myc-MyD88  K. Ruckdeschel (expression vector for myc-MyD88) 
 
Plasmids generated in the lab: 
pCR3-Ig    K. Brzózka (pCR3 with Ig-tag sequence upstream of MCS) 
pCR3-MV-C   S. Moghim (pCR3 with MV C ORF) 
pCR3-MV-P   S. Moghim (pCR3 with MV P mRNA) 
pCR3-MV-V   S. Moghim (pCR3 with MV V mRNA) 
pCR3-RV-P   K. Brzózka (pCR3 with RV P ORF) 
pFLAG-TBK1   K. Brzózka, S. Marozin (expression vector for Fl-TBK1) 
pSAD-G-DsRed   S. Finke (pSAD-L16 with add. DsRed gene behind G gene) 
pSAD-L16   K. Conzelmann (Schnell et al., 1994) 
pSAD-PΔIND2   K. Brzózka (Brzózka et al., in preparation) 
pTIT-RV-L   S. Finke (Finke and Conzelmann, 1999) 
pTIT-RV-N   S. Finke (Finke and Conzelmann, 1999) 
pTIT-RV-P   S. Finke (Finke and Conzelmann, 1999) 
 
Plasmids generated during this thesis: 
plasmid name template primer 
pair 
restriction 
sites 
vector 
backbone 
pCR3-Fl-MV-PΔC pCR3-MV-PΔC 10, 37 EcoRI, XhoI pCR3 
pCR3-Fl-MV-VΔC pCR3-MV-VΔC 10, 38 EcoRI, XhoI pCR3 
pCR3-Fl-MV-C pCR3-MV-C 11, 39 EcoRI, XhoI pCR3 
pCR3-Ig-MV-P pCR3-MV-PΔC --- EcoRI, NotI pCR3-Ig-RV-P
pCR3-Ig-MV-V pCR3-MV-VΔC --- EcoRI, NotI pCR3-Ig-RV-P
pCR3-Ig-MV-C pCR3-MV-C --- EcoRI, NotI pCR3-Ig-RV-P
pCR3-Ig-MV-PVN pCR3-MV-VΔC 40, 46 EcoRI, XhoI pCR3-Ig
pCR3-Ig-MV-PC pCR3-MV-PΔC 47, 43 EcoRI, XhoI pCR3-Ig
pCR3-Ig-MV-VC pCR3-MV-VΔC 42, 45 EcoRI, XhoI pCR3-Ig
pCR3-MV-VΔ284-
299 
pCR3-MV-VΔC
 
40, 129
 
EcoRI, XhoI 
 
pCR3 
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plasmid name template primer 
pair 
restriction 
sites 
vector 
backbone 
pET28a-MV-PΔC pCR3-MV-PΔC 48, 49 NheI, NotI pET28a 
pET28a-MV-VΔC pCR3-MV-VΔC 48, 50 NheI, NotI pET28a 
pET28a-MV-
V(165-299) 
pCR3-MV-VΔC
 
97, 50
 
NheI, NotI 
 
pET28a 
 
pET28a-MV-
V(232-299) 
pCR3-MV-VΔC
 
98, 50
 
NheI, NotI 
 
pET28a 
 
pET28a-MV-PVN pCR3-MV-VΔC 48, 100 NheI, NotI pET28a 
pET28a-MV-PV(1-
164) 
pCR3-MV-VΔC
 
48, 99
 
NheI, NotI 
 
pET28a 
 
pET28a-MV-
PC(232-507) 
pCR3-MV-PΔC
 
101, 49
 
NheI, NotI 
 
pET28a 
 
pCR3-PIV5-V pCOOL-PIV5-V 126, 127 EcoRI, XhoI pCR3 
pCR3-PIV5-V:MV-
V284-299 
pCOOL-PIV5-V
 
126, 128
 
EcoRI, XhoI 
 
pCR3 
 
pSAD-G-MVP pCR3-MV-PΔC 48, 49 NheI, NotI pSAD-G-DsRed
pSAD-G-MVV pCR3-MV-VΔC 48, 50 NheI, NotI pSAD-G-DsRed
pSAD-G-MVC pCR3-MV-C 59, 60 NheI, NotI pSAD-G-DsRed
pSAD-PΔIND2-G-
MVP 
pSAD-G-MVP
 
---
 
SnaBI, MluI 
 
pSAD-
PΔIND2(49.1) 
pSAD-PΔIND2-G-
MVV 
pSAD-G-MVV
 
---
 
SnaBI, MluI 
 
pSAD-
PΔIND2(49.1) 
pSAD-PΔIND2-G-
MVC 
pSAD-G-MVC
 
---
 
SnaBI, MluI 
 
pSAD-
PΔIND2(49.1) 
pCR3-Fl-IRAK1 pOTB7-IRAK1 4, 5 Acc65I, NotI pCR3 
pCR3-Fl-IRAK1c pOTB7-IRAK1c 4, 5 Acc65I, NotI pCR3 
pCR3-Fl-IRAK4 pDNR-LIB-IRAK4 6, 7 Acc65I, NotI pCR3 
pCDNA3.1-FL-
IRF3-5D 
pIRF3-5D
 
106, 107
 
EcoRV, XhoI 
 
pCDNA3.1-
Flag-IRF3 
pCDNA3.1-FL-
IRF7-2D 
pIRF7-2D
 
104, 105
 
EcoRV, XhoI 
 
pCDNA3.1-
Flag-IRF3 
pET28a-IRF7 pFLAG-CMV2-mIRF7 93, 94 NheI, NotI pET28a 
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plasmid name strategy template primer 
pair 
pCR3-MV-PΔC mutagenesis pCR3-MV-P 8, 9
pCR3-MV-VΔC mutagenesis pCR3-MV-V 8, 9
pCR3-MV-V(H232D) mutagenesis pCR3-MV-VΔC 110, 113
pCR3-MV-V(H232D,S237G) mutagenesis pCR3-MV-VΔC 111, 113
pCR3-MV-V(T259A) mutagenesis pCR3-MV-VΔC 114, 115
pCR3-MV-V(C272R) mutagenesis pCR3-MV-VΔC 116, 117
pCR3-MV-V(H232D,C272R) mutagenesis pCR3-MV-V(H232D) 116, 117
pCR3-MV-V(R244E) mutagenesis pCR3-MV-VΔC 134, 135
pCR3-MV-V(A265F,R266E) mutagenesis pCR3-MV-VΔC 136, 137
pCR3-MV-V(R244E,F246R,D248F) mutagenesis pCR3-MV-VΔC 140, 141
pCR3-MV-V(R244E,F246K,D248T) mutagenesis pCR3-MV-VΔC 142, 143
pCR3-MV-
V(T259A,L260A,G261A,T262A) 
mutagenesis pCR3-MV-VΔC 144, 145
pCR3-PIV5-V(E183R) mutagenesis pCR3-PIV5-V 130, 131
pCR3-PIV5-V(F204A,E205R) mutagenesis pCR3-PIV5-V 132, 133
 
2.1.10 Buffers and solutions 
Mini Preparation 
Flexi I 100
10
200
mM
mM 
µg/mL 
Tris-HCl, pH 7.5 
EDTA 
Rnase 
 
Flexi II 200
1
mM
% (w/v) 
NaOH
SDS 
 
Flexi III 3
2
M
M 
K-acetate
Acetic acid, pH 5.75 
 
Immuneprecipitation 
Co-IP buffer 50
150
2
1
0.5
1
mM
mM 
mM 
mM 
% (v/v) 
tablet 
Tris-HCl, pH 7.5 
NaCl 
EDTA 
Na3VO4 
NP-40 substitute 
Complete protease inhibitor 
cocktail / 50 mL 
 
Protein gels
10 % APS 10 % (w/v) Ammoniumpersulfate 
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Jagow gel buffer 3
0.3
M
% (w/v) 
Tris-HCl, pH 8.45 
SDS 
 
Jagow anode buffer 2 M Tris-HCl, pH 8.9 
 
Jagow kathode buffer 1
1
1
M
M 
% (w/v) 
Tris-HCl, pH 8.25 
Tricine 
SDS 
 
Protein lysis buffer 62.5
2
10
6
5
0.01
0.01
mM
% (v/v) 
% (v/v) 
M 
% (v/v) 
% (w/v) 
% (w/v) 
Tris-HCl, pH 6.8 
SDS 
Glycerine 
Urea 
β-Mercapto ethanol 
Bromphenol blue 
Phenol red 
 
Coomassie staining 
Staining solution 50
10
0.1
% (v/v)
% (v/v) 
% (w/v) 
Methanol
Acetic acid 
Brilliant blue 
 
Wash solution 50
10
% (v/v)
% (v/v) 
Methanol
Acetic acid 
 
Western blotting 
10x Semi dry buffer 480
390
0.05
mM
mM 
% (w/v) 
Tris-HCl, pH 8.6 
Glycine 
SDS 
 
1x Semi dry buffer 100
180
720
mL
mL 
mL 
10x Semi dry buffer 
Methanol abs. 
H2O 
 
1x PBS 1.37
27
12
65
M
mM 
mM 
mM 
NaCl
KCl 
KH2PO4 
Na2HPO4x2H2O (pH 7.4) 
 
PBS-Tween 1
0.05
X
% (v/v) 
PBS
Tween-20 
 
Agarose gels
10x TAE 2
0.25
0.25
M
M 
M 
Tris-HCl, pH 7.8 
Na-acetate trihydrate 
EDTA 
 
1x TAE +EtBr 300
2700
150
mL
mL 
µL 
10x TAE
H2O 
Ethidium bromide solution 1 % 
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OG loading buffer 50
15
0.125
% (v/v)
% (w/v) 
% (w/v) 
10x TAE
Ficoll 400 
Orange G 
 
10x TE 100
10
mM
mM 
Tris-HCl, pH 7.5 
EDTA 
 
Blue juice 0.125
0.125
0.125
15
50
% (w/v)
% (w/v) 
% (w/v) 
% (w/v) 
% (v/v) 
Bromphenol blue 
Xylenecyanol 
Orange G 
Ficoll 400 
10x TAE 
 
1 kb marker buffer 380
100
20
µL
µL 
µL 
1x TE
Blue juice 
1 kb DNA ladder 
 
Northern blot 
RNA agarose gel 2
4
26.7
167.3
g
mL 
mL 
mL 
Agarose (RNA grade) 
50x Phosphate buffer 
Formaldehyde, 37 % 
H2O ultra pure 
 
50x Phosphate buffer 250
250
mM
mM 
Na2HPO4x2H2O (pH 6.8-7.0) 
NaH2PO4xH2O 
 
Glyoxal solution 8.8 M Glyoxal
 
10x SSC 1.5
150
M
mM 
NaCl
Na-citrate x2H2O (pH 7.0) 
 
Zeta Hybridising buffer 250
250
1
7
mM
mM 
mM 
% (w/v) 
Na2HPO4x2H2O (pH 7.2) 
NaH2PO4xH2O 
EDTA 
SDS 
 
Zeta Wash buffer 5 % 8
1
5
% (v/v)
mM 
% (w/v) 
50x Phosphate buffer 
EDTA 
SDS 
 
Zeta Wash buffer 1 % 8
1
1
% (v/v)
mM 
% (w/v) 
50x Phosphate buffer 
EDTA 
SDS 
 
Bacteria growth media 
LB 85
0.5
1
1
mM
% (w/v) 
% (w/v) 
mM 
NaCl
Bacto yeast extract 
Bactotryptone 
MgSO4 
 
LB++ 1
20
10
X
mM 
mM 
LB
MgSO4 
KCl 
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Ni-NTA purification 
5x Lysis/wash buffer 250
1
75
mM
M 
mM 
KH2PO4, pH 7.5 
NaCl 
Imidazole 
 
5x Elution buffer 250
1
1.5
mM
M 
M 
KH2PO4, pH 7.5 
NaCl 
Imidazole 
 
1x Lysis/wash buffer /
1x Elution buffer 
20
0.07
% (v/v)
% (v/v) 
5x buffer
β-Mercaptoethanol 
 
In vitro assay buffers 
5x Kinase assay buffer 125
0.05
50
5
2.5
25
10
mM
% (v/v) 
mM 
mM 
mM 
mM 
mM 
HEPES, pH 7.5 
Triton X-100 
MgCl2 
EGTA 
Na3VO4 
β-Glycerophosphate 
DTT 
 
Kinase dilution buffer 20
10
0.02
0.1
0.5
2
mM
% (v/v) 
% (v/v) 
mg/mL 
mM 
mM 
Tris-HCl, pH 7.5 
Glycerol 
Triton X-100 
BSA 
Na3VO4 
DTT 
 
Immunofluorescence 
3 % PFA/PBS 1
3
X
% (w/v) 
PBS
Paraformaldehyde 
 
80 % Acetone 800
200
mL
mL 
Acetone p.a.
H2Odd 
 
50 mM NH4Cl/PBS 1
50
X
mM 
PBS
NH4Cl 
 
0.5 % Triton X-100/ PBS 1
0.5
X
% (v/v) 
PBS
Triton X-100 
 
0.1 % Triton X-100/ PBS 80
20
% (v/v)
% (v/v) 
1x PBS
0.5 % Triton X-100/PBS 
 
Cell preparation 
Erythrocyte lysis buffer 
(ACK) 
1
150
0.1
mM
mM 
mM 
KHCO3, pH 7.4 
NH4Cl 
EDTA 
Cell culture 
5 mM EDTA/PBS 1
5
X
mM 
PBS
EDTA 
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Phosphate-free Krebs-
Ringer-Bicarbonate 
Medium (PKRB) 
20
118
4.75
1.2
0.2
25
10
mM
mM 
mM 
mM 
mM 
mM 
mM 
HEPES, pH 7.5 
NaCl 
KCl 
MgCl2 
CaCl2 
NaHCO3 
D-Glucose 
 
2.1.11 Equipment 
Berthold Centro LB960 luminometer 
Biometra® Standard Power Pack P25 
Biometra® Thermocycler T3 
Biometra® Vacu-Blot System 
BioRAD Gel Doc System 
Branson Digital Sonifier W-250 D 
Daewoo C.R.S. microwave oven 
Eppendorf Centrifuge 5417C (rotor F45-30-11) 
Eppendorf Centrifuge 5804R (rotor F-45-30-11) 
Eppendorf Mixer 5432 
Eppendorf Pipettes (2.5 / 10 / 20 / 100 / 200 / 1000 µL) 
Eppendorf Thermomixer 5436 
Gilson Pipettes (2 / 10 / 20 / 200 / 1000 µL) 
Heraeus Variofuge 3.0R (rotor #8074) 
Hermle Centrifuge Z160M 
IBS Pipetboy acu 
IBS Vacusafe comfort vacuum pump system 
IKA® Minishaker MS1 
Integra Biosciences Fireboy plus 
Kern GJ Balance 
Kühner bacteria shaker ISF-1-W 
Labotect Forma Scientific Water-Jacketed Incubator 3250 
Liebherr Freezer GU1202 
Liebherr Fridge KU1710 
Marienfeld Neubauer improved counting chamber 
Molecular Devices Versamax microplate reader 
Molecular Dynamics PhosphoScreen 
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Molecular Dynamics Storm Scanner 
MS Laborgeräte Optimax Typ TR developing machine 
Nikon TMS light microscope 
Nunc™ ilShin® Deep freezer 
Olympus IX71 UV-light microscope 
Peqlab Horizontal Gel System S/M/L/XL 
Peqlab Nanodrop ND-1000 Spectrophotometer 
Peqlab Semi Dry Blotting System 
Peqlab Vertical Gel Electrophoresis System (Size S/M/L) 
Pharmacia Biotech Electrophoresis Power Supply EPS 200 
Sorvall Centrifuge Evolution RC (SLC6000 and SS34 rotors) 
Stuart roller mixer SRT2 
The Baker Company Sterilguard Class II Type A/B3 sterile workbench 
Thermo Scientific Nanodrop ND-1000 
Vacuubrand Vacuum Pump Unit ME 2S 
VELP Scientifica Magnetic Stirrer/heater Unit 
Zeiss LSM-510 Laser Scanning Microscope (Ar- / HeNe 633nm- / HeNe 543nm-
laser) 
 
2.1.12 Miscellaneous 
0.25 mL polypropylene reaction tubes (Eppendorf) 
0.5 / 1.5 / 2 mL polypropylene reaction tubes (Eppendorf) 
0.5 – 10 kb RNA ladder (Invitrogen) 
1 kb DNA ladder (Invitrogen) 
15 / 50 mL reaction tubes (BD Falcon®) 
18 x 18 mm Coverslips (Roth) 
2 / 10 / 20 / 200 / 1000 µL SafeSeal® Tips (Biozym®) 
2 mL serological pipettes (costar) 
3.5 / 6 / 10 cm cell culture dishes (BD Falcon®) 
5 / 10 / 25 mL serological pipettes (Sarstedt) 
6 / 12 / 24 / 48 / 96-well multiwell™ plates (BD Falcon®) 
Agarose Electrophoresis grade (Invitrogen) 
Amicon Ultra-15 Centrifugal Filter Devices MWCO 10,000 (Millipore) 
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Anti-FLAG® M2 Affinity Gel (Sigma-Aldrich) 
ATP (Sigma-Aldrich) 
ATP, gamma[32P]- (Hartmann Analytic) 
CTP, alpha[32P]- (Hartmann Analytic) 
dNTP Set (BIOLINE) 
Duralon-UV™ membranes (Stratagene®) 
Hyperfilm-ECL (GE Healthcare Amersham) 
Immobilon-P (PVDF) membrane (Millipore) 
Low molecular weight DNA marker (New England Biolabs) 
Microscope slides, 76 x 26 mm (Roth) 
Nitrocellulose membrane (Schleicher&Schuell) 
Nunclon 60-well plates (Nunc™) 
Precision Plus Protein Standard All Blue (Biorad) 
Protein A-HRP (Zymed) 
Protein A-Sepharose (GE Healthcare) 
SnakeSkin Pleated Dialysis Tubing 3,500 MWCO (Pierce) 
T25 / T75 / T125 cell culture flasks (BD Falcon®) 
Western lightning chemiluminescence reagent plus (Perkin-Elmer) 
Whatman paper (3MM) 
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2.2  Methods 
2.2.1  Molecular biological methods 
2.2.1.1 Cloning and mutagenesis 
Polymerase-chain-reaction (PCR) 
Standard reaction batches for the amplification of DNA fragments contained: 
100 – 500 ng template DNA
0.25 µM primer A (fwd)
0.25 µM primer B (rev)
10 % 
(v/v) 
DMSO
1 X reaction buffer
0.25 µM dNTPs (each)
2.5 U DNA Polymerase
@ 100 µL H2Odd
In case of fragments below 5,000 bp bioPfu DNA polymerase (biomaster) was 
used for amplification. Herculase (Stratagene) was used for the amplification of 
bigger fragments. 
A typical PCR program consisted of the following elements: 
# temperature time function slope 
1 95 °C/ 98 °C 60 s/ 30 s enzyme activation
2 95 °C/ 98 °C 30 s/ 10 s melting
30 – 35 cycles 
3 42 – 50 °C 30 s primer annealing
4 72 °C 1 min/ 500 bp 
(bioPfu) 
or 
15 s/ 1000 bp 
(Herculase) 
elongation
5 72 °C 10 – 20 min final elongation
6 4 °C ∞ cooling
PCR fragments were purified using the QIAquick PCR Purification Kit (QIAGEN). 
 
 
 
 
2  Materials and Methods  SUBVERSION OF TOLL-LIKE RECEPTOR 7/9 SIGNALING 
BY MEASLES VIRUS − V HOLDS THE KEY 
 
37 
Mutagenesis PCR 
These reactions were carried out to introduce nucleotide mutations into 
plasmids: 
100 – 500 ng template DNA
0.25 µM primer A (fwd)
0.25 µM primer B (rev)
1 X reaction buffer
0.25 µM dNTPs (each)
2.5 U DNA Polymerase
@ 100 µL H2Odd
 
# temperature time function slope 
1 95 °C/ 98 °C 60 s/ 30 s enzyme activation
2 95 °C/ 98 °C 30 s/ 10 s melting
 
 
 
18 - 20 
cycles 
3 42 – 50 °C 30 s Primer annealing
4 72 °C 1 min/ 500 bp 
(bioPfu) 
or 
15 s/ 1000 bp 
(Herculase) 
elongation
5 72 °C 10 min final elongation
6 4 °C ∞ cooling
 
Upon completion of PCR, template DNA was digested using 2.5 U of the 
restriction enzyme DpnI, which was added directly to the PCR reaction batch 
(37 °C, 1 – 4 h). Mutagenesis PCR batches were transformed directly into XL-1 
Blue chemically-competent cells without additional purification of the DNA. 
 
Agarose gel electrophoresis 
Gels containing 1x TAE and 1 % agarose were used to analyze the length of PCR 
products and restrictions. For the analysis of fragments > 10,000 bp, gels 
containing 0.7 % agarose were used and for fragments < 500 bp, gels 
containing 2 % agarose were used. 
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Probes were mixed with 20 % (v/v) Orange G, loaded onto the gels and 
subjected to electrophoresis at 120 – 140 V for 30 – 150 min, depending on the 
length of the fragments and agarose concentration. Electrophoresis buffer 
contained 1 x TAE and 50 µL/L of a 1 % Ethidiumbromide solution. 
Gels were analyzed on a Biorad GelDoc System using UV light. 
 
Restriction assays 
1 µg of plasmid was digested with restriction enzymes to verify them by their 
restriction pattern. Reactions were performed in 10 µL total volume as 
recommended by the supplier. 
To create sticky ends in PCR fragments or for quantitative plasmid restriction, 5 
– 10 µg of DNA was digested in a total volume of 50 µL. 
 
Gel extraction 
DNA fragments were subjected to agarose gel electrophoresis and bands of 
required length were cut out of the gel. DNA was purified from the gel slice 
using the QIAquick Gel Extraction Kit (QIAGEN). 
Ligation 
DNA fragments and vector backbones were ligated using T4 DNA Ligase (New 
England Biolabs). Reaction batches contained: 
0.5 µL Purified vector backbone
7 µL Purified DNA fragment
1 X T4 DNA Ligase reaction buffer 
200 U T4 DNA Ligase
@ 20 µL H2Odd
Reactions were incubated either at R.T. for 2 h or at 16 °C o/n. 10 µL of the 
reaction were transformed directly into XL-1 Blue chemically-competent cells 
without further purification. 
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2.2.1.2 Working with bacteria 
Transformation 
50 µL of the chemical-competent strain XL-1 Blue were thawed on ice and 0.5 – 
1 µg of plasmid DNA was added. The mixture was incubated for 20 min on ice, 
followed by a heat shock (42 °C, 2 min) and repeated incubation on ice for 2 
min. Afterwards, 200 µL of LB++ medium were added and the bacteria were 
shaken at 37 °C for at least 30 min (~800 rpm). 
In case of transformation of bacteria for expression of recombinant protein, 20 
µL of the chemical-competent strain Rosetta (DE3) were used instead of XL-1 
Blue. 
 
Plating 
Transformed bacteria were plated on LB-agar plates supplied with 25 mg/mL 
of antibiotics (ampicillin, kanamycin, chloramphenicol) according to the 
resistance genes on the transformed plasmids. The plates were incubated at 37 
°C o/n until single bacteria colonies were visible. 
 
Liquid culture 
For Mini preparation, single colonies were inoculated into 1 mL of LB-medium 
supplied with 25 mg/mL of antibiotics and shaken at 37 °C  o/n. 
For Midi preparation, 75 µL of the suspension of transformed bacteria were 
directly inoculated to 50 mL of LB-medium supplied with 25 mg/mL of 
antibiotics and shaken at 37°C o/n. 
For expression of recombinant proteins, single colonies were inoculated into 1 
mL of LB-medium supplied with 25 mg/mL of kanamycin and 25 mg/mL of 
chloramphenicol and shaken at 37 °C o/n. 
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Glycerol stocks 
For expression of recombinant proteins, o/n liquid cultures were mixed with an 
equal amount of pure glycerol and stored at -86 °C. These stocks were used to 
inoculate 50 mL liquid cultures (see 2.2.3.9). 
 
2.2.1.3 Plasmid preparation 
Mini Preparation 
1 mL of an o/n culture of transformed bacteria was pelleted (14,000 rpm, 1 
min, R.T.) and the supernatant was discarded. The pellet was resuspended in 
200 µL of Flexi I solution. 200 µL of Flexi II solution were added, mixed gently 
and incubated at R.T. for 5 min. After complete lysis of the bacteria, 200 µL of 
Flexi III solution were added, mixed gently and incubated on ice for another 5 
min. The resulting debris was pelleted by centrifugation (14,000 rpm, 7 min, 
R.T.) and the cleared lysate was mixed with 400 µL of pure Isopropanol. 
Plasmid DNA was pelleted by centrifugation (14,000 rpm, 7 min, R.T.), the 
supernatant was discarded, the pellets were dried at R.T. and resolved in 50 µL 
H2Odd by shaking for several minutes. 
 
Midi Preparation 
Plasmid DNA for transfection experiments was extracted from 50 mL of an o/n 
culture of transformed bacteria using the Nucleobond AX-100 Kit 
(Macherey&Nagel) according to the manufacturer’s proceedings. 
DNA concentration was determined using the Nanodrop 1000 (Peqlab) and 
DNAs were stored at -20 °C. 
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2.2.1.4 Sequencing 
Sequencing reactions were performed by MWG Eurofins (Martinsried, 
Germany) using the Value Read Tube protocol. 1 – 2 µg of template DNA were 
mixed with 15 pmol of a sequencing oligo and the total volume was adjusted 
with H2Odd to 15 µL. 
The results were analyzed electronically using the DNAMAN (Version 5.0 or 
higher) and Chromas (Version 1.45) software. 
 
2.2.1.5 RNA isolation 
Total cellular RNA was isolated using the RNeasy Mini Kit (QIAGEN). 1x106 cells 
were lysed in 200 – 400 µL buffer RLT containing 0.1 % β-mercapto ethanol. 
The lysates were mixed with 1 equivalent of DEPC treated 70 % ethanol and 
mixed thoroughly. The lysates then were loaded onto columns and centrifuged 
(10,000 rpm, 30 s, R.T.). The flow through was discarded and the colums were 
washed once with 700 µL of buffer RW1 and two times with 500 µL of buffer 
RPE again by centrifugation (10,000 rpm, 30 s, R.T.).  Afterwards, the columns 
were centrifuged two times (14,000 rpm, 2 min, R.T.) to remove residual buffer. 
The RNA was eluted by two times centrifugation of 30 µL of DEPC treated H2Odd 
(10,000 rpm, 1 min, R.T.). RNA concentration was determined using the 
Nanodrop 1000 (Peqlab) and RNAs were stored at -20 °C. 
 
2.2.2 Cell biological and virological methods 
2.2.2.1  Cell culture 
Passaging of cell lines 
Cell lines were kept in specific growth media (see 2.1.7) and cell culture flasks 
(T25 or T75) in incubators at 37 °C and 5 % CO2. 
Adherent growing cells were trypsinated using Trypsin/EDTA and split every 
3-4 days at various ratios from 1:4 to 1:10 depending on the growth rate of 
each cell line. 
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Cell lines growing in suspension were split directly. 
BSR-T7/5 cells were supplemented with 2 mg/mL G418 (Geneticin) every 
other passage. U3A3 cells were supplemented with 2 mg/mL G418 (Geneticin) 
and 0.5 mg/mL Hygromycin every other passage. 
 
Seeding of cells 
Adherent growing cell lines were trypsinated and resuspended in growth 
medium. Cell numbers/mL were calculated based on estimated cell 
numbers/flask (T25: 3x106; T75: 9.4x106) or determined using a Neubauer 
counting chamber.  
Cells were seeded in various culture dishes as follows: 
dish number of cells total volume of growth 
media 
10 cm² dish 1.5x106 10 mL
6 cm² dish 6x105 2-5 mL
3.5 cm² dish 3x105 2 mL
  
6-well 3x105 2 mL
12-well 2x105 0.5-1 mL
24-well 1x105 300-500 µL
48-well 5x104 200-400 µL
96-well 1-2x104 100-200 µL
 
 
2.2.2.2  Isolation and cultivation of bone marrow derived cells (BMDCs) 
Femur and tibia were isolated from hindlimbs of C57/BL6 mice and bone 
marrow was extracted by extensively flushing with 1x PBS. Bone marrow was 
passed through a 40 µm cell strainer using 1x PBS and the cell suspension was 
centrifuged (400 g; 4°C; 7 min). 
The supernatant was discarded and the cell pellet was resuspended in 2 mL of 
1x ACK and incubated at R.T. for 2 min (erythrocyte lysis). 28 mL of 1x PBS 
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were added to stop the lysis process and the cells were pelleted again by 
centrifugation (400 g; 4 °C; 7 min). 
The pellet was resuspended in 10 mL of 1x PBS and the cell number was 
determined using a Neubauer counting chamber. 2-3x106 cells/mL were 
cultivated in T25 cell culture flasks. 
To stimulate differentiation of BMDCs into pDCs, 20 ng/mL of human 
recombinant Flt3-L as well as 50 µM of β-mercaptoethanol were added to the 
cell culture and cells were incubated at 37 °C and 5 % CO2 for 7 days. 
 
2.2.2.3  Transfection 
Cells were transfected with DNA, RNA or peptides using Lipofectamine 2000 
(Invitrogen) or calciumphosphate method (Mammalian Transfection Kit; 
Stratagene) according to the manuals. 
For co-immunoprecipitation assays, a solution containing 1 µg/µL PEI instead 
of Lipofectamine 2000 solution was used following the Lipofectamine 2000 
protocol. 
 
2.2.2.4  Infection assays 
According cell numbers were seeded in multiwell plates and directly infected in 
suspension with calculated MOIs of rapidly thawed virus stocks. 
 
2.2.2.5  Generation of MV stocks 
Two confluent T75 flasks of Vero cells were harvested and pelleted by 
centrifugation (1,600 rpm, 4 °C, 10 min). The supernatant was discarded, cells 
were resuspended in 500 µL of growth medium and infected with MV to an MOI 
= 0.25. The total volume was adjusted to 2.5 mL and the suspension was 
incubated at 37 °C for 1 h with shaking gently every 10 min. Afterwards, the 
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infected cells were seeded equally in 6 T75 cell culture flasks with a total of 16 
mL growth medium/flask and incubated at 37 °C for 40-48 h. 
As soon as most cells had formed numerous small syncytia, the cells were 
frozen at -20 °C. Cells were thawed on ice and lysates were cleared from cell 
debris by centrifugation (1,600 rpm, 4 °C, 10 min). Cleared lysates were 
aliquoted and stored at -86 °C. 
 
2.2.2.6  Generation of RV stocks 
One confluent T25 flask of BSR-T7/5 cells was split 1:4, the cells were infected 
with RV at an MOI = 0.1 and incubated at 37 °C. 
The supernatant was collected 72 h p.i. (1st harvest), cleared from cell debris by 
centrifugation (1,600 rpm, 4 °C, 10 min), aliquoted and stored at -86 °C. Cells 
were supplied with fresh growth medium and incubated at 37 °C. 
A 2nd harvest was performed analogous to the first harvest 144 h p.i. 
 
2.2.2.7  Generation of recombinant RV (helper virus free) 
BSR-T7/5 cells were seeded in 6-well plates 16 h prior to transfection. Growth 
medium was replaced with D-MEM 1 h prior to transfection. 
10 µg of pSAD (RV genome encoding plasmid) and 5 µg pTIT-RV-N, 2.5 µg pTIT-
RV-P and 2.5 µg pTIT-RV-L helper plasmids were transfected using the 
calciumphosphate method. The cells were washed twice with growth medium, 
supplied with 2 mL of growth medium 3.5 h p.tr. and incubated at 37 °C for 72 
h. 
The supernatant was collected 72 h p.tr., cell debris was removed by 
centrifugation (1,600 rpm, 4 °C, 10 min) and put on freshly seeded BSR-T7/5 
cells in 6-wells. These were incubated at 37 °C for 72 h (Supernatant passage 
1A). The transfected cells were supplied with 2 mL of fresh growth medium and 
incubated at 37 °C for another 72 h. 
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The supernatants of the transfected cells were collected again 144 h p.tr. and 
treated as before (Supernatant passage 1B). The transfected cells were 
trypsinized and 25 % of the cells were seeded in new 6-wells (Split), whereas 
75 % of the cells were seeded in T25 cell culture flasks and incubated at 37 °C 
for further 72 h. 
All 6-wells (Supernatant passage 1A, 1B; Split) were analyzed by IF using 
acetone fixation and FITC-labelled anti-N antibody (see 2.2.3.7) for the 
formation of viral foci. 
The supernatants of virus containing T25 cell culture flasks were harvested, cell 
debris was removed by centrifugation (1,600 rpm, 4 °C, 10 min), supernatants 
were aliquoted and stored at -86 °C. Viral titers were determined as described 
in 2.2.2.8. 
 
2.2.2.8 Titration of virus stocks 
In case of MV, Vero cells were used for titration of virus stocks, in case of RV, 
BSR-T7/5 cells were used. 
2x104 cells were seeded into 96-wells to a total volume of 100 µL/well and 
incubated at 37 °C for 2 h. 
500 µL of virus stocks were thawn on ice and serially diluted 1:10, resulting in 
dilution series from (100 [=undiluted] to 10-8). 
100 µL of each dilution was added to one well in duplicates and cells were 
incubated at 37 °C for 48 h. 
Cells were fixed using the PFA/NH4Cl (for MV) or acetone (for RV) protocol (see 
2.2.3.7). Cells were stained with diluted FITC-labelled anti-N antibodies (MV: 
Millipore; RV: FDI) and incubated either at 4 °C (MV) or 37 °C (RV) for 2 h. 
Foci were counted from each well using a UV microscope (Olympus) and foci 
forming units per mL (ffu/mL) were calculated from these results. 
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2.2.3  Biochemical and immunological methods 
2.2.3.1 Luciferase reporter gene assays 
The Dual luciferase reporter gene system (Promega) was used according to the 
manual with a few modifications. 
1x105 cells/well of HEK-293T, Huh7.5, or BSR-T7/5 cells were seeded approx. 
16 h prior to transfection in 24-well plates in a total volume of 300 µL. 
Cells were transfected using Lipofectamine 2000 with 100 ng of firefly-reporter 
plasmid, 10 ng of renilla-reporter plasmid and various expression plasmids 
with a total DNA amount of 0.5 – 2 µg/well. 
In case of stimulation with RLR-ligands, TLR-ligands, or interferon, stimulating 
agents were added to the medium 6 h p. tr. 
Cells were lysed 24 h p. tr. using 200 µL of 1x Passive Lysis Buffer (Promega) 
and 20 µL of each lysate was transferred to a 96-well plate for luminescence. 
Measurement of luciferase activity was performed in a LB 960 Luminometer 
(Berthold) using 40 µL of each substrate solution and a measuring time of 5 
s/well for each luciferase. Results were analyzed using the MikroWin 2000 
(Mikrotek) and Microsoft Excel (Microsoft) software. Assays were performed in 
at least triplicates and mean values and standard deviation were calculated. 
 
2.2.3.2 Co-Immunoprecipitation 
6x105 cells of HEK-293T cells were seeded in 6 cm² dishes approx. 16 h prior to 
transfection in a total volume of 2 mL. 
Cells were transfected using Lipofectamine 2000 or the PEI-method with 
various combinations of tagged and untagged cellular and viral protein 
expression vectors. 
Cells were harvested 24 h p. tr. using 1 mL/well of PBS/EDTA and divided in a 
900 µL and a 100 µL fraction. Both fractions were pelleted by centrifugation 
(2,500 rpm, 4 °C, 5 min). Supernatants were discarded and the 100 µL pellets 
were taken up in 250 µL of Protein lysis buffer (= 10 % input). The 900 µL 
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pellets were lysed in 300-500 µL of Co-IP buffer for 30-120 min at 4 °C on a 
rolling incubator. The cell debris was pelleted by centrifugation (14,000 rpm, 4 
°C, 15 min) and the cleared supernatants were transferred on either Protein A-
conjugated Sepharose beads for pull-down of Ig-tagged proteins or on FLAG 
M2-agarose beads for pull-down of FLAG-tagged proteins. Cell lysates and 
beads were incubated for 2-4 h at 4 °C on a rolling incubator. Beads were 
pelleted by centrifugation (14,000 rpm, 4 °C, 2 min) and the supernatant was 
discarded. The beads were resuspended in 500 µL Co-IP buffer and incubated 
for 10 min at 4 °C on a rolling incubator. This wash step was repeated 3 times. 
Afterwards pellets were resuspended in 250 µL of Protein lysis buffer (= 90 % 
Co-IP) and the probes were subjected to denaturating PAA-gel electrophoresis 
and Western blotting.  
 
2.2.3.3 Denaturating Polyacrylamid (PAA)-gel electrophoresis 
component separating gels stacking 
gel 
 8 % 10 % 12 % 16 % 4 %
Acrylamid 7.2 mL 9.0 mL 10.8 mL 14.4 mL 1.4 mL
Jagow gel 
buffer 
12.0 mL 12.0 mL 12.0 mL 12.0 mL 3.5 mL
H2Odd 14.6 mL 12.9 mL 11.1 mL 7.4 mL 9.0 mL
Glycerol 2.0 mL 2.0 mL 2.0 mL 2.0 mL --
TEMED 17.0 µL 17.0 µL 17.0 µL 17.0 µL 18.0 µL
10 % APS 175.0 µL 175.0 µL 175.0 µL 175.0 µL 116.0 µL
 
Jagow PAA-separating gels were casted with a content of PAA varying from 8 to 
16 % (standard: 10 %) and a standard size of approx. 15 x 10 cm² with the 
substances listed below. Following polymerization of the separating gels, 4 % 
Jagow stacking-gels were casted and 15-pocket or 24-pocket combs were used 
to create pockets. 
Protein lysates were incubated at 95 °C for 5 min and centrifuged shortly to 
pellet residual cell debris or Co-IP beads. Up to 50 µL of protein lysates were 
casted in each pocket. As molecular weight standard, 8 µL of Precision Plus 
Protein Standard (Biorad) was loaded directly into one pocket. 
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Gel electrophoresis was carried out o/n at 30 – 75 V in an electrophoresis 
chamber filled with Jagow Kathode and Anode buffers. 
 
2.2.3.4 Western blot (Semi dry method) 
After gel electrophoresis, stacking gels were removed and separating gels were 
washed in 20 mL of 1x Semi dry buffer for 5 min. 
Whatman paper and nitrocellulose membranes were soaked with 1x Semi dry 
buffer. In case of the usage of PVDF membranes instead of nitrocellulose 
membranes, these were activated by washing with methanol p.a. first, followed 
by washing with 1x Semi dry buffer. 
Layers of Whatman paper, membrane, PAA gel and finally Whatman paper 
again were put on top of each other according to the manual of the blotting 
chamber (Peqlab). Blotting was performed at 400 mA/gel for 2 h. 
Afterwards, membranes were incubated for at least 1 h in blocking solution (2.5 
% milk powder or BSA in PBS/Tween (nitrocellulose) or 2.5 % milk powder or 
BSA in PBS (PVDF)). 
 
2.2.3.5 Immunodetection 
After blocking, membranes were washed extensively in PBS/Tween (e.g. 20 mL, 
3x 10 min) followed by incubation with primary antibodies either at R.T. on a 
shaking device for 2 h or at 4 °C on a rolling incubator o/n. 
Primary antibodies were diluted as recommended by the supplier in 
PBS/Tween supplemented with 0.04 % (w/v) sodium azide and 150 µg/mL 
BSA. 
Following repeated washing steps with PBS/Tween (e.g. 20 mL, 3x 10 min), the 
membranes were incubated with HRP-conjugated secondary antibodies, which 
were diluted 1:10,000 in PBS/Tween at R.T. for 2 h. In some cases, HRP-
conjugated Protein A (diluted 1:10,000) was used instead of antibodies. 
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Afterwards, excessive antibody was removed by extensive washing (e.g. 20 mL, 
3x 10 min). 
ECL solution (500 µL/blot) was prepared according to the supplier’s manual, 
blots were incubated with the solution and chemiluminescence was detected 
immediately using Hyperfilm-ECL (GE Healthcare Amersham) for various 
periods of time. 
 
2.2.3.6 Immunofluorescence (IF) 
Cells were seeded on glass cover slips for confocal IF microscopy. 
For fixation, cells were washed once with 1x PBS and incubated either with 80 
% (v/v) acetone at 4 °C for 20 min, or with 3 % (w/v) PFA/PBS at R.T. for 20 
min followed by incubation with 50 mM NH4Cl/PBS at R.T. for 10 min. 
In case of PFA/NH4Cl fixation, cells were permeabilized by incubation with 0.5 
% (v/v) Triton X-100/PBS at R.T. for 5 min. 
Afterwards cells were incubated with 2.5 % (w/v) milk powder or BSA 
dissolved in 0.1 % (v/v) Triton X-100/PBS at R.T. or 4 °C for 15 – 30 min to 
block unspecific antibody binding sites. 
After extended washing steps (e.g. 3x PBS), cells were incubated with primary 
antibody solution prepared in 0.1 % (v/v) Triton X-100/PBS according to the 
suppliers’ recommendations (standard: 1:200 – 1:2,000) at R.T. for 45-120 min. 
The volume of the antibody solutions was kept as low as possible. 
Afterwards cells were washed again 3x with PBS and incubated with 
fluorescence dye-labelled secondary antibody solution (standard: 1:200 in 0.1 
% (v/v) Triton X-100/PBS) at R.T. or 4 °C for 120 min. In case of the usage of 
directly labelled primary antibodies, this step was skipped. 
Cover slips were washed again 3x with PBS and 1x with H2Odd and fixed on 
microscope slides using Vectashield mounting medium (Vector Labs). Slides 
were dried o/n at 4 °C. 
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Confocal analysis was performed on a Laser Scanning Microscope (Zeiss) using 
LSM Meta software (Zeiss). 
Non-confocal UV-microscopy was performed on a UV-microscope (Olympus) 
using analySIS software (Olympus). 
 
2.2.3.7 Enzyme-linked immunosorbent assay (ELISA) 
ELISA for murine IFNα was performed with supernatants of treated pDC 
cultures using the Mouse Interferon Alpha (Mu-IFN-α) ELISA Kit (PBL) according 
to the supplier’s protocol. The readout was performed with a Versamax 
Microplate reader (Molecular Devices) using the software Softmax Pro 
(Molecular Devices) and Microsoft Excel (Microsoft). 
 
2.2.3.8 Expression and Ni-NTA purification of recombinant proteins from bacteria 
100 mL LB medium supplemented with 25 mg/mL of Kanamycin and 25 
mg/mL of Chloramphenicol were inoculated with few µL of transformed 
Rosetta (DE3) from glycerol stocks and grown at 37 °C o/n. 
20 mL of this bacteria culture were inoculated to 1 L of LB-medium 
(+Kan/Cam) and grown at 37 °C to an OD = 0.5. As soon as this OD was reached, 
IPTG was added to the culture at a final concentration of 0.5 mM to induce 
protein expression from the pET28a-vector. The bacteria culture was shaken at 
18-20 °C o/n. 
After pelleting of the bacteria by centrifugation (6,000 rpm, 4°C, 40 min), the 
bacteria were resuspended in 5 mL/g wet weight of cold 1x Lysis/wash buffer 
and lysed by sonication at 4 °C for 10-30 min. 
The suspension was cleared from cell debris by centrifugation (17,000 rpm, 4 
°C, 45 min) and the supernatant was incubated with Ni-NTA agarose beads (1 
mL/ 10 mL lysate) on a rolling incubator at 4 °C for 2 h. 
The lysate-beads-suspension was loaded on a chromatography column at 4 °C 
and the flow through was collected. The beads were washed with 10 mL of cold 
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1x Lysis/wash buffer three times and the wash fractions were collected. 
Afterwards, resin bound protein was eluted by 5x 3 mL of 1x Elution buffer. All 
fractions were collected separately. 
25 µL of each collected fraction were mixed with an equal amount of Protein 
lysis buffer and subjected to PAA gel-electrophoresis. The gels were stained 
with Coomassie blue to visualize protein content. 
Elution fractions containing protein of the predicted size were combined and 
dialyzed against 1x ATPase buffer. 
In case of low protein content, the yieling solution was concentrated using 
Amicon Ultra-15 Centrifugal Filter Devices by centrifugation (3,500 rpm; 4°C; 
10-60 min). 
Protein content was determined using the BCA Protein Assay Kit (Pierce). 
Protein lysates were shock frosted in liquid nitrogen and stored at -86 °C. 
 
2.2.3.9 In vitro kinase assays 
Recombinant proteins were combined using 100 ng of recombinant kinases 
(His-IKKα / -IKKβ / -TBK1) per reaction volume, 100 – 500 ng of substrate 
(GST-I-κB-α  / His-IRF7) and increasing amounts of recombinant viral proteins 
(His-MV-V / -MV-P / fragments), varying from 0 – 1,600 pmol / reaction 
volume. 
In a second vial, 5x Kinase assay buffer and ATP (final conc. 200 µM) were 
mixed and tracing amounts of γ-32P-labelled ATP were added. The ATP reaction 
mix was added to start the reaction. Aliquots were taken from the reaction 
volume at defined time points and mixed with Protein lysis buffer to stop the 
reaction. 
The lysates were separated using PAA gel electrophoresis (10 % PAA-Gel; 40 V; 
o/n) and blotted on nitrocellulose or PVDF membranes (400 mA; 2 h). The 
membranes were exposed to a PhosphoScreen (Molecular Dynamics) for 2 – 72 
h and screens were scanned using a STORM Scanner (Molecular Dynamics). 
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Images were analyzed using the ImageQuant (Molecular Dynamics) and 
Microsoft Excel (Microsoft) software. 
 
2.2.3.10 In vivo 32P-labelling 
6x105 Huh7.5 cells were seeded in 6 cm culture dishes and transfected with 
plasmids encoding Fl-tagged IKKα, IRF7, and MV V (2 µg/plasmid) using 
Lipofectamine 2000. Cells were washed three times with PKRB and pulsed with 
1 mCi/well of H332PO4 (in PKRB) 3 h p. tr. for further 3 h. Afterwards, PKRB was 
removed, cells were washed once with growth medium and incubated for 18 h 
at 37 °C and 5 % CO2. 
Fl-tagged proteins were pulled down using the anti-FLAG® M2 affinity gel 
(Sigma-Aldrich) as described in section 2.2.3.2. After SDS-PAGE (1 % PAA; 60 V; 
o/n) and Western blotting (nitrocellulose membrane; 400 mA; 2 h), the blots 
were exposed to a PhosphoScreen for 72 h and autoradiography was detected as 
described above. 
 
2.2.3.11 Northern blot 
Total RNA extracts of infected BSR-T7/5 cells were prepared 48 h p. i. as 
described above (see section 2.2.1.5). 2 µg total RNA were adjusted to 7.2 µL 
total volume. 3 µL of 5x Phosphate buffer and 1.8 µL of glyoxal solution were 
added. The mixture was heated to 56 °C for 30 – 45 min and spinned down. 
Finally, 3 µL of Blue juice were added to the solution. 
2 g of agarose (RNA grade) were dissolved in 167.3 mL of H2Odd (ultrapure) and 
4 mL of 50x Phosphate buffer by heating and stirring. 26.7 mL of 37 % 
formaldehyde were added to the solution after cooling down to approx. 30 °C 
and the final volume was adjusted to 200 mL with H2Odd (ultrapure). A 24 cm x 
20 cm gel was casted from the solution. 
RNA probes were loaded to the gel and electrophoresis was performed using 1x 
Phosphate buffer at 25 V o/n. RNA was stained using acridine orange solution 
and 1x Phosphate buffer as washing solution to visualize rRNAs. 
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The RNA was transferred to a nylon membrane (Strategene®; 2 h, -100 mbar) 
using the Vacu-Blot system (Biometra®). After drying, the RNA was cross-
linked with the membrane (0.125 J). 
Probes were generated by radioactive labelling of specific PCR products (25 ng) 
with α-32P-CTP using the Ready prime II Kit (GE Healthcare) according to the 
manual. 
Membranes were pre-incubated with Zeta hybridising buffer (68 °C) for 10 min, 
then incubated with probes in 8 mL Zeta hybridising buffer at 68 °C o/n. 
Afterwards, the membranes were washed once with Zeta wash buffer 5 % and 
twice with Zeta wash buffer 1 % (68 °C; 20 min each). Membranes were dried 
and exposed to a PhosphoScreen o/n. Autoradiography was detected as 
described above. 
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3  Results 
 
3.1  Reconstitution of MyD88-dependent induction of IFNα in cell 
lines and establishment of luciferase reporter gene assays 
The MyD88-dependent induction of IFNα via TLR7/8/9 is naturally available 
only in pDCs. However, this highly specialized hematopoietic cell type is neither 
suitable for cultivation like an immortalized cell line and therefore has to be 
extracted freshly each time from blood probes or bone marrow, nor is it 
applicable for transfection of DNA or purified proteins. 
For this reason, I decided to study the MyD88-dependent induction of IFNα in 
cultured cell lines, in which this signaling pathway naturally is not active, since 
main components, namely TLRs and the transcription factor IRF7, are not 
expressed constitutively. Therefore, as a first point, the signaling complex had 
to be reconstituted in those cell lines. It is a well established procedure to 
activate signaling processes simply by overexpressing components of the 
signaling complex. In this case, expression of IRF7 is essential, as this factor is 
not expressed in cell lines, but crucial for functional induction of IFNα. 
Overexpression of IRF7 of either human (h) or murine (m) origin by 
transfection of an expression vector resulted in a dose-dependent and strong 
activation of different IFNα promoters (α1, α4, and α6), as could be shown in 
luciferase reporter gene assays (Fig. 7A). However, as I did not yet know how 
this signaling cascade is inhibited by MV, I also wanted to study the influence of 
other components of the signaling complex. Therefore, I decided to reduce the 
amount of transfected IRF7 expression vector to only intermediate induction 
activity and to increase the IFNα promoter activity by co-expression of MyD88 
as scaffold protein for the signaling compley, and the crucial 
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Figure 7: Reconstitution of the MyD88-dependent signaling complex leading to the 
induction of IFNα in cell lines.  
(A) Luciferase reporter-gene assay with IRF7 constructs of human (h) and murine (m) origin 
using reporter genes under the control of murine IFNα1, α4, and α6 promoters. Murine IRF7 
works best with IFNα4- and IFNα6-promoters. (B) Luciferase reporter-gene assay with IRF7, 
TRAF6, and increasing amounts of MyD88 using the IFNα4-promoter driven reporter gene. 
Increasing amounts of MyD88 have a cumulative effect on the reporter activity. (C) Luciferase 
reporter gene assay with IRF7, MyD88, TRAF6, and increasing amounts of IRAK1 or IRAK1c 
constructs. Both splicing variants of IRAK1 have a negative impact on the induction of IFNα4-
promoter driven luciferase. (D) Luciferase reporter-gene assay with IRF7, MyD88, TRAF6, and 
increasing amounts of IRAK1, IRAK4, or IKKα. Only IKKα strongly enhances the IFNα4-
promoter driven expression of luciferase. All assays are normalized using co-transfection of 
CMV-promoter driven renilla luciferase. Mock transfection is set to 1. 
 
E3-ubiquitin ligase TRAF6 (Fig. 7B). This resulted in a moderate increase of the 
promoter activity, which was dependent on the dose of transfected expression 
vectors, which was kept constant at 500 ng/well in case of TRAF6, but varied in 
case of MyD88 from 0 – 500 ng/well. Already co-transfection of only 100 ng of 
the MyD88 expression vector led to a 3-fold increase of the promoter activity. 
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Co-transfection of 500 ng of the expression vector increased the promoter 
activity by 7-fold, whereas co-transfection of the same amount of the TRAF6 
expression vector resulted in less than 2-fold increase. However, the promoter 
activation was only moderate, so it was likely that still a crucial component was 
missing to completely reconstitute the signaling complex. Several kinases had 
been described to play a crucial role in the MyD88-dependent TLR-signaling, 
among them IRAK1, IRAK4, and IKKα. Overexpression of these kinases resulted 
in diverse phenotypes. Overexpression of IRAK1 and IRAK1c, a splicing variant 
of IRAK1, from 20 – 400 ng of expression vector resulted in a strong and dose-
dependent inhibition of the IFNα promoter activity (Fig. 7C and D). 
Overexpression of IRAK4 by co-transfection of 50 – 100 ng of expression vector 
did not show a significant influence on the activation of the promoters (Fig. 7D). 
Only overexpression of IKKα showed a strong and dose-dependent increase of 
the signal, when comparable levels of the expression vector were co-
transfected (50 – 100 ng/well). This indicated that IKKα is crucial for the 
activation of IRF7 (Fig. 7D). 
Optimization of the protocol resulted an optimal ratio of 1:5:5:5 of expression 
plasmids for IRF7:MyD88:TRAF6:IKKα. This transfection mix was further used 
to stimulate IFNα promoter activity in different cell lines like human HEK-293 
or HEK-293T cells, Huh7.5 cells, or hamster BHK21-derived BSR-T7/5 cells. 
However, the total amount of transfected DNA varied in different cell lines and 
was optimized individually (data not shown). For Huh7.5 and HEK-293T cells, 
the amount of plasmid mix transfected was 300 ng/well. 
Having established this tool, I now was able to analyze the influence of viral 
proteins on this signal transduction complex. 
 
3.2  Identification of V as inhibitor of MyD88-dependent induction 
of IFNα 
Several functions of paramyxoviral P gene products P, V, and C as antagonists of 
the innate immune system have already been described. I therefore  
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Figure 8: Identification of the viral antagonist of IFNα induction.  
Luciferase reporter-gene assays with IRF7, MyD88, TRAF6 and IKKα, as well as luciferase under 
the control of various IFN-promoters. Co-transfection of increasing amounts of viral expression 
plasmids (250; 500; 750 ng/well). (A) IFNα4-promoter driven luciferase expression is inhibited 
by MV V co-expression in a dose-dependent manner. MV P and RV P have no inhibitory activity. 
(B) IFNα6-promoter driven luciferase expression is inhibited by MV V in a similar way like 
IFNα4-Luc. (C) Luciferase reporter-gene assay with TBK1 and IRF3, inducing 55c1b (IRF3-
binding site of IFNβ-promoter) driven luciferase expression. MV P and V do not inhibit IFNβ 
induction, but RV P strongly prevents IFNβ induction. (D) MV C co-expression also negatively 
influences IFNα4-promoter driven luciferase expression. All assays are normalized using co-
transfection of CMV-promoter driven renilla luciferase. Mock transfection is set to 1. 
 
investigated the role of these proteins in the inhibition of the MyD88-
dependend IFNα inducing pathway. Huh7.5 cells were used in luciferase 
reporter gene assays as these cells express non-functional RIG-I, which is 
unable to induce IFNβ production upon recognition of viral (triphosphate or 
double-stranded) RNA due to a point mutation. 
Cells were co-transfected with the IFNα-inducing plasmid mix containing IRF7, 
MyD88, TRAF6, and IKKα expression vectors (300 ng/well), and increasing 
amounts of expression vectors (250 – 750 ng/well) for MV P, MV V (both 
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unable to express MV C due to silent mutations), or RV P, which was chosen as a 
control protein with well characterized functions in inhibition of TBK1/IRF3-
mediated induction of IFNβ. Cells were harvested 24 h p. tr. and cell lysates 
were analyzed for luciferase expression. Indeed, overexpression of MV V 
showed an inhibitory effect on the expression of firefly luciferase either under 
control of the IFNα4 (Fig. 8A), or IFNα6 promoter (Fig. 8B), indicating that MV 
V is able to counteract the activation of IFNα promoters by 
IRF7/MyD88/TRAF6/IKKα. In contrast, neither MV P nor RV P showed an 
inhibitory effect on this signaling complex. 
Similar experiments were performed simulating the induction of IFNβ by TLR3, 
or RIG-I, respectively. In this case, TBK1 and IRF3 expression vectors were 
transfected instead of the plasmid mix for IFNα induction. Expression of firefly 
luciferase was controlled by the p55-C1B promoter element, which consists of 
repeats of the IRF3-binding site of the natural IFNβ promoter (Fig. 8C). Co-
expression of RV P showed a dose-dependent inhibitory effect on this pathway, 
as it has been described earlier (Brzózka et al., 2005). In contrast, neither MV P, 
nor MV V showed a negative effect on this signal transduction complex. 
I also examined whether MV C could play a role in inhibition of the MyD88-
dependent IFNα inducing pathway. Therefore, MV C expression vector was co-
transfected (500 – 1250 ng/well) with the IFNα-inducing plasmid mix and 
luciferase reporter gene assays were performed analyzing the IFNα4 promoter 
activity (Fig. 8D). The result clearly shows that MV C also has a negative impact 
on the functionality and efficiency of the MyD88-dependent signaling complex. 
In summary, MV V and C could be identified as antagonists of MV inhibiting the 
MyD88-dependent IFNα induction. In contrast, MV P does not share this 
function. Also, this inhibitory function of MV V is specific for the MyD88-
dependent signaling complex consisting of IRF7/MyD88/TRAF6/IKKα, but the 
TRIF- or IPS1-dependent signaling complex (IRF3/TBK1) is not inhibited by MV 
V. 
In the next step, I tried to identify the targets of MV V and C, assuming direct 
protein-protein interactions being responsible for the inhibitory effect. 
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3.3  Identification of interaction partners of V 
I performed co-immunoprecipitation experiments in order to identify potential 
interaction partners of MV V. For this reason, expression vectors for MV P, V, 
and C proteins were generated in which an Ig-tag was fused N-terminally to the 
viral proteins (Ig-MV-P/V/C). These fusion proteins were co-expressed with 
FLAG®-tagged signaling components in HEK-293T cells. The cells were lyzed 
24 h p. tr. and Ig- tagged proteins were precipitated under native conditions 
using protein A conjugated sepharose beads. The precipitates were analyzed 
for interaction partners by Western blotting, using specific antibodies against 
signaling proteins or FLAG®-epitope tag antibody in case of FLAG®-tagged 
 
 
Figure 9: Identification of interaction partners of MV V.  
Co-immunoprecipitation experiments reveal specific interaction of MV V with IKKα and IRF7. 
(A and B) Pull-down of Ig-tagged MV P, V, or C (or Ig-empty vector) with sepharose A beads. (A) 
Co-expression of the kinases Fl-IKKα, -IKKβ, -TBK1, or -IKKε. Only Fl-IKKα co-precipitates 
specifically with Ig-MV-V. (B) Co-expression of the transcription factors Fl-IRF7 or Fl-IRF3. Fl-
IRF7 co-precipitates with Ig-MV-V, while Fl-IRF3 does not. (C and D) Pull-down of Fl-tagged 
IKKα, IRF7, TBK1, or IRF3 (or empty vector) with Anti-FLAG® agarose beads. Co-expression of 
MV P, V, or C. (C) Only MV V co-precipitates with Fl-IKKα, and -IRF7, while MV P and C do not. 
(D) IP of Fl-tagged IKKα, IRF7, TBK1, and IRF3. 
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signaling proteins. Two components of the signaling complex were co-
precipitated: both Fl-IKKα and Fl-IRF7 bound specifically to Ig-MV-V, but not to 
Ig-MV-P, or –C, or Ig-tag only (Fig. 9A and B). In contrast, neither the IKKα-
homologs IKKβ, IKKε, or TBK1, nor the IRF7-homolog IRF3 bound specifically 
to Ig-MV-V, emphasizing the specificity of MV V for IKKα and IRF7 as 
interaction targets. 
To confirm these results, extracts of cells co-expressing Fl-tagged signaling 
components and untagged MV P, V, or C were subjected to co-
immunoprecipitation experiments using anti-FLAG® agarose beads to pull 
down Fl-tagged proteins and analyzed for binding of viral proteins by Western 
blot. Again, MV V was co-precipitated specifically with Fl-IKKα, as well as with 
Fl-IRF7, but not with Fl-TBK1, or Fl-IRF3 (Fig. 9C and D). Moreover, only MV V, 
but not MV P, or C bound to Fl-IKKα and Fl-IRF7. 
Taken together, I could show that MV V specifically interacts with two 
components of the MyD88-dependent signaling complex. These are the 
transcription factor IRF7 and IKKα, the kinase responsible for the activation of 
IRF7. The interaction could be confirmed by co-immunoprecipitation 
experiments when pulling down either viral or signaling protein. Furthermore, 
MV V specifically interacted only with IKKα, and IRF7, but not with their 
homologous proteins, which are involved either in induction of IFNβ (TBK1, 
IKKε, IRF3), or in the activation of NF-κB (IKKβ). On the other hand, no 
interaction partners of MV C could be identified. This leads to the assumption 
that MV C may control gene expression on a different stage. I further 
concentrated on the function of MV V. 
 
3.4  Identification of the V interaction domain 
The next goal was to narrow down the domains of MV V interacting with IKKα 
and IRF7. As V and P share a common N-terminal domain of 231 amino acids, 
and only V, but not P showed binding to IKKα, and IRF7, the interaction with 
both signaling components must be mediated by the V-specific C-terminus of 
the protein, and not to the N-terminus. In order to confirm this theory, we 
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Figure 10: Identification of the MV V interaction domain.  
(A – C) Co-immunoprecipitation experiments with truncated MV P and V narrow interaction 
domain of V down to the V C-terminus. (A) Pull-down of Ig-tagged P, V, or truncated PVN, PC, or 
VC (or empty vector) with sepharose A beads. Co-expression of Fl-IKKα, or -TBK1 reveals 
specific interaction of IKKα with the VC domain of V. (B) Co-expression of Fl-IRF7 or -IRF3 
shows interaction of IRF7 with VC. (C) Pull-down of Fl-tagged IKKα, IRF7, TBK1, or IRF3 with 
anti-FLAG® agarose beads and co-expression of truncated Ig-tagged PVN, PC, or VC. IKKα and 
IRF7 are bound specifically to the VC domain. (D) Luciferase reporter gene assay with IRF7, 
MyD88, TRAF6, and IKKα, as well as luciferase under the control of the IFNα6-promoter. Co-
expression of increasing amounts of (untagged) MV V, or Ig-tagged PVN, or VC (250; 500; 750 ng 
expression vector). While full-length MV V acts as inhibitor, truncated Ig-fusion proteins are 
unable to do so. The assay is normalized using co-transfection of CMV-promoter driven renilla 
luciferase. Mock transfection is set to 1. 
 
generated expression vectors for N-terminally Ig-tagged PVN (Ig-MV-PVN; 
common N-terminal domain of P, and V), PC (Ig-MV-PC; P-specific C-terminus), 
and VC (Ig-MV-VC; V-specific C-terminus) proteins. Co-immunoprecipitation 
experiments were performed with signaling proteins using these protein 
domains. As expected, Ig-MV-VC specifically pulled down both Fl-IKKα and Fl-
IRF7, but not Fl-TBK1 or Fl-IRF3 (Fig. 10A and B). Neither Ig-MV-PVN nor Ig-
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MV-PC was able to bind any of the tested proteins. Also, when pulling down Fl-
IKKα, and Fl-IRF7, only Ig-MV-VC could be co-precipitated, but not Ig-MV-PVN or 
–PC (Fig. 10C). 
I also was interested in the question, whether the VC domain alone would be 
sufficient for the inhibition of IFNα-promoter activity. I therefore performed a 
luciferase reporter gene assay, comparing the effect of full length MV V with the 
PVN, and VC fragments. Unfortunately, untagged VC could not be expressed or 
was not detectable by Western blot due to its small MW. I therefore decided to 
test Ig-MV-VC (and –PVN) in the reporter gene system. In contrast to full length 
MV V, neither Ig-MV-PVN nor Ig-MV-VC was able to inhibit IFNα6-promoter 
activity (Fig. 10D). Indeed, Ig-MV-VC strongly increased the promoter activity, 
which might be due to unspecific effects of the Ig-tag. Therefore, the question, 
whether VC alone is sufficient to inhibit IFNα induction could not be answered 
so far. 
Taken together, these data support the assumption that the interaction of MV V 
with IKKα, and IRF7 requires the V-specific C-terminus. Both functions of MV V 
seem to be strongly connected to each other, as they are both performed by the 
same protein domain, which comprises a 68 aa Zinc-finger motif. 
In the next step, the consequences of binding of MV V to IKKα and IRF7 on the 
signaling proteins had to be elucidated. 
 
3.5  Influence of V on activation of IRF7 by IKKα 
There are multiple possibilities, how binding of MV V to IKKα and IRF7 could 
block downstream signaling. On the one hand, MV V binding to IRF7 could 
capture the transcription factor and hinder its recruitment to the signaling 
complex – or, in case of binding post activation, the release of active IRF7, or its 
transport to the nucleus. On the other hand, binding to IKKα could inhibit its 
kinase activity, or the recruitment and activation of IRF7. 
In order to address these questions, prokaryotic expression vectors for N-
terminally 6xHis-tagged V (His-MV-V), and IRF7 (His-IRF7) were generated.  
 
3  Results  SUBVERSION OF TOLL-LIKE RECEPTOR 7/9 SIGNALING 
BY MEASLES VIRUS − V HOLDS THE KEY 
 
63 
 
Figure 11: Purification of recombinant proteins from E. coli.  
His-tagged MV V and IRF7 were expressed in E. coli and purified via Ni-NTA affinity 
chromatography. Different steps of the purification procedure were analyzed by SDS-PAGE and 
stained with Coomassie. (A) Purification of His-MV-V reveals high amounts of recombinant 
protein in the eluate. (B) His-IRF7 is expressed to lower levels than His-MV-V and only a minor 
fraction is found in the eluate. 
 
The recombinant proteins were expressed in E.coli and purified via a Ni-NTA 
affinity-matrix (Fig. 11A and B). I performed in vitro kinase assays using 100 ng 
of commercially available recombinant His-IKKα and equal amounts of the 
purified His-IRF7 as substrate. Increasing amounts of His-MV-V (200 – 1600 
pmol/reaction) were added and kinase activity within 16 min of reaction time 
was determined by 32P-labeling of the recombinant proteins and Western blot 
analysis (Fig. 12A). Increasing amounts of MV V indeed had an inhibitory effect 
on kinase activity of IKKα in terms of generation of 32P-labeled IRF7. However, 
total protein amounts of His-IKKα and His-IRF7 were equal in all reaction 
batches as confirmed by detection of total proteins using an anti-His antibody. 
Strikingly, His-MV-V itself acted as an excellent substrate for IKKα and was 
phosphorylated to a high extent. Quantification of the intensity of the 32P-IRF7 
bands gave a closer insight into the inhibitory mechanism (Fig. 12B). Low doses 
of His-MV-V (200, 400 pmol/reaction) could not prevent IRF7-phosphorylation 
over the reaction time. In contrast, high doses of His-MV-V (800, 1600 
pmol/reaction) almost completely inhibited the phosphorylation of IRF7 even 
during 16 min of reaction time. This indicates a competitive mechanism by 
which MV V inhibits phosphorylation of IRF7. Accordingly, V binds to IKKα 
instead of IRF7, gets phosphorylated and is released again afterwards. As long 
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as unphosphorylated V is available, IRF7 phosphorylation is inhibited, but as 
soon as all available V has been phosphorylated, IRF7 can be recruited to IKKα 
and will be activated via phosphorylation. 
To proof in vivo the data obtained in vitro, Fl-tagged versions of IKKα, IRF7, and 
MV V were transfected into HEK-293T cells and the cells were harvested 24 h p. 
tr. Native cell lysates were prepared and Fl-tagged components were 
precipitated using the anti-FLAG® affinity gel, which had been used also for co-
immunoprecipitation experiments before. The precipitates were analyzed by 
 
 
Figure 12: Inhibition of phosphorylation of IRF7 by IKKα in the presence of V.  
(A and B) Time resolved in vitro kinase assay using recombinant His-IKKα, -IRF7, and MV-V. (A) 
Autoradiography of 32P-labelled probes and Western blot control using an anti-His-tag 
antibody. While V acts as a substrate for IKKα, phosphorylation of IRF7 is inhibited in a dose-
dependent manner. (B) Quantification of phospho-IRF7 bands. Increasing amounts of V lead to 
a stronger inhibition of IRF7-phosphorylation. (C) Pull-down of Fl-tagged IKKα, IRF7, and MV V 
with anti-FLAG® agarose beads. An additional shifted band of IRF7 (corresponding to pIRF7) 
appears in the presence of IKKα. Co-expression of V leads to a decrease of the amount of pIRF7. 
(D) In vivo 32P-labeling and pull-down of Fl-IKKα, -IRF7, and -V. Autoradiography of pull-down 
extracts and Western blot control using an anti-FLAG® antibody. Phosphorylation of V can be 
detected in the presence or absence of Fl-IKKα. IRF7 phosphorylation cannot be detected 
although expression of Fl-IRF7 can. 
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Western blotting with anti-FLAG® antibody (Fig. 12C). Specific bands were 
obtained with MWs of approx. 86 kDa representing Fl-IKKα, 53 kDa 
representing Fl-IRF7, and 37 kDa representing Fl-MV-V. An additional specific 
band (marked by *) with a higher MW than Fl-IRF7 was observed in cells co-
transfected with Fl-IKKα and Fl-IRF7, which most likely represents the 
phosphorylated (activated) form of Fl-IRF7. A clear reduction of the intensity of 
this band was observed, when Fl-MV-V was expressed in addition to Fl-IKKα 
and Fl-IRF7. These data confirm the inhibition of IRF7-phosphorylation by MV 
V in transfected cells. However, although large amounts of MV V were 
indicatedly apparent, phosphorylation of MV V could not be demonstrated by 
this experiment. For this reason, 32P-labeling experiments in cell culture were 
performed. Huh7.5 cells were transfected with Fl-IKKα, Fl-IRF7, and Fl-MV-V 
and labeled with 32P-phosphoric acid. Fl-tagged proteins were pulled down and 
analyzed by SDS-PAGE for incorporation of 32P by autoradiography and for 
protein expression by Western blotting (Fig. 12D). In the Western blot control, 
Fl-IRF7 as well as Fl-MV-V could be detected, whereas the band for Fl-IKKα 
appeared to be very faint. However, on the autoradiogram, phosphorylation 
could be detected only for Fl-MV-V, but not for Fl-IRF7. As the levels of pulled 
down Fl-IRF7 in contrast to Fl-MV-V were not very high, this could be the 
reason for the undetectable levels of 32P-IRF7. Furthermore, phosphorylation of 
Fl-MV-V seemed to be independent of the expression of Fl-IKKα, leading to the 
assumption, that Fl-MV-V is a potential substrate for endogenous IKKα and 
possibly other kinases. 
To further characterize the phosphorylation sites of MV V, I expressed and 
purified different N- or C-terminally deleted mutants of His-MV-V, as well as 
His-MV-P and tested in vitro the ability of the proteins to serve as substrate for 
His-IKKα (Fig. 13A and B). Unexpectedly, all tested N-terminally deleted 
constructs showed similar phosphorylation levels (Fig. 13A). Only His-MV-V232-
299, which comprises the MV VC-terminus (VC), did not appear as a clear band 
on the autoradiogram. Also full length His-MV-P, as well as the N-terminal 
domain of P/V (His-MV-PV1-231), ashorter C-terminally deleted fragment, His-
PV1-164, and also the MV P C-terminus (His-MV-P232-507) served as a substrate 
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Figure 13: In vitro kinase assay with truncated MV V and P and kinases IKKα, IKKβ, and 
TBK1.  
N- and C-terminally truncated His-tagged MV V and P were expressed in bacteria, purified via 
Ni-NTA affinity chromatography and subjected to in vitro kinase assays to detect 
phosphorylation sites of V. Probes were analyzed by Western blot and 32P-autoradiography. (A) 
All N-terminally deleted V constructs (V45-299, V105-299; V165-299, V232-299) are phosphorylated by 
IKKα comparable to full length V. (B) C-terminally deleted constructs (PV1-164; PV1-231) as well as 
full length P and PC (P232-507) serve as substrates for IKKα. (C) V, P, and N-terminally deleted V 
proteins serve as substrates for His-IKKβ, and His-TBK1. 
 
 
for His-IKKα (Fig. 13B). These data suggest that more than one phosphorylation 
site can be found in different domains of MV V, and also of MV P. Interestingly, 
His-MV-P may act as a substrate for IKKα in vitro, although an interaction of 
these proteins in co-immunoprecipitation experiments could not be detected. 
Furthermore, His-IKKβ, and His-TBK1 were tested for their ability to 
phosphorylate His-MV-V constructs in vitro (Fig. 13C). Like His-IKKα, both 
kinases were able to phosphorylate all tested constructs of His-MV-V except for 
His-MV-V232-299. 
As His-MV-P also served as a substrate for His-IKKα, I had to prove the specifity 
of His-MV-V to inhibit the phosphorylation of IRF7. Therefore, I performed in 
parallel in vitro kinase assays comparing the effects of His-MV-V and His-MV-P 
on IRF7- phosphorylation (Fig. 14A and B). In the autoradiogram, 
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Figure 14: MV V, but not P is able to inhibit IRF7-phosphorylation in vitro.  
Time resolved in vitro kinase assay comparing the effects of His-V and His-P on the 
phosphorylation of IRF7 by IKKα. Probes were analyzed by Western blot and 32P-
autoradiography. (A) The 32P-autoradiogramm shows decreased levels of pIRF7 in presence of 
V, but not P. (B) Quantification of phospho-IRF7 bands confirm the inhibitory effect of V, but not 
of P. 
 
phosphorylated His-MV-V as well as His-MV-P could be detected (Fig. 14A). 
However, although both recombinant proteins served as a substrate for His-
IKKα, only His-MV-V showed a clear inhibitory effect on the phosphorylation of 
IRF7, as the amount of 32P-IRF7 was clearly reduced in the presence of His-MV-
V, but not of His-MV-P (Fig. 14B). 
Taken together, we were able to show in vitro and in cell culture that MV V acts 
as a decoy substrate for IKKα, thereby preventing the phosphorylation and 
activation of IRF7. Phosphorylation sites of MV V could not be identified by in 
vitro kinase assays due to the high reactivity of recombinant kinases, which also 
may lead to the phosphorylation of non-physiological substrates. However, 
serving as a decoy substrate for IKKα does not seem to be sufficient for effective 
inhibition. Binding of MV V to IRF7 should also be an important factor of the 
inhibitory mechanism. For this reason, in the next step we focused on the 
interaction of V and IRF7. 
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3.6  Inhibition of both inactive and active IRF7 by V 
Binding of MV V to IRF7 could inhibit the induction of IFNα both prior to and 
after phosphorylation of IRF7. Binding to inactive IRF7 would lead to the 
obstruction of recruitment of IRF7 to the signaling complex. On the other hand, 
I had to test the option, whether IRF7 could also be bound by MV V and thereby 
 
 
Figure 15: Inhibition of active IRF7 by MV V.  
(A – C) Luciferase reporter gene assay using luciferase under the control of the IFNα6-
promoter. (A) IRF7, MyD88, TRAF6, and IKKα were expressed to stimulate luciferase 
expression. Increasing amounts of V (250; 500; 750 ng of expression vector) inhibit luciferase 
expression dose-dependently. (B) Only IRF7 (100 ng expression vector) was used to stimulate 
luciferase expression. Co-expression of V inhibits luciferase expression. (C) Constitutive active 
IRF7-2D (100 ng of expression vector) induce high amounts of IFNα6-promoter driven 
luciferase. V is able to inhibit also activated IRF7. All assays are normalized using co-
transfection of CMV-promoter driven renilla luciferase. Mock transfection is set to 1. (D) Pull-
down of Ig-tagged MV P, V, PVN, PC, or VC (or empty vector) with sepharose A beads. Co-
expression of Fl-tagged IRF7-2D or IRF3-5D. Only Fl-IRF7-2D co-precipitates with Ig-MV-V and 
-VC comparably to Fl-IRF7. As the Ig-tag is recognized by the secondary antibody used, bands of 
Ig-MV-V, Ig-MV-PVN, and Ig-MV-PC are visible on both blots (marked by *) for Fl-IRF7-2D and Fl-
IRF3-5D. 
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inhibited in its activated (phosphorylated) form. A mutant IRF7 construct has 
been shown to act as a constitutive active form of IRF7 (Lin et al., 2000). Two 
serine mutations to aspartate (S477D, S479D) generate a phosphomimetic form 
of IRF7 (IRF7-2D). 
First, I compared the inhibitory effect of MV V on wild type and constitutive 
active IRF7 in our reporter gene system (Fig. 15A-C). The induction of IFNα6-
promoter activity either by expression of IRF7, MyD88, TRAF6, and IKKα as 
described above (including 20 ng of IRF7 expression vector), or by high level 
overexpression of IRF7 only (100 ng of plasmid), was inhibited efficiently by 
increasing amounts of MV V (Fig. 15A and B). Overexpression of IRF7-2D by 
transfection of 100 ng of the expression vector caused an approx. 200-fold 
higher activation of the IFNα6-promoter, compared to the other methods, in 
which IRF7 needs to be phosphorylated first to reach an activated level (Fig. 
15C). Also in this case, MV V showed a clear inhibitory effect in a dose-
dependent manner, however, this effect was much less prominent (≈ 60 % 
reduction of promoter activity) compared to the transfection mix (≈ 92 %), or 
IRF7 only (≈ 73 % reduction).  
Next, I performed co-immunoprecipitation experiments with Fl-IRF7-2D to 
prove that MV V is able to bind IRF7 independently of its phosphorylation 
status (Fig. 15D). Indeed, when pulling down Ig-MV-V, or Ig-MV-VC, I was able 
to co-precipitate Fl-IRF7-2D, but not with Ig-MV-P, Ig-MV-PVN, or Ig-MV-PC. In 
contrast, Fl-IRF3-5D, a constitutive active form of IRF3 (Lin et al., 2000), did not 
bind to Ig-MV-V or any other tested construct. Obviously, bands of the Ig-tagged 
V, PVN, and PC (marked by *) reacted with the secondary antibody and, 
unfortunately, appeared in the blot at a position similar to Fl-IRF7-2D, as these 
constructs have similar MWs. The bands can also be observed in the blot 
against Fl-IRF3-5D, but this construct migrates to a lower MW. 
In summary, these data support the hypothesis that MV V is able to bind both 
the inactive and the active form of IRF7, thereby preventing recruitment of 
IRF7 to the signaling complex, but also further downstream signaling of 
activated IRF7. 
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3.7  Infection studies of primary BMDC with recombinant rabies 
viruses expressing MV P, V, or C 
So far, all experiments were done in transfectable cell lines using cDNA to 
overexpress the viral and cellular proteins, thereby creating an artificial 
system, in which the signaling complex of TLR7/9 was reconstituted and the 
effect of V was studied. Now, the data obtained should be confirmed in primary 
pDCs differentiated from murine bone marrow derived cells (BMDCs). As MV is 
almost  
exclusively restricted to humans and some primates, and, as a second reason, a 
reverse genetics system for MV is not available in the lab, I generated 
recombinant rabies viruses (RV) derived from the laboratory strain SAD-L16 
(in the following entitled as wt RV) expressing MV proteins P, V, or C from a 
newly introduced additional gene (Fig. 16A). The generation of these 
recombinant viruses was performed as previously described (Schnell et al., 
1994). Furthermore, recombinant RVs with a deletion in the RV-P gene (Δ aa 
181-186 = ΔIND2), which leads to a defect in inhibition of IFNβ induction by the 
TBK1/IRF3-dependent RLR signaling (SAD-PΔIND2; (Brzózka et al., 2005) and 
unpublished data), were engineered to express MV P, V or C. 
The recombinant viruses were characterized on BSR-T7/5 cells by growth 
curves (Fig. 16B and C), on RNA level by Northern blot (Fig. 16E and F), and on 
protein expression level by Western blot (Fig. 16G). The different viruses 
showed similar growth kinetics in comparison with wt SAD-L16 (Fig. 16B) or 
SAD-PΔIND2, respectively (Fig. 16C). Even the mutation in the essential RV P 
gene does not influence the growth of the recombinant viruses on IFN 
incompetent BSR-T7/5 cells. All viruses show comparable levels of mRNA for 
the RV nucleoprotein (RV N), as well as comparable amounts of genomic / 
antigenomic RNA (Fig. 16E). The different lengths of the genomic RNAs arise 
from the insertion of the ORFs of MV P, V, or C, which are approx. 1.6 kb, 1.0 kb, 
or 0.5 kb in length, respectively. Using a specific probe for the MV C coding 
sequence, we were able to visualize the mRNAs for MV P, V, and C, which are 
expressed from the particular viruses (Fig. 16F). The amounts of the different 
mRNAs are on equal levels. Western blot analysis of cell lysates revealed that all  
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Figure 16: Generation and characterization of recombinant rabies viruses expressing MV 
P, V, or C.  
(A) Schematic representation of the genomic organization of recombinant wt RV (SAD-L16) and 
recombinant RVs expressing MV P (SAD-G-MVP), V (SAD-G-MVV), or C (SAD-G-MVC) from an 
additional gene inserted between RV G and L genes. Corresponding recombinant RVs were 
generated using a recombinant RV with a deletion in the RV P gene (ΔIND2). (B – C) 
Characterization of recombinant RVs by growth curves on BSR-T7/5 cells. (B) Wt derived 
recombinant RVs grow to similar titers as SAD-L16. SAD-G-MVC grows with slightly increased 
kinetics. (C) SAD-PΔIND2 derived recombinant RVs grow to similar titers as parental virus. In 
addition, the growth kinetics are comparable to SAD-L16. (D) Comparison of growth kinetics of 
wt RV and MV (Schwarz strain) on BSR-T7/5 cells. Although the cells are of non-human origin, 
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the MV(Schwarz) produces detectable titers in the supernatant of infected cells. (E – F) 
Northern blot analysis of infected BSR-T7/5 cells. Total RNA was extracted 48 h p. i. (MOI = 1) 
and subjected to Northern blot analysis. (E) Detection of RV N mRNA and genomic/antigenomic 
RNA using a N specific 32P-labeled probe. Different lengths of RV genomes due to the inserted 
genes are visible. The amount of N mRNA differs slightly among the viruses. (F) Detection of MV 
specific mRNAs and genomic/antigenomic RNA using a C specific 32P-labeled probe. Genomes of 
rec. RVs expressing MV genes, as well as mRNAs for MV P, V, and C are detectable usinig the C 
specific probe. The genomes are of different length reflecting the length of the inserted ORFs (P: 
+1.6 kb; V: +1.0 kb; C: +0.5 kb). P/C and V/C mRNAs are detectable in MV infected cells. They 
appear as one band, as they differ only in 1 nt in length. MV genomic RNA is not detectable. (G) 
Western blot analysis of BSR-T7/5 cells infected (MOI = 1) with recombinant RVs or 
MV(Schwarz). Cell lysates were prepared 48 h p. i. Levels of RV specific proteins (G, N, P) are 
comparable in all recombinant viruses. The mutated PΔIND2 protein migrates to a slightly 
lower MW. MV P, V, and C are expressed by the respective viruses to comparable levels. In 
MV(Schwarz) infected cells, H, P, as well as C proteins are detectable, while V is expressed very 
weakly. 
 
viruses show equal expression levels of RV essential proteins N, P, and G (Fig. 
16G). In addition, MV P, V, or C are expressed to a high extent from respective 
recombinant viruses. 
In these experiments, we infected BSR-T7/5 cells also with MV (Schwarz 
strain). Although the cells are hamster derived, we clearly saw productive 
infection with MV, though at low level. On mRNA level, the MV P+C and V+C 
mRNAs, which differ only in one nucleotide in length, can be detected as a 
single band with the MV C probe (Fig. 16F). On protein level, high levels of MV H 
could be detected, as well as low levels of MV P, and the non-structural MV C, 
which should be detectable only after successful infection and viral 
transcription (Fig. 16G). MV V levels were very low in these experiments, but 
detectable after long exposure of the hyperfilm. Virus progeny could also be 
shown by growth curves (Fig. 16D). Notably, only virus titers from 
supernatants of infected cells were determined, although in the case of MV 
most of the virus is cell associated. MV infectivity was also determined on other 
non-human cell lines, like murine NA cells (data not shown and (Abdullah et al., 
2009)). 
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The recombinant RVs and MV were used in the next step to analyze their ability 
to infect BMDC-derived murine pDCs and thereby inhibit the production of 
IFNα by these cells in vitro. BMDCs were extracted from femur and tibia of 
C57/BL6 mice and differentiated with Flt3-L into a cell population, which 
contained approx. 14 % of pDCs, as confirmed by FACS staining specific for 
CD11c and B220 (Fig. 17A). These cells were infected with recombinant RVs, or 
MV (Schwarz strain) at an MOI of 3. The cells were stimulated 24 h p. i. either 
with the TLR9 ligand CpG ODN2216 (3 µg/mL), or with the TLR7 ligand R848 
(2 µg/mL), or left untreated. Supernatants and cells were harvested 48 h p. i. 
and murine IFNα specific ELISA was performed with the supernatants (Fig. 
17B). PDCs produced low amounts of IFNα upon infection with recombinant 
RVs, or MV. No significant differences between different RVs, or between RV 
and MV infection were detectable. Uninfected pDCs responded with the 
 
 
Figure 17: IFNα production in murine bone marrow-derived pDCs.  
BMDCs were isolated from C57/BL6 mice and cultivated in the presence of Flt-3L. Cells were 
infected with recombinant RVs or MV(Schwarz) at a MOI of 3 and treated with 3 µg/mL CpG 
ODN2216 24 h p. i., or left untreated. 24 h later, cells were harvested and lysed, and 
supernatants were harvested and IFNα production was measured by ELISA. (A) FACS analysis 
of cultivated BMDCs 7 d p. treatment with Flt-3L. Cells were stained against pDC markers B220 
and CD11c. 14 % of the cells were B220+ CD11c+ and therefore claimed to represent pDCs. 49.6 
% were B220− CD11c+ mDCs. (B) IFNα ELISA of supernatants. All infected cells produce low 
amounts of IFNα in comparison to uninfected cells. Uninfected cells produce high amounts of 
IFNα upon stimulation with CpG ODN2216. In infected cells, IFNα production upon ODN2216 
treatment is abolished. (C) Western blot analysis of cell lysates. Infection was determined by 
viral antigens (RV G, N; MV H, P, V, C) and compared to β-actin. While MV infection was 
successful, RV infection was poorly detectable. 
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production of high amounts of IFNα to treatment with ODN2216. Infection with 
MV, but also with wt RV, minimized the levels of IFNα in the supernatants 
almost to the levels of infected, but untreated cells. Additional expression of MV 
P, V, or C from the recombinant RVs did not significantly alter the levels of IFNα 
production. Only in case of infection with SAD-G-MVP a decrease of IFNα 
compared to wt RV was detectable. Infection was confirmed by Western blot 
analysis of the cell lysates (Fig. 17C). The murine pDCs were productively 
infected by MV, as MV H, P, and the non-structural C were expressed at 
detectable levels. In contrast, RV infection produced almost undetectable levels 
of RV N and G. As a consequence, MV P, V, and C expression was not detectable 
in the respective recombinant RV infected cells. Taken together, these results 
imply that infection of murine pDCs with MV leads to a block in TLR9 signaling. 
In contrast, RV infection might affect the cells in an early step of infection so 
that virus replication is hindered, as the Western blot control suggests. In 
addition it appears that the functionality of the pDCs is also drastically 
disturbed, as RV infected cells do not respond any more to ODN2216. One 
explanation might be that RV infection kills the cells at a very early stage of 
infection. Therefore, the recombinant RVs are not suitable to study the effect of 
MV V in primary dendritic cells. 
 
3.8  Analysis of V of different strains – search for IFNα-ineffective V 
mutants 
In the literature, many examples can be found, in which wt MV was attenuated 
by passaging on IFN-incompentent cell lines. As a result of this attenuation the 
viruses generally show an increased immunogenicity. Comparison of the V 
protein sequences of wt and attenuated MVs reveal specific mutations in the 
gene products (Fig. 18). As one example, attenuation of the MV strain G954 
(G954-PBL) by passaging 13 times on Vero cells leads to a critical mutation in 
the V gene (H232D), which might have a negative effect on the functionality of 
the V C-terminus (Druelle et al., 2008). This attenuated virus (G954-V13) shows 
higher responsiveness to treatment with type-I IFN than the parental strain, 
implying a crucial role of VC in the inhibition of JAK/STAT signaling, which has 
also been investigated in vitro (Ramachandran et al., 2008). 
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In addition to the G954 strain, the Davis87 strain was described to show a 
comparable phenotype in a rhesus macaque model (Bankamp et al., 2008). 
Interestingly, the attenuated Davis87 (D-CEF), which has been propagated on 
chicken embryonic fibroblasts (CEFs) for several passages, showed the same 
mutation H232D that was observed in G954-V13. Furthermore, the mutation 
Y110H appeared in Davis87 (D-CEF). This tyrosine residue has been shown to 
be critical for binding of STAT1, as the Y110H mutants of MV P, and V have been 
described to be defective in STAT1 binding (Ohno et al., 2004; Caignard et al., 
2007; Devaux et al., 2007). 
In the CAM-70 strain, which is a highly attenuated Japanese vaccine strain 
(Borges et al., 2008), Y110 is mutated to cysteine, which could result in the 
same STAT1-binding deficient phenotype as the Y110H mutation. 
 
Figure 18: V protein amino acid sequence comparison of different MV strains.  
MV (Schwarz strain) V sequence is compared to V sequences of wt and attenuated strains 
Edmonston wt (EDM. (WT)), Edmonston-Zagreb (EDM.-ZAG); G954-PBL, G954-V13; Davis87, 
Davis87 (D-CEF) (Davis87 (D)); CAM-70 and CAM-70 vaccine strain (CAM-70 (VA)). Amino acid 
mutations are indicated by single letter code. Mutations introduced into MV (Schwarz strain) V 
are highlighted in red. 
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In contrast, the V protein of the Edmonston wild-type strain, which is the 
parental strain of the Schwarz vaccine strain (as well as of other vaccine strains 
like Edmonston-Zagreb, Rubeovax, Moraten, and AIK-C), shows almost 
complete sequence identity to Schwarz strain V, except G225, which originally 
is a glutamic acid residue in Edmonston wt (Parks et al., 2001). This suggests 
that Schwarz strain V should have wt MV function. 
The Davis87 and G954 strains bore two further mutations, which were 
interesting for our studies. S237G appeared both in the wt and attenuated 
Davis87 strain, T259A was present in the wt and attenuated G954 strain. Both 
mutations affected potential phosphorylation sites in the VC domain, which 
could be of importance for the inhibition of IKKα. 
In the following, H232D, H232D-S237G, and T259A mutations were introduced 
into the Schwarz strain V protein (Table 1). Additionally, the C272R mutant was 
generated, although this mutation has not been described to occur during 
attenuation. However, this residue has been described to be crucial for STAT2-
binding activity of V (Ohno et al., 2004) and therefor was thought to exhibit a 
positive control for deficiency in IFN signaling. 
Mutations were introduced into the V ORF by PCR mutagenesis as described in 
section 2.2.1.1. 
 
Table 1: Nucleotide mutations introduced into MV(Schwarz) V to generate specific aa mutants. 
mutant wt amino 
acid 
mutation wt codon mutation
MV V H232D H232 D C694 G
MV V H232D-S237G H232
S237 
D
G 
C694 
A709 
G
G 
MV V T259A T259 A A775 G
MV V C272R C272 R T814 C
MV V H232D-C272R H232
C272 
D
R 
C694 
T814 
G
C 
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Figure 19: Analysis of V mutants for their capacity to inhibit IFNα induction and type-I 
IFN signaling.  
Luciferase reporter-gene assays for IFNα induction or type-I IFN signaling. (A and C) IFNα4-
promoter driven luciferase expression by IRF7, MyD88, TRAF6, and IKKα. Increasing amounts 
of mutant V proteins (250; 500; 750 ng expression vector) show no or only little (H232D) 
differences from inhibition by V wt. (B and D) ISRE-promoter driven luciferase expression 
stimulated with 100 U/ well of recombinant type-I IFN A/D. Mutations of Zn-binding amino 
acids H232, and C272 show loss of inhibition capacity compared to V wt. All assays are 
normalized using co-transfection of CMV-promoter driven renilla luciferase. Mock transfection 
is set to 1. 
(A and B) Western blot analysis of the luciferase assay lysates. The different V mutants are 
expressed like wt V dependent on the amount of transfected plasmid (250 / 500 / 750 ng). 
 
The mutant V proteins were tested in the luciferase reporter gene system for 
their ability to inhibit the activation of the IFNα4 promoter by the 
overexpression of IRF7/MyD88/TRAF6/IKKα and compared with wt V (Fig. 
19A). All mutants showed similar inhibition capacities like wt V and were 
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expressed to similar levels as confirmed by Western blot analysis of the 
luciferase assay lysates. In contrast, when I investigated the functionality of the 
mutant V proteins in inhibition of type-I IFN signaling, I was able to observe 
significant effects of some mutants (Fig. 19B). Cells were transfected with 
different amounts of wt or mutant V, as well as a luciferase reporter contolled 
by the ISRE-promoter. Cells were stimulated with 100 U of recombinant type-I 
IFN (IFNA/D) 6 h p. tr. V constructs with mutations in the Zn-binding C-
terminus showed significant defects in their ability to inhibit JAK/STAT 
signaling: H232D, H232D-S237G, and C272R all showed a decrease of the 
inhibitory function of approx. 50 %, which might be due to a destabilization of 
the Zn-finger domain (model see Fig. 20A). However, the remaining capacity to 
inhibit ISRE-Luc promoter activity was still very strong. Again, expression of all 
V constructs was analyzed by Western blot (Fig. 19B). All constructs were 
expressed to equal levels dependent on the amount of transfected expression 
vector. Therefore, I was interested, whether we could further destabilize the C-
terminus by simultaneous mutation of two Zn-binding residues. I generated the 
H232D-C272R mutant and tested, whether this construct had lost its inhibitory 
function in both IFNα induction and type-I IFN signaling. In comparison with wt 
V or the single amino acid mutants H232D and C272R, the double mutant 
H232D-C272R did not show an altered phenotype in the inhibition of IFNα 
induction (Fig. 19C). In addition, also the inhibitory capacity in IFN signaling 
could not be further decreased by combining H232D and C272R mutations (Fig. 
19D). 
In summary, the approach of comparison of V sequences of different MV strains 
did not lead to the identification of crucial amino acids responsible for the 
inhibition of IFNα induction by MV V. However, I was able to show that the 
destabilization of the C-terminal domain of V leads to a decrease in the ability to 
block type-I IFN signaling, which might be due to weaker binding of STAT2. In 
the next step, I went further to analyze the sequences of V proteins of different 
paramyxoviruses. 
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3.9  Sequential and mutational analysis of paramyxoviral V proteins 
V protein sequences of the following viruses from the subfamiliy of 
Paramyxovirinae were collected and aligned using the ClustalX2 software 
(Larkin et al., 2007): Newcastle disease virus (Genus: Avulavirus),  Hendra virus 
(HENV), Nipah virus (NiV; both Henipavirus), canine distemper virus (CDV), 
dolphin morbillivirus (DMV), measles virus, peste-des-petits-ruminants virus 
(PPRV), rinderpest virus (RPV; all Morbillivirus), Sendai virus (SenV; 
 
 
Figure 20: Amino acid sequence comparison of V from different Paramyxovirinae. 
(A) Sequence alignment of the VC domain of V using ClustalX2. The Zn-binding domain is highly 
conserved among almost all viral V proteins. A consensus sequence was generated by choosing 
amino acids with conservation of ≥ 50 %. (B and C) Phylogenetic trees based on the complete V 
protein sequence (B) or N protein sequence (C) using TraceSuite II. The V protein based tree 
reveals grouping of V proteins according to the different genera. Similar results are obtained 
comparing N sequences. Colored frames indicate different genera. Red: Rubulaviruses; blue: 
Morbilliviruses; green: Henipaviruses. Unframed: other genera and unclassified 
Paramyxovirinae. 
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Respirovirus), human parainfluenza virus2 (hPIV2), Mapuera virus, mumps  
virus (MuV), parainfluenza virus 5 (PIV5; formerly known as simian virus 5 – 
SV5), porcine rubulavirus, simian virus 41 (all Rubulavirus), Beilong virus, fer-
de-lance virus, J-virus, Menangle virus, Mossman virus, Tioman virus, and 
Tupaia virus (all unclassified Paramyxovirinae). The N-terminus of the V 
protein shows high variability over all Paramyxovirinae, but sequences within 
the different genera show high homology (see Appendix B). Notably, the C-
terminal Zn-finger domain is conserved among all viruses (Fig. 20A). This  
 
 
Figure 21: Sequence comparison of MV VC and rubulaviral VC and homology modelling of 
MV VC based on the PIV5 VC structure.  
(A) Sequence alignment of VC domains of MV, PIV5, MuV, and hPIV2. Secondary structure 
elements are indicated by arrows (β-strands) and numbers (1, 2: Zn-binding residues). Amino 
acids of Box1, Box2, and Box3 are highlighted by red, green, or blue frames, respectively. Amino 
acids mutated in MV V are highlighted in red and green. (B) PIV5 VC structure model. Box1 and 
Box2 elements are highlighted in red or green respectively. Zn-binding residues and mutated 
residues are highlighted as stick-models. (C) Homology model of MV VC based on the PIV5 VC 
structure information. Highlights as in (B). The Box3 region could not be modeled and is 
therefore displayed as a dotted line. Both MV model and PIV5 structure are closely related to 
each other. However, the detailed conformation of selected residues strongly differs in both 
models. 
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indicates the important role of the domain. With the help of the Evolutionary 
Trace Server (TraceSuite II; (Innis et al., 2000)), I generated a phylogenetic tree 
based on the sequence alignment of the V protein (Fig. 20B) and compared this  
phylogenetic tree with the N protein-based tree (Fig. 20C; alignment see 
Appendix A). Viruses of the genera Morbillivirus (blue box) or Rubulavirus (red 
box) grouped nicely into branches of both trees. The unclassified Tioman virus 
and Menangle virus shared highest homology to Rubulaviruses. The V proteins 
of Morbilliviruses have are separated very early from Rubulavirus or 
Henipavirus (green box) V proteins.  This might explain the unique function of 
MV V concerning binding to IKKα and IRF7, which is not shared by V proteins of 
other genera. In contrast, N protein sequences are not separated as 
conspicuously as V protein sequences and show higher homology to 
Henipavirus N proteins. The unclassified Paramyxoviruses Beilong virus and J-
virus V proteins cluster together with Henipaviruses, whereas N proteins share 
similarity with Morbillivirus sequences. Vice versa behave the sequences of 
Tupaia paramyxovirus. SenV is the most distant Paramyxovirus regarding both 
V and N sequences. 
Next, I had a closer look on the sequences of MV V and Rubulavirus V proteins, 
namely of MuV, hPIV2, and PIV5. These V proteins have recently been described 
to inhibit TBK1/IKKε/IRF3 dependent induction of IFNβ by a very similar 
mechanism as MV V inhibits IKKα/IRF7 (Lu et al., 2008). Sequence alignment of 
the V C-terminal domains of these viruses revealed few amino acid mutations 
within the highly conserved domain (Fig. 21A). These mutations could 
determine the specificity of V in inhibition of either the one or the other 
signaling complex. Also the binding of STAT2 has recently been mapped for MV 
V to two subdomains within the C-terminus, further referred to as Box1 (aa 
241-249), and Box2 (aa 260-266), which both cooperate in STAT2 binding 
(Ramachandran et al., 2008). 
A homology model of the MV V C-terminus was created (Fig. 21C; Johannes 
Söding, Gene Center), using the crystal structure of PIV5 V as template (Fig. 
21B; (Li et al., 2006)). Due to the high homology of both sequences, the 
resulting model of the MV V C-terminus was extremely similar to the PIV5 V 
crystal structure. However, although the architecture of the domains is equal, 
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they contain striking differences on single amino acid level, which might 
explain the functional differences of PIV5 V and MV V. These mutations could 
have impact on the protein surface charge or polarity and thereby could 
determine substrate binding specificity. I selected amino acids, which differed 
between MV and the rubulaviral V proteins and generated amino acid exchange 
mutants of MV V and MuV V or PIV5 V, respectively (Table 2).  
The mutation R244E and the triple mutations R244E-F246R-D248F (based on 
the MuV V sequence), and R244E-F246K-D248T (based on the PIV5 V 
sequence) all lie within the Box1 region, whereas the mutants T259AAAA and 
A265F-R266E affect the Box2 region. We also generated PIV5 V mutants 
containing the respective MV V amino acid residues: E183R and F204E-E205R. 
A third class of mutants was generated in which we deleted the Box3 region 
from MV V (MV VΔ284-299) and fused these amino acids to PIV5 V (PIV5 V:MV-
V284-299). 
The MV and PIV5 V mutants were tested for their ability to inhibit IFNα4 
promoter activation in luciferase reporter gene assays and compared to wt MV 
and PIV5 V (Fig. 22A). MV V R244E and A265F-R266E did not show an altered 
phenotype compared to wt MV V, neither did PIV5 V E183R. The mutant PIV5 
A204F-E205R was more competent in inhibiting IFNα induction than wt PIV5 
V, but the effect was less intense than inhibition by wt MV V. Deletion of Box3 in 
MV V (MV VΔ284-299) led to an increased inhibitory function compared to wt 
MV V (Fig. 22B). On the other hand, fusion of MV V284-299 to the C-terminus of 
PIV5 V (PIV5 V:MV-V284-299) had no effect on PIV5 V. This leads to the 
assumption that the Box3 region of MV V does not mediate the inhibitory 
function of MV V, but rather could suppress this function. 
As the mutation of one amino acid in Box1, or of two amino acids in the Box2 
region was not sufficient to completely abolish MV V functionality, I generated 
mutants with three amino acid exchanges in Box1 (R244E-F246R-D248F and 
R244E-F246K-D248T), or four amino acid exchanges in the Box2 region 
(T259AAAA). These mutants were also tested in their ability to suppress IFNα4 
promoter activity (Fig. 23A), or type-I IFN-dependent ISRE activation (Fig. 23B) 
in luciferase reporter gene assays. MV V R244E-F246R-D248F and R244E-  
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Table 2: Nucleotide mutations introduced into MV(Schwarz) V to generate specific rubulavirus 
analog mutants. 
mutant 
wt amino 
acid 
mutation 
wt 
nucleotide 
mutation
MV V R244E
 
 
R244
 
 
E
 
 
C730 
G731 
C732 
G
A 
G 
MV V R244E-F246R-
D248F 
(“MuV-like”) 
 
 
 
 
 
R244
 
 
F246 
 
 
D248 
 
E
 
 
R 
 
 
F 
 
C730 
G731 
C732 
T736 
T737 
T738 
G742 
A743 
G
A 
G 
C 
G 
T 
T 
T 
MV V R244E-F246K-
D248T 
(“PIV5-like“) 
 
 
 
 
 
R244
 
 
F246 
 
 
D248 
 
E
 
 
K 
 
 
T 
 
C730 
G731 
C732 
T736 
T737 
T738 
G742 
A743 
G
A 
G 
A 
A 
A 
A 
C 
MV V A265F-R266E 
(“PIV5-like”) 
 
 
A265
 
R266 
 
F
 
E 
 
G793 
C794 
A796 
G797 
T
T 
G 
A 
MV V T259A-L260A- 
G261A-T262A 
(= T259AAAA) 
 
 
T259
L260 
 
G261 
T262 
A
A 
 
A 
A 
A775 
C778 
T779 
G782 
A784 
G
G 
C 
C 
G 
MV VΔ284-299 Deletion of amino acids 284-299 (Box3) 
PIV5 V E183R 
(“MV-like”) 
E183
 
R
 
G547 
A548 
A
G 
PIV5 V F204A-E205R 
(“MV-like“) 
 
 
F204
 
E205 
 
A
 
R 
 
T610 
T611 
G613 
A614 
G
C 
A 
G 
PIV5 V:MV-V284-299 C-terminal fusion of MV V Box3 (aa 284-299) 
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Figure 22: Inhibition of IFNα induction by MV and PIV5 V mutant proteins.  
Luciferase reporter-gene assays with IRF7, MyD88, TRAF6 and IKKα, as well as luciferase under 
the control of the IFNα4-promoter. (A) Single or double amino acid exchanges from MV V to 
PIV5 V and vice versa do not alter the phenotypes of wt MV V or PIV5 V. MV V inhibits IFNα 
induction, while PIV5 V does not. (B) Deletion of Box3 (aa 284 – 299) from MV V and insertion 
of these amino acids to the PIV5 V C-terminus has no negative influence on MV V or PIV5 V 
activity. MV VΔ284-299 rather inhibits IFNα induction better than wt MV V. All assays are 
normalized using co-transfection of CMV-promoter driven renilla luciferase. Mock transfection 
is set to 1. 
 
F246K-D248T only showed minor differences in inhibition of IFNα induction 
compared to wt MV V. In contrast, MV V T259AAAA was unable to accomplish 
its inhibitory function. In comparison, all mutants still were able to inhibit type-
I IFN signaling (Fig. 23B), however, this function was slightly declined 
compared to wt MV V. This might be due to the fact, that the mutations 
introduced only affect binding of STAT2, whereas STAT1 binding and 
degradation is still functional (Ramachandran et al., 2008). 
Next, I tested whether the mutants MV V R244E-F246R-D248F, R244E-F246K-
D248T, and T259AAAA still were able to bind IKKα and IRF7, or whether the 
binding capacity was lost in the mutants (Fig. 23C). In accordance with the 
results of the reporter gene assay, I found both mutants MV V R244E-F246R-
D248F and R244E-F246K-D248T still being able to bind to both IKKα and IRF7, 
whereas the mutant MV V T259AAAA was no longer able to fulfill the binding. 
I further was interested whether these amino acids are exposed to the surface 
of the protein. I therefore generated a surface model of the full length PIV5 V 
from the crystal structure of the protein (Fig. 24A). As expected, the respective 
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amino acids A199-A200-A201 (shown in green) are located at the surface of 
PIV5 V and form a pocket, which could be responsible for protein-protein 
interactions. Assuming that the tertiary structure of MV V is similar to PIV5 V, 
one may conclude that the amino acids L260-G261-T262 are also exposed to 
the surface of MV V and form a characteristic binding pocket. 
 
 
Figure 23: Inhibition of IFNα induction by Box1 and Box2 mutants of MV V.  
(A) Luciferase reporter-gene assay with IRF7, MyD88, TRAF6 and IKKα, as well as luciferase 
under the control of the IFNα4-promoter. Expression of the mutant MV 
V(T259A,L260A,G261A,T262A) (= T259AAAA; 125 ng expression vector) is no longer able to 
inhibit IFNα induction. The other mutants tested also show slight defectiveness compared to V 
wt. (B) Luciferase reporter-gene assay for type-I IFN signaling. ISRE-promoter driven luciferase 
expression is stimulated with 100 U /well of recombinant type-I IFN A/D. All mutants show 
slight decrease of inhibitory activity compared to wt V. All assays are normalized using co-
transfection of CMV-promoter driven renilla luciferase. Mock transfection is set to 1. (C) Pull-
down of Fl-tagged IKKα or IRF7, (or empty vector) with Anti-FLAG® agarose beads. Co-
expression of wt or mutant MV V. The mutant V(T259A,L260A,G261A,T262A) is unable to bind 
to IKKα, and also IRF7. 
3  Results  SUBVERSION OF TOLL-LIKE RECEPTOR 7/9 SIGNALING 
BY MEASLES VIRUS − V HOLDS THE KEY 
 
86 
In summary, by comparing the sequences of the C-terminal domains of MV on 
the one side and MuV / hPIV2 / PIV5 on the other side, I was able to identify 
several amino acids that may influence the substrate specificity of MV V. These 
mutants were generated and tested in luciferase reporter gene assays and co-
immunoprecipitation experiments and compared with wt MV V. The mutant 
MV V T259AAAA showed a clearly reduced inhibitory function and was unable 
to bind to IKKα or IRF7. 
 
Figure 24: MV V peptides.  
(A) Location of the Box2 amino acid analogs on the surface model of PIV5 V. Color code: gray: 
PVN, red: VC, green: A199,A200,A201 of Box2. The Box2 amino acids are located in a pocket at 
the surface of the protein. (B) Sequence alignment of PIV5 VC and MV VC. Color code for PIV5 VC 
is analog to (A). Peptides were synthesized including Box1+2 (aa 240 – 264) of MV V or Box2 
only (aa 257 – 266). Peptides were designed either with the MV V wt sequence or with the 
mutations equal to T259AAAA. (C and D) In vitro kinase assay with IKKα, IRF7, and full length 
His-MV-V (3) or peptides V240-264 (5) and Vmut240-264 (6). As peptides are dissolved in DMSO, a 
control with DMSO is included (4). Reactions with DMSO do not show kinase activity. (E and F) 
In vitro kinase assay with IKKα, IRF7, and full length His-MV-V (3) or peptides V257-266 (4) or 
Vmut257-266 (5).  Both peptides show only minor effects on IKKα kinase activity in contrast to 
full length V. (D and F) Quantification of phospho-IRF7 bands. 
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In the next step, I was interested, whether peptides including the crucial amino 
acids 259-262 also could inhibit the activation of IRF7 by IKKα. 
 
3.10  MV V peptides 
Peptides were designed including either both Box1 and Box2 (V240-264) or Box2 
alone (V257-266) as well as peptides with the T259AAAA mutation (Vmut240-264 
and Vmut257-266; Fig. 24B). The peptides were synthetized and purified by HPLC 
(Metabion). Unfortunately, the peptides V240-264 and Vmut240-264 were not 
soluble in water and therefore could not be purified and were used as crude 
extracts dissolved in DMSO. I tested in vitro whether the peptides could block 
phosphorylation of IRF7 by IKKα. Surprisingly, a strong inhibition of IRF7-
phosphorylation was found in presence of either V240-264 or Vmut240-264, which 
was comparable to full length His-MV-V (Fig. 24C and D). Unfortunately, when I 
added an equal volume of DMSO to the reaction instead of peptide solution, the 
kinase activity of IKKα was completely blocked (Fig. 24C, lane (4)) so that I 
conclude that the effect detected with the peptides is due to the solvent and not 
peptide specific. The peptides including Box2 (V257-266 and Vmut257-266) were 
also tested in the in vitro kinase assay system (Fig. 24E and F). These peptides 
are soluble in water and were pure up to 90 %. A weak decline of kinase 
activity was detected in the presence of V257-266, but the effect was also 
detectable with Vmut257-266, which should be unable to bind to IKKα. 
From this data I conclude that small peptides including only the amino acids 
responsible for binding to IKKα and IRF7 are not able to act as inhibitors. 
Presumably, the formation of the whole binding pocket, which is composed of 
amino acids from the N-terminal domain (see Fig. 20A; shown in grey) as well 
as the C-terminal domain (shown in red and green) in case of PIV5 V (Fig. 24A) 
is necessary for a fully active V protein. This conclusion is coherent with the 
previous findings that the V C-terminus alone is not sufficient to inhibit the 
induction of IFNα, but may require also residues from the N-terminus. 
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3.11  Functions of MV V in NF-κB activation 
Not only IFNα, but also NF-κB is activated via TLR-signaling, and, in addition, 
IKKα is also involved in this signaling process. So it was obvious to test, 
whether V is also able to inhibit activation of NF-κB by IKKα. Luciferase 
reporter gene assays were performed using a NF-κB promoter driven firefly 
luciferase. Induction of this gene was achieved by transfecting 300 ng of 
expression vectors for either IKKα (Fig. 25A) or its homologue IKKβ (Fig. 25B), 
which are both involved in the formation of the IKK-complex consisting of 
IKKα, IKKβ and IKKγ. In both cases some dose-dependent inhibitory effect of 
MV V could be detected, however, the inhibition was not as significant as in 
IFNα induction. As this result was not very clear, I decided to do confocal 
immunofluorescence experiments and tracked nuclear localization of the NF-κB 
subunits p65/RelA (Fig. 25C) and RelB (Fig. 25D) upon stimulation of cells with 
TNFα in the presence or absence of transfected Fl-MV-V. HEp-2 cells were 
transfected with empty vector or Fl-MV-V, stimulated with 5 U of recombinant 
TNFα 24 h p. tr. or left untreated, and fixed and stained 30 min post stimulation. 
Without stimulation, nuclear localization of neither p65/RelA nor RelB could be 
detected (top lane). In case of stimulation with TNFα, a clear activation of both 
forms of NF-κB could be detected, as nuclear accumulation of the transcription 
factors occurs (middle lane). In the presence of Fl-MV-V, nuclear localization of 
p65/RelA was inhibited in most of the cells, however, some showed nuclear 
localization (bottom lane). Also activation of RelB was inhibited by Fl-MV-V 
only to some extent. An in vitro kinase assay was performed using 100 ng of 
recombinant His-IKKα and 1 µg of GST-I-κB-α (Fig. 25E and F). In contrast to 
His-IRF7, phosphorylation of GST-I-κB-α by IKKα was not inhibited by His-MV-
V, and also His-MV-P did not influence the phosphorylation of GST-I-κB-α. 
In summary, these data suggest a substrate specific inhibition by MV V. 
Although NF-κB activation is also mediated by IKKα – at least in parts – this 
function of IKKα is not inhibited as clearly as the activation of IRF7. 
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Figure 25: Effects of MV V on NF-κB activation.  
(A and B) Luciferase reporter-gene assays with overexpression of IKKα (A) or IKKβ (B) to 
stimulate luciferase expression under the control of the NF-κB-promoter. Co-expression of MV 
V (500 ng; 750 ng; 1000 ng; 1250 ng; 1500 ng) shows minor effects on the expression of NF-κB 
promoter-driven luciferase. All assays are normalized using co-transfection of CMV-promoter 
driven renilla luciferase. Mock transfection is set to 1. (C and D) Confocal immunofluorescence 
of nuclear translocation the conventional NF-κB subunit p65/RelA (C) or the alternative NF-κB 
subunit RelB (D) upon stimulation of HEp-2 cells with 5 U of recombinant TNFα and effect of 
transfected Fl-MV-V. Color code: green: p65/RelA, or RelB (stained with p65/RelA or RelB 
specific antibodies; red: Fl-MV-V (stained with anti-FLAG® M2); blue: ToPro3 nuclear staining. 
Both p65/RelA and RelB are distributed in the cytoplasm (lane 1) and translocate to the 
nucleus upon stimulation (lane 2). In the presence of Fl-MV-V, the translocation of both 
subunits is inhibited in some cells, but many still show full translocation of p65/RelA or RelB 
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into the nucleus (lane 3). (E and F) In vitro kinase assay with IKKα, GST-tagged I-κB-α, and MV V 
(3) or MV P (4). Neither V nor P is able to inhibit the phosphorylation of I-κB-α by IKKα. (F) 
Quantification of phospho-I-κB-α bands. 
 
3.12  Control of autophagy by Measles virus 
Autophagy has been shown to be closely connected to TLR7 signaling. On the 
one hand, viral nucleic acids are transported via autophagy from the cytoplasm 
of infected pDCs to endosomal compartments, where TLRs are located (Lee et 
al., 2007). On the other hand, stimulation of TLR7 leads to increased formation 
of autophagosomes (Delgado et al., 2008). We addressed the question, whether 
MV is able to influence autophagy during infection and whether the V protein is 
also important in these mechanisms. 
An experimental setting was designed to follow the induction of autophagy 
during MV infection. The results were with starvation conditions, a natural 
inducer of autophagy (Martinet et al., 2006). The autophagy-related protein 
light chain 3 beta (LC3B, or LC3) was chosen as readout for the induction of 
autophagy. This protein is exported from the nucleus and incorporated into 
autophagosomal membranes upon activation. U3A cells stably transfected with 
a plasmid encoding a GFP-LC3 fusion protein were used to visualize autophagy. 
The cells were treated with Bafilomycin (200 nM), an inhibitor of membrane 
fusion, which thereby inhibits the lysosomal degradation of autophagosomes. 
The cells were infected with MV (MOI = 1) at the time of Bafilomycin treatment, 
kept in starvation using EBSS medium without nutrients and serum, or left 
further untreated for 24 h, followed by fixation and staining of MV N as 
infection marker, as well as nuclear staining. The cells were analyzed using IF 
microscopy (Fig. 26A). In non infected and non starving cells, GFP-LC3 exists 
mostly in an inactive form, which is distributed in both cytoplasm and nucleus 
(top lane). In most cells some vesicular GFP-LC3 is visible, however, it has been 
shown that this is due to localization to the smooth endoplasmic reticulum, 
which is independent of autophagy (Korkhov, 2009). In both infected cells 
(middle lane) and starving cells (bottom lane) GFP-LC3 is activated within 24 h 
p. i. / p. treatment, which results in an accumulation of GFP-LC3 containing 
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Figure 26: Effect of MV infection on the activation of autophagy.  
U3A cells stably expressing GFP-LC3 (green) were analyzed for activation of autophagy. (A) 
Cells were treated with Bafilomycin (200 nM) and left further untreated (lane 1), were 
subsequently infected with MV at an MOI = 1 (lane 2), or were starved in EBSS medium (lane 3) 
for 24 h in each case. MV N was stained with anti-MV-N (red) and nuclei were stained with 
ToPro3 (blue). In untreated cells, GFP-LC3 appears to be distributed in both cytoplasm and 
nucleus, with few autophagosomes in the cytoplasm. In contrast, in both MV infected and in 
starving cells, GFP-LC3 is activated and incorporated into autophagosomes as indicated by the 
lack of nuclear GFP-LC3. (B) Cells were counted for GFP-LC3 localization in both cytoplasm and 
nucleus, or in cytoplasm only. Untreated cells mainly show inactive nuclear GFP-LC3, whereas 
GFP-LC3 is exported from the nucleus both in MV infection and in starvation. (C) Cells were 
infected with MV (MOI = 1) and treated with Bafilomycin (200 nM) either subsequently (lane 1) 
or 24 h p. i. (lane 2). Cells were fixed 24 h p. treatment in each case. Early upon infection (0 – 24 
h; lane 1) MV induces the formation of autophagosomes. In contrast, at the later time point (24 
– 48 h; lane 2) GFP-LC3 is not activated upon infection. 
 
vesicles in the cytoplasm and a complete loss of nuclear GFP-LC3. Similar 
numbers of cells were counted and examined for activation of GFP-LC3 (Fig. 
26B). In untreated cells, 97 % of all cells exhibited inactive GFP-LC3 in their 
3  Results  SUBVERSION OF TOLL-LIKE RECEPTOR 7/9 SIGNALING 
BY MEASLES VIRUS − V HOLDS THE KEY 
 
92 
nuclei, whereas in only 3 % of the cells GFP-LC3 was cytoplasmic. In contrast, 
under starvation conditions, in 80 % of the cells GFP-LC3 was completely 
activated, whereas 20 % of the cells still showed nuclear GFP-LC3. Also during 
MV infection, the majority (92 %) of infected cells showed completely active 
GFP-LC3, whereas in 8 % of the infected cells nuclear GFP-LC3 was detectable. 
This indicates that autophagy is induced upon MV infection comparable to 
starvation of the cells. 
Induction of autophagy by MV at different stages of infection can be followed by 
treating the cells with Bafilomycin at various time points p. i. Autophagosomes 
fuse with lysosomes after formation and undergo subsequent degradation. The 
fusion step is inhibited by Bafilomycin. As a consequence, induction of 
autophagy can be visualized from the time of treatment with Bafilomycin until 
fixation of the cells. 
U3A cells stably expressing GFP-LC3 were infected with MV (MOI = 1) and 
treated with Bafilomycin either subsequently or 24 h p. i. (Fig. 26C). The cells 
were fixed 24 h p. treatment with Bafilomycin. In the case of simultaneous 
infection and Bafilomycin treatment, vesicular accumulation of active GFP-LC3 
can be detected (top lane). In contrast, when cells are treated with Bafilomycin 
24 h p. i., most GFP-LC3 appears in the inactive form in the nuclei of infected 
cells. GFP-LC3 that has been activated during the first 24 h of infection has 
already been degraded before the treatment with Bafilomycin. These results 
indicate that the virus performs a switch in the cell from induction of autophagy 
to inhibition during infection. This might be due to a viral factor that is 
expressed at later stages of infection. This factor could be one of the non 
structural proteins V or C. 
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4  Discussion 
 
4.1 Mechanism of the inhibition of IFNα induction by MV V 
In summary, the mechanism of the inhibition of TLR7/9 signaling by MV could 
be clarified on a molecular level (Fig. 27). The non-structural V protein was 
identified as the major antagonist of this signaling cascade involving MyD88, 
TRAF6, IKKα and IRF7. V acts as a decoy substrate for the crucial kinase IKKα 
and prevents activation of the transcription factor IRF7 by IKKα through a 
direct interaction with both the kinase (IKKα) and the substrate (IRF7). 
Upon binding to IKKα, V inhibits the phosphorylation of IRF7 by IKKα, which 
leads to a strong downregulation of the levels of activated phospho-IRF7 
(pIRF7) in the presence of V. I was able to show this effect both in vitro and in 
cell culture. Here, V acts as a decoy substrate for IKKα. N- and C-terminal 
deletion mutants of the protein were generated to identify phosphorylation 
sites of V. Notably, all mutants tested were phosphorylated by IKKα and other 
related kinases (IKKβ, TBK1) in vitro, and also purified P was phosphorylated. 
This suggests a high degree of unspecific reactions in vitro. However, although 
both full length proteins V and P were phosphorylated, only V was able to 
compete with IRF7, but P did not. V was also unable to inhibit the 
phosphorylation of I-κB-α by IKKα. This shows the specificity of V as an 
antagonist of IKKα/IRF7. The inhibition of phosphorylation of IRF7 by V is 
competitive and non-catalytic. Higher amounts of V are needed to inhibit 
activation of IRF7 for a longer period of time, whereas low amounts of V are 
suitable to fulfill their inhibitory function for a shorter period of time. Once all 
available V has undergone phosphorylation, it appears to be no longer available 
as a potential decoy factor in vitro. 
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Figure 27: Model of the inhibitory mechanism of MV V.  
Taking together the data obtained, we are able to create a model of the mechanism of inhibition 
of IFNα induction by MV V. This mechanism includes multiple steps, which are mediated by 
binding of MV V to IKKα and IRF7. (1) Binding to IRF7 inhibits the recruitment of the 
transcription factor to the activating signaling complex. (2) Binding to IKKα competes with 
IRF7 for the phosphorylation by IKKα. (3) Binding to phospho-IRF7 may inhibit the formation 
of pIRF7-dimers, or, in case of binding to pIRF7-dimers, (4) may inhibit the translocation of 
these dimers to the nucleus. In summary, all single steps of the mechanism may contribute to 
the downregulation of IFNα production by TLR7/9 signaling. 
 
In parallel to its function as a decoy substrate for IKKα, V is also able to bind 
IRF7. This could prevent the recruitment of IRF7 to the signaling complex and 
thereby also would lead to the inhibition of the activation of IRF7. But V is also 
able to bind to IRF7-2D, a constitutive active form of IRF7 (Lin et al., 2000). 
Thus, V is able to prevent the last steps of the singaling cascade. It could not be 
clarified, whether V binds to pIRF7 monomers, thereby preventing the 
dimerization of pIRF7, or if it is able to bind also to active pIRF7 dimers, 
thereby preventing the translocation of the transcription factor to the nucleus. 
The first variant is certainly the more probable one, as the antagonistic 
functions of V in this pathway could be explained very simply assuming that V 
acts as an IRF7 mimic. V appearing as a “false IRF7” is able to bind to IKKα like 
IRF7, and it should also be able to form heterodimers with IRF7, thereby 
forming a complex that is unable to enter the nucleus and/or to act as a 
transcription factor for the expression of IFNα genes. 
4  Discussion  SUBVERSION OF TOLL-LIKE RECEPTOR 7/9 SIGNALING 
BY MEASLES VIRUS − V HOLDS THE KEY 
 
95 
The interaction of V with the signaling proteins is mediated by the C-terminal 
V-specific Zn-finger domain (VC). I could show that VC is sufficient for binding to 
IKKα and also to IRF7. However, in the luciferase reporter gene assay, VC fused 
to an Ig-tag (Ig-MV-VC) did not inhibit the IFNα6-promoter activity. Several tags 
were fused to VC, among them FLAG®, His, myc, and DsRed. Fusion proteins 
with high MW tags (Ig-MV-VC, DsRed-MV-VC) were detectable on protein level, 
but did not influence the induction of IFNα. Fusion proteins with small tags (Fl-
MV-VC, myc-MV-VC, His-MV-VC) or untagged VC also did not show inhibition of 
IFNα-promoter activation, but as they could not be detected by Western blot 
analysis of lysates of transfected cells, it is not clear whether these constructs 
were not functional or simply not expressed. This leads to the assumption that 
also parts of the PV N-terminus might be required to get a completely 
functional V protein. This is supported by the structure of the PIV5 V protein, 
which is highly homologous to MV V. Here, the Zn-finger domain functions as a 
scaffold for the formation of the tertiary protein structure. 
The VC domain is conserved among all V proteins in the family of 
Paramyxoviridae. However, it has been shown that specific VC-domains of 
different viruses show different antagonistic functions. MV V binds and inhibits 
IKKα/IRF7, as shown here, whereas others have shown that the V proteins of 
Rubulaviruses, like MuV, hPIV2 or PIV5, inhibit TBK1/IKKε/IRF3 dependent 
signaling via a mechanism that differs on the molecular level (Lu et al., 2008). 
Rubulavirus V proteins mainly interact with the kinases, but they are unable to 
interact with the involved transcription factor IRF3. The interaction of 
rubulaviral V proteins with IKKε or TBK1 leads to the ubiquitinylation and 
degradation of TBK1 and IKKε, which, in the end, inhibits the activation of IRF3. 
In addition, V is ubiquitinylated and degraded. In both cases, V proteins act as 
decoy substrates for kinases of different signaling cascades in a competitive 
manner. 
In contrast, it was shown that PIV5 V mediates the proteasomal degradation of 
STAT1, which plays a crucial role for IFN signaling (Precious et al., 2007). The 
MV V protein also inhibits IFN signaling by various mechanisms, as it was 
shown by several groups. MV V targets both STAT1 and STAT2 independently 
of each other. STAT1 is recruited by a domain including Y110 (Caignard et al., 
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2007) and this function is shared with MV P (Devaux et al., 2007). In contrast to 
rubulaviral V proteins, MV V interaction with STAT1 does not involve the 
DDB1-Cul4A ubiquitin ligase and does not lead to the degradation of STAT1, as 
shown for PIV5 V (Precious et al., 2005). The interaction of V with STAT2 is 
mediated by the V C-terminus and inhibits also the phosphorylation of STAT2 
(Ohno et al., 2004). The interaction surface of V with STAT2 could be further 
narrowed down to few amino acids of Box1 and Box2 (Ramachandran et al., 
2008). Homology modeling indicated that the crucial amino acids form a pocket 
to which STAT2 could bind. Interestingly, I was able to locate the domain 
responsible for the inhibition of IFNα induction to the same pocket. By 
exchanging four amino acids in of MV V Box2 (T259, L260, G261, T262) to 
alanine (which represent the analogous PIV5 V sequence), I was able to 
generate a mutant V that lacks the ability to bind IKKα and IRF7. However, 
interference of this mutant with type-I IFN signaling (via STAT2 binding) is 
disturbed only to a minor extent. This becomes clear, considering that the MV 
sequence was exchanged mainly by the homologous sequence of PIV5 V, which 
also binds STAT2, but is unable to inhibit IKKα/IRF7 mediated IFN induction. 
With this study, the inhibitory functions of MV V regarding IFN signaling and 
IFNα induction could be separated from each other. So far it has not been 
tested, whether the generated mutants are still able to bind to MDA-5, another 
common target of paramyxoviral V proteins. This function is also mediated by 
the C-terminal domain of the V proteins. Considering that all V proteins among 
the Paramyxovirinae are able to bind MDA-5, it would not be surprising to see 
the MV mutants still being able to bind to MDA-5, thereby prooving that this 
function is also independent of the ability to inhibit downstream signaling of 
either IKKα/IRF7 or IKKε/IRF3. 
The different evolution of V proteins of Morbilliviruses from other members of 
the Paramyxoviridae family was also shown by phylogenetic comparison of V 
protein sequences from a selection of viruses from all genera within the 
subfamily of Paramyxovirinae. Interestingly, sequence comparison revealed 
that the Morbillivirus V proteins form a branch in the pylogenetic tree different 
from Rubulaviruses and Henipaviruses. In contrast, comparison of N protein 
sequences showed that the genus Rubulavirus differs to a higher extent from 
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the Morbilliviruses and Henipaviruses. This indicates the special role of V 
proteins of the Morbilliviruses. However, it remains to be tested, whether the V 
proteins of RPV, CDV, PPRV and DMV also show the same phenotype like MV V. 
On the other hand, Morbilliviruses all share haematotropic characteristics, 
meaning that they predominantly infect and replicate in blood cells like 
lymphocytes and monocytes (Tatsuo et al., 2001). In case of MV it is clear that 
the virus infects pDCs, a DC subset which expresses TLR7/9 and is responsible 
for the production of large amounts of IFNα upon activation of this signaling 
pathway, although not many progeny virus is made. 
Peptides of either Box2 alone or in combination with Box1 were generated 
based on the wt MV V sequence and also on the T259A-L260A-G261A-T262A 
mutant. Unfortunately, the peptides including Box1 and Box2 were not solube 
in water, but DMSO and the solvent led to a drastic loss of functionality of in 
vitro kinase assays. The Box2-peptides were soluble in water so that they could 
be tested in the in vitro kinase assay to test whether the wt Box2-peptide was 
able to inhibit IRF7-phosphorylation by IKKα. I could show that both wt 
derived and mutant derived peptides led to only minor inhibition of kinase 
activity in comparison to full length His-MV-V. This result supports the theory 
that VC alone or even smaller parts of the protein are not sufficient to inhibit the 
activation of IRF7 by IKKα.  However, the peptides should also be tested in the 
cell culture system and in luciferase reporter gene assays. Liposomal 
transfection reagents are now available to introduce peptides into living cells as 
well as cell-penetrating arginine-rich fusion peptides like the HIV Tat-peptide 
(Schmidt et al., 2009). However, detection of the peptides is critical as no 
antibodies directed against the Box2 epitope are currently available. 
 
4.2 Interaction of MV with pDCs 
In order to study the antagonistic function of MV V in a natural system, i. e. 
pDCs, I established a rabies virus based vector system for the expression of MV 
P, V and C proteins. Recombinant RVs were generated expressing either MV 
protein from an additional gene. This was necessary as primary pDCs are 
hardly transfectable using lipofection or calciumphosphate protocols. As a 
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second reason, a reverse genetics system for MV is not yet established in the 
lab, which would allow the deletion of V expression in the virus context or the 
expression of mutant V proteins. Third, the source for primary pDCs of human 
origin is peripheral blood, however, the amount of pDCs per mL is very low and 
the purification procedure is difficult and time consuming. Therefore, I decided 
to extract precursor cells from murine bone marrow and differentiated them 
into a mixed culture containing pDCs. As the human pathogenic MV should not 
be able to infect cells of murine origin, the species barrier crossing zoonotic RV 
was used to infect the cells and thereby to induce the expression of the MV 
proteins. Surprisingly, I found MV infecting murine pDCs much better than RV. I 
could not figure out the reasons for this in detail, however, the expression of 
either MV P, V or C did not alter the RV phenotype. Therefore I conclude that 
induction of IFNα and its inhibition ob MV V is not a crucial factor in the context 
of RV infection. Other factors different from IFNα induction must play a role in 
the inhibition of RV replication in murine pDCs. One possibility is that RV only 
very inefficiently enters the cells. However, pDCs exposed to RV (either wt or 
expressing MV proteins) did not respond to external stimulation of TLR9 with 
CpG ODN. This suggests that pDCs are inactivated or killed upon exposure to 
RV. This assumption could have been followed by performing a cytokine ELISA, 
e.g. against IL-6. Unfortunately, no other cytokine ELISA was available. 
It has been shown in vitro that vaccine strains of MV are able to infect pDCs 
(Schlender et al., 2005), although the infection may not be productive (i.e. lead 
to production and release of new virus). However it still has to be clarified, 
whether wt strains are also able to do so in vivo. PDCs naturally do not express 
CD150 (reviewed in (Tahara et al., 2008)), the entry receptor for wt MV strains 
(de Swart et al., 2007), but they express CD46, which can be used in addition as 
a receptor by attenuated strains (Dörig et al., 1993). However it has been 
shown that MV is able to induce the expression of CD150 upon binding of the H 
protein to TLR2 (Bieback et al., 2002). Although TLR2 is expressed only weakly 
in pDCs (Hornung et al., 2002), this might give a hint that wt MV is also able to 
enter pDCs. There, TLR7 might be able to detect viral ssRNA. A third yet 
uncharacterized set of receptors mediates virus entry independent of CD150 or 
CD46 and is involved in entry of MV to epithelial cells (Tahara et al., 2008). We 
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and others were able to show that MV is able to infect even cells of non-primate 
origin, at least in vitro (BSR-T7/5; murine BMDCs; see also (Abdullah et al., 
2009)). This receptor set may also play a role in the infection of human pDCs in 
vivo. The model of the infectious route of MV in vivo also admits a central role of 
DCs (either mDCs or pDCs) to the dissemination of the virus. Another option 
instead of infecting pDCs to migrate to lymph nodes is the attachment of the 
virus to the cell surface without entry, which is mediated by DC-SIGN (de Witte 
et al., 2006). 
Another question to discuss is the kinetics of the activation of the antiviral 
immune response in pDCs and the inhibition by MV V. As V is a non-structural 
protein and therefore not incorporated into virus particles, replication has to 
take place before V is available. However, viral genomic RNA could be 
recognized by TLR7 even before the virus starts to replicate, i.e. following 
endocytosis of virus particles. This would lead to the production of IFNα and 
the immediate elimination of the virus. However, MV particles directly release 
their RNPs into the cytoplasm upon fusion of the viral and cellular membranes 
and are not endocytosed (Hashimoto et al., 2002) so that TLR7 will not be 
activated upon virus entry. This could argue against the involvement of TLR7 in 
the immune response to MV infection. 
Recent studies provided evidence that nucleic acids of replicating viruses are 
transported from the cytoplasm to TLR-containing compartments via 
autophagy, as could be shown for vesicular stomatitis virus and Sendai virus 
(Lee et al., 2007). PDCs respond with the production of high amounts of IFNα 
upon autophagocytosis of viral RNA. This fact, and also the observation that the 
formation of autophagosomes is triggered by stimulation of TLR7 with ssRNA 
or R848 (Delgado et al., 2008), exhibit a direct connection of two antiviral 
mechanisms, i.e. TLR-signaling and autophagy (Fig. 28). In this case, it is 
necessary for the virus to express an antagonist as the replication rate 
increases (i.e. when high amounts of viral nucleic acids are found in the 
cytoplasm). This could be fulfilled exactly by the V protein. 
MV V inhibits the activation of IRF7 and also – but to a minor extent – the 
activation of NF-κB, as it was shown in this study. Both transcription factors are 
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activated upon stimulation of TLR7, which might be triggered by autophagy of 
cytoplasmic MV RNAs (Fig. 28). 
It was shown in this study that MV induces autophagy in early steps of the 
infection, i.e. in the time up to 24 h p. i. The induction was comparable to 
autophagy processes induced by starvation. The GFP-LC3 marker protein was 
activated in both cases, which resulted in the export of inactive GFP-LC3 out of 
the nucleus and accumulation of autophagosomes in the cytoplasm. It still has 
to be clarified, whether this induction of autophagic processes is needed for 
virus replication or whether it is a cellular response to the infection. Notably, 
the induction of autophagy observed here is independent of the presence and 
functionality of the TLR7 signaling complex, as the cell lines used for this study 
(U3A; Vero) do not express TLR7 or IRF7 constitutively. 
I was also able to show that autophagy is inhibited at later stages of infection. In 
the time 24 – 48 h p. i. GFP-LC3 was newly expressed, but remained in the 
inactive form mainly in the nuclei of infected cells. This indicates the 
involvement of a viral factor, which gains its functionality or which is expressed 
to required levels only after viral replication has started. The non-structural 
 
 
Figure 28: Model of TLR7/8/9 signaling, JAK/STAT signaling and autophagy. 
Activation of TLR7/8/9 leads to the production of type-I IFN via IRF7 and of proinflammatory 
cytokines via NF-κB. IFN induction in turn activates JAK/STAT signaling, leading to the 
expression if ISGs, among which TLRs and IRF7 are upregulated. All three signal transduction 
pathways are modulated by the V protein of MV, leading to a block of cytokine production. 
Autophagy processes are also actvated upon recognition of viral nucleic acids by TLR7/8/9, 
which leads to an increased uptake of viral PAMPs into endodomal compartments and thereby 
increased TLR activation. Induction of autophagy is inhibited by MV factors, but it is not clear, 
whether also the connection between TLR signaling and autophagy is affected. 
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proteins V and C perfectly fulfill these criteria and it has to be tested, which 
viral proteins are involved in the inhibition of autophagy. However, molecular 
targets of MV proteins in the autophagy process have to be identified. Also, it 
still remains unclear whether the signaling processes leading to the feedback 
mechanism of autophagy and TLR7 signaling are also directly modulated by MV 
proteins. The results obtained so far only show the modulation of TLR7-
independent autophagy processes. 
 
4.3 MV induced immunosuppression and impact of IFNα inhibition 
MV causes a generalized immunosuppression upon infection of the host. This 
involves lymphopenia of B cells, monocytes, neutrophils, CD4+ and CD8+ T 
cells. Furthermore, MV causes a severe cytokine imbalance as well as silencing 
of PBMCs (reviewed in (Schneider-Schaulies and Schneider-Schaulies, 2009)). 
An initial Th1 cell activation is shifted to a prolonged Th2 cell response during 
MV infection. This leads to the suppression of the cellular immune response to 
secondary viral and bacterial infections. The interaction of MV with DCs seems 
to play a crucial role in these effects of immunosuppression. On the one hand, 
MV infection modulates DC maturation, cytokine production, antigen 
presentation, and T cell activation. Homing of infected DCs to local lymph nodes 
leads to the transfer of the virus to T cells either via direct infection, or by 
fusion of infected DCs with target cells (Fugier-Vivier et al., 1997). Modulated 
DC functions lead to the silencing of T cells. Proliferation of T cells is 
additionally inhibited by contact with MV infected cells (Schlender et al., 1996), 
which involves the viral glycoproteins H and F. 
The findings provided in this study suggest a novel mechanism of modulation of 
the antiviral response by MV, which might contribute to the 
immunosuppressive phenotype of MV. 
PDCs play a central role in the antiviral immune response (Fitzgerald-Bocarsly 
and Feng, 2007). They are described as major IFNα producing cells upon viral 
infections (Siegal et al., 1999; Cella et al., 1999), which leads to the activation of 
a Th1 biased adaptive immune response (Brinkmann et al., 1993). IFN of course 
also activates direct antiviral mechanisms of the innate immune response, 
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including the production of Mx (Horisberger and Hochkeppel, 1987) and 2’-5’-
OAS (Baglioni and Maroney, 1980). It is therefore a major factor connecting 
both branches of the host immune response (reviewed in (Le Bon and Tough, 
2002)). Thus it is surprising that MV may have chosen this cell type to invade 
the host. However, by the development of powerful tools to subvert pDC 
functions, MV is able to “hide” in or at the surface of these cells like in a Trojan 
horse to spread into the lymphatic sites of replication. The TLR7/9 mediated 
induction of IFNα is one of the central antiviral signaling processes performed 
by pDCs (and obviously plays in these cells a more important role than RLR 
signaling). By the inhibition of this signaling pathway by MV V, pDCs are 
strongly malfunctioning and this impairs the immune response to MV infection 
in vivo.  
 
4.4 Components of the TLR7/9 signaling complex 
To investigate the role of the MV V protein, the signaling complex recruited to 
TLR7/9 was reconstituted in cell lines. Naturally, TLR7 and 9 are constitutively 
expressed in immune cells like pDCs, but not in other cell types like epithelial 
cells. The same is true for IRF7. A functional signaling complex was 
reconstituted in epithelial cell lines (HEK-293T), hepatocytes (Huh7.5), and 
other non-immune cell lines, by transfection of expression vectors and 
overexpression of selected components of the complex. The adapter protein 
MyD88 is required as a scaffold protein, and also TRAF6 has been shown to 
play a crucial role (Kawai et al., 2004). TRAF3 was originally thought to play an 
important role in IFNβ induction via TLR3 or RLRs and therefore was not tested 
in this study. However, it has also been described as a crucial factor in TLR7/9 
signaling more recently (Oganesyan et al., 2006), but as I had already shown 
the interaction of the MV V protein with IKKα and IRF7 at that time, I did not 
follow the influence of TRAF3. 
IRAK1, IRAK4 and IKKα have been described previously to play essential roles 
in the activation of IRF7 through signaling of TLR7/9 (Uematsu et al., 2005; 
Hoshino et al., 2006; Kim et al., 2007). However, when overexpressed in cell 
lines, only IKKα showed an increase in IFNα-promoter activity in the assay 
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established in this study. IRAK4 did not influence the IFNα-promoter activity, 
and IRAK1, as well as a splicing variant IRAK1c, strongly decreased the IFNα-
promoter activity when overexpressed. This might give hint to a regulatory role 
of IRAK1 in the signaling complex. IRF7 is phosphorylated at multiple sites 
during the activation (Lin et al., 2000). Overexpression of IRAK1 might result in 
a deregulation of the kinetics of the activation of IRF7, which might lead to a 
premature proteasomal degradation of IRF7 and thereby loss of IFNα-promoter 
activation. 
 
4.5 Inhibition of TLR7/9 signaling by the MV C protein 
Here, I tested the proteins expressed from the MV P gene, namely MV P, V and 
C, for their ability to inhibit IFNα induction by the signaling complex of TLR7/9. 
I could show that both MV V and C are able to act as inhibitors for the activation 
of IFNα promoters and I was able to clarify the underlying mechanism for the V 
protein. However, the role of the C protein remains elusive and must be 
addressed in a separate project. MV C has been shown to be involved in the 
inhibition of protein kinase R (PKR) activity (Toth et al., 2009). This RNA 
helicase recognizes dsRNA and induces apoptosis and mitogen activated 
protein kinase (MAPK) signaling. PKR activation also leads to increased type-I 
IFN production and to the activation of NF-κB (Williams, 2001). Moreover, PKR 
leads to the phosphorylation of the eukaryotic translation initiation factor 2α 
(eIF2α), which leads to a shut down in protein synthesis (reviewed in 
(Balachandran and Barber, 2007)). However, here I could show that MV C must 
have additional functions apart from the inhibition of PKR-dependent signaling. 
I could show that C does not directly interact with components of the signaling 
complex. Others have described several functions of the C protein, which might 
be involved also in its ability to block IFNα induction. On the one hand, MV C 
possesses a nuclear localization signal (NLS) as well as a nuclear export signal 
(NES), which both contribute to the ability of the C protein to shuttle between 
cytoplasm and nucleus (Nishie et al., 2007). Thereby, signal transduction 
processes like the nuclear translocalization of IRF7 might be disturbed by the C 
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protein. Similar results were found for the RPV C protein, which inhibits the 
induction of IFNβ by IRF3 (Boxer et al., 2009). 
 
4.6 Future perspectives 
In this study I used the V protein of the Schwarz vaccine strain, which is derived 
from the original Edmonston wt isolate by several passages on different cell 
lines (Rota et al., 1994). Direct nucleotide comparison reveal only minor 
changes in the coding regions of parental and attenuated strains (Parks et al., 
2001). Only one amino acid mutation (E225G) occurs within the V protein of 
MV(Schwarz) compared to the parental MV(Edmonston wt). The inhibitory 
function of V regarding TLR7/9 signaling was existent in the V protein of the 
attenuated Schwarz strain. It is assumed that also the V protein of wt MV 
should have the same function and probably should function even more 
effective than Schwarz strain V. However, this has to be clarified and therefore 
we will directly compare the functions of Schwarz strain V with the V protein of 
a wild type isolate (MVi/Berlin.DEU/04.08, genotype D5; RKI Berlin) on the 
molecular level as well as the ability to block IFNα induction in the virus 
context. It has been reported that the wt isolate of the G954 strain showed 
strong IFNα production in human pDCs, and passaging of the virus on Vero cells 
(G954-V13) did not change this phenotype, although the resulting virus was 
highly attenuated (Druelle et al., 2008). Comparing the V protein sequences of 
MV G954 and Schwarz revealed that in both G954-PBL and G954-V13 a 
mutation T259A was introduced. However, the mutation of Schwarz strain MV 
V T259A did not lead to a non-functional V protein in our study. Only by 
mutating also the subsequent amino acids led to a mutant (MV V T259A-L260A-
G261A-T262A), which was unable to inhibit IFNα induction and did neither 
bind to IKKα, nor to IRF7. 
Using a reverse genetics system for MV (Devaux et al., 2007), the biochemical 
data obtained in this study will be confirmed in the virus context in the future. 
Generation of recombinant V knock-out MV and recombinant MV expressing 
mutated forms of V instead of the original protein will further clarify the role of 
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V in infection studies. Chimeric recombinant MVs expressing V from wt strains 
will elucidate, whether wt V differs in its functions from Schwarz strain V. 
The results described here may bring new aspects into the field of autoimmune 
disorders. Systemic lupus erythematosus (SLE; (Barrat et al., 2005)) and many 
other autoimmune disorders have been shown or are suspected to be 
dependent on the activation of TLR7/9. MV V is a specific antagonist of the 
MyD88-dependent induction of IFNα and therefore could be used to specifically 
block the TLR7/9 dependent signal transduction. Recombinant MV V could be 
used in murine SLE model organisms to study the effect in vivo (Christensen et 
al., 2006). By narrowing down the functional domain of V, smaller peptides 
could be generated to facilitate the local admission and agency of V. 
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5 Summary 
Measles virus (MV) is a haematotropic member of the Paramyxoviridae family 
(order Mononegavirales, genus Morbillivirus) and an important human 
pathogen. It induces a generalized transient immune suppression as well as a 
specific immune response that provides life-long protection. This paradoxical 
effect is most likely due to early interactions of MV with cells immune cells, 
including conventional and plasmacytoid dendritic cells (cDCs and pDCs, 
respectively).  A remarkable feature of MV is the ability to shut down 
interferon-alpha (IFNα) production in response to Toll-like receptor (TLR) 7 
and TLR9 ligands in human pDCs, as shown previously in this laboratory. The 
MV proteins involved and the molecular mechanisms behind remained elusive. 
To identify these proteins involved, the IFN-inducing TLR pathway of pDCs, 
which involves the adapter MyD88, the kinases IRAK1, IRAK4 and IKKα, and 
the transcription factor IRF7, was reconstituted in HEK-293T cells by 
expression of the recombinant proteins from transfected plasmids. Co-
expression of individual MV proteins in reporter gene assays led to the 
identification of the MV V protein as a potent inhibitor. MV V was previously 
described to bind STAT1/2 and MDA-5, thereby interfering with other 
important immune signaling cascades as well. 
MV V is expressed from the MV phosphoprotein (P) gene by mRNA editing and 
is composed of an N-terminal sequence identical to that of P and a unique 68-
amino-acid Cys-rich and zinc-binding C-terminal domain. As shown by co-
immunoprecipitation experiments, V specifically binds to both IKKα and IRF7 
but not to the closely related IKKβ, TBK1 and IKKε or IRF3, respectively. 
Binding of MV V to IKKα resulted in phosphorylation of V on the expense of 
IRF7 phosphorylation both in living cells and in vitro, as illustrated by in vitro 
kinase experiments. In addition to interfering with activation of IRF7 by 
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preventing phosphorylation, MV V also binds to phosphomimetic IRF7 which 
contributes to preventing transcriptional activity of IRF7. The MV V-specific 68-
amino-acid C terminal domain was identified as an autonomous targeting 
module directing V to IKKα and IRF7, while sequences of the common N-
terminal domain were necessary for potent inhibition of IRF7-mediated IFNα 
promoter activation.  
Among the V proteins of paramyxoviruses, which share organization as well as 
STAT-, and MDA-5-binding, MV V is unique in targeting MyD88-dependent 
IKKα/IRF7 activation, as exemplified by experiments using the V protein of 
parainfluenzavirus type 5 (PIV5; genus Rubulavirus). A mutant MV V protein 
carrying PIV5-like mutations at amino acids 259 – 262, lost the ability to bind 
both IKKα and IRF7 and therefore did not inhibit IFNα activation. In contrast, 
JAK/STAT signaling was not affected by this mutant, revealing independent 
inhibitory functions. 
In addition to IFNα induction, MV V inhibited NF-κB activation, which is also 
triggered by TLR-signaling. Activation of NF-κB is partially dependent on IKKα. 
However, the efficiency of inhibition of NF-κB activation was not as prominent 
as of IFNα induction. The exact mechanisms involved could not be clarified in 
this study. 
Autophagy, which has recently been identified to be involved in the localization 
of viral nucleic acids to TLR-containing compartments, could be shown to be 
activated at early stages of MV infection, but it is blocked efficiently at later 
stages of infection. This gives hint that a viral factor is counteracting also this 
pathway involved in the innate immune response, but whether this factor is the 
MV V or a different protein still needs to be clarified. 
The results provided here open the way for mutagenesis experiments to 
generate recombinant MV with specific defects in blocking either IKKα, 
JAK/STAT, or MDA-5 signaling, in order to appreciate the contribution of these 
individual functions to MV immune biology. Such studies will not only lead to 
recombinant vaccine viruses with abolished or reduced capacity to undermine 
the host immune response, but may also help to develop tools to specifically 
interfere with immunopathological TLR signaling. 
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5 Zusammenfassung 
Das Masernvirus (MV) gehört zur Familie der Paramyxoviridae (Ordnung 
Mononegavirales, Genus Morbillivirus). Das hämatotrope Virus führt zu einer 
generalisierten Immunsuppression, löst aber auch eine spezifische 
Immunantwort aus, die einen lebenslangen Schutz gewährt. Dieses „Masern-
Paradoxon“ lässt sich am ehesten durch eine Interaktion des Virus mit Zellen 
des Immunsystems früh nach Eintritt der Infektion erklären. Dies sind unter 
anderem konventionelle und plasmazytoide dendritische Zellen (cDCs und 
pDCs). Eine Besonderheit des MV besteht in der Inhibition der TLR7/9-
abhängigen Produktion von Interferon-alpha (IFNα) in pDCs. In dieser Arbeit 
konnte das virale Protein, das die Inhibition vermittelt, identifiziert und der 
zugrundeliegende molekulare Mechanismus aufgeklärt werden.  
Zu diesem Zweck wurde der TLR7/9 abhängige Signaltransduktionskomplex, 
welcher zur Aktivierung von IFNα Promotoren führt, in HEK-293T Zellen 
rekonstituiert. Ausgewählte Proteine des Komplexes wurden transient 
überexprimiert, unter anderem das Adaptermolekül MyD88, die Serin-/ 
Threoninkinasen IRAK1, IRAK4 und IKKα, sowie der Transkriptionsfaktor IRF7. 
Darüber hinaus wurden verschiedene virale Proteine koexprimiert. Im Falle 
des V Proteins des MV (MV V) führte dies zu einer starken Reduktion der IFNα-
Promotoraktivierung im Reportergensystem. Aus anderen Studien war bereits 
bekannt, dass das V Protein auch die MDA-5-abhängigen und JAK/STAT 
Signaltransduktionswege des angeborenen Immunsystems inhibiert. 
Das MV V Protein ist im Phosphoprotein (P) Gen des MV kodiert und entsteht 
durch kotranskriptionelle Editierung der mRNA. Dadurch besitzt das V Protein 
einen N-Terminus, der mit dem des P Proteins identisch ist und eine spezielle 
Cys-reiche und Zn-bindende C-terminale Domäne. Ko-Immunpräzipitations-
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experimente zeigten, dass diese C-terminale Domäne für eine direkte 
Interaktion von V mit den Faktoren IKKα und IRF7 des Signaltransduktions-
komplexes verantwortlich ist. Nahe verwandte Proteine, IKKβ, TBK1, IKKε und 
IRF3, werden jedoch nicht gebunden. In vitro Kinasestudien zeigten, dass die 
Bindung an IKKα zu einer Phosphorylierung des V Proteins führt und dadurch 
die Phosphorylierung von IRF7 verhindert wird. Dies konnte in lebenden Zellen 
bestätigt werden. Zusätzlich ist V in der Lage, an phosphomimetisches, 
konstitutiv aktives IRF7 zu binden und dadurch dessen transkriptionelle 
Aktivität zu inhibieren. Obwohl die C-terminale Domäne für die Bindung 
ausreichend war, bedurfte es des gesamten V Proteins, um die IFNα-
Promotoraktivierung vollständig zu unterbinden. 
Unter allen V Proteinen der Viren aus der Familie der Paramyxoviridae, welche 
als gemeinsame Funktionen die Inhibition von MDA-5-abhängiger und 
JAK/STAT-Signaltransduktion besitzen, ist das MV V Protein das Erste, welches 
die Aktivierung von IRF7 durch IKKα inhibiert. Aminosäureaustausche im MV V 
hin zur Sequenz des in dieser Hinsicht inaktiven V Proteins des 
Parainfluenzavirus Typ 5 (PIV5 V, Genus Rubulavirus) im Bereich der 
Aminosäuren 259 – 262 hatten zur Folge, dass weder IKKα oder IRF7 gebunden 
werden konnte. Auch die Aktivierung von IFNα-Promotoren konnte durch diese 
Mutante nicht mehr inhibiert werden. Im Gegensatz dazu war die Inhibition der 
JAK/STAT-Signaltransduktion unbeeinflusst, woraus sich schließen lässt, dass 
beides unabhängige Funktionen des MV V Proteins sind. 
Darüber hinaus konnte gezeigt werden, dass MV V die Aktivierung von NF-κB 
inhibiert, jedoch in einem geringeren Maß. NF-κB wird ebenfalls durch TLR7/9 
in einer Signaltransduktionskaskade aktiviert, welche teilweise von IKKα 
abhängig ist. Die molekularen Mechanismen dieser Inhibition sind allerdings 
bisher noch unklar. 
Es konnte des Weiteren gezeigt werden, dass im frühen Verlauf einer 
Maserninfektion Autophagie induziert wird. Dadurch gelangen virale 
Nukleinsäuren aus dem Zytoplasma infizierter Zellen in endosomale 
Kompartimente, wo sie zur Aktivierung von TLR7 und zur IFNα Expression 
beitragen. Es konnte gezeigt werden, dass diese frühe Aktivierung von 
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Autophagie im späteren Verlauf der Infektion vom Virus blockiert wird. Ob das 
V Protein auch bei dieser Inhibition eine Rolle übernimmt muss weiter geklärt 
werden. 
Die hier vorgelegten Ergebnisse eröffnen die Möglichkeit zu Studien mit 
rekombinanten MV, bei denen spezifisch eine oder mehrere inhibierende 
Funktionen des V Proteins ausgeschalten werden. Dies wird zu einem tieferen 
Verständnis der Immunbiologie des MV beitragen und könnte zur Entwicklung 
rekombinanter Vakzinen mit reduzierten oder vollständig ausgeschaltenen 
immunmodulatorischen Fähigkeiten führen. Andererseits könnte man diese 
Fähigkeiten des V Proteins zur Therapie von immunpathologischen 
Erkrankungen nutzen, bei denen TLR7/9-abhängige Signaltransduktion eine 
Rolle spielen. 
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